annual reportmarch shareholders start one could imagined dramatically world change due virus impacted billions people every nation measure year dominated uncertaintyyet pandemic helped clarify priorities reinforce values familiar yard signs may faded message resonant ever together covid profound new appreciation gratitude doctors nurses hospital staff serving front lines care everyday heroism essential workers show keep worlds critical healthcare infrastructure running expectations companies must drive positive change behalf everyoneno matter liveare higher ever alex gorsky served important reminder chairman chief executive officer central good health collective prosperity security society fundamental level worlds largest nothing essential every person every broadlybased healthcare company family every town every nation earth health whether covid touched directly unique perspective indirectly individuals life left unchanged global health profound pandemicand together gained shared responsibility lead called understanding universal truth one safe untileveryone safe soon dna sequencing covid virus made built times like available role clear even early january impossible guess exactly nascent pandemic would unfold though success anything johnson johnson investing guaranteed johnson applying best science take johnson would everything serious public health threats centuryand never question power develop safe effective would contribute full breadth depth efficient vaccine largest companys expertise global efforts number people around world combat covid chairmans letter ambitious urgent goal driving us forward excellence execution set follow science make confidence placed us patients physicians potential vaccine available notforprofit basis customers consumers today result pandemic emergency use superb sustained delivery commitments makeand exception work done around clock innovative models publicprivate partnerships cidcidcidwhile development covid vaccine new heights purposedriven collaboration months incredible triumph face successes challenges science significant continually affirmed commitment safety achievement pharmaceutical business scientific integrity transparency exactly continued outperform industry across one year officially began development therapeutic areas regions process able share positive topline marked th consecutive year results phase ensemble clinical trial market adjusted operational growthall companys singledose covid vaccine keeping pipeline submissions approvals shortly based totality scientific track well achieving greater patient evidence received emergency use authorization enrollment clinical trials compared us food drug administration received approval subcutaneous singledose covid vaccine immediately formulation multiple myeloma drug darzalex began shipping doses us daratumumab ahead scheduled us pdufa date new formulation took monumental achievement enduring multihour intravenous treatment point pride us decades come perhaps subcutaneous delivery executed remarkable successful development minutes focused educating healthcare covid vaccine one many practitioners successfully launched incredible accomplishments made year product virtual environmentreaffirming like company strong commercial capabilities thanks resilience dedication cid consumer health business didnt meet exceeded goals year agile resourcefulness colleagues enough recognize quickly adapt fulfilling around world johnson increased demand products liketylenol johnson didnt survive listerine millions homes worldwide recording approximately yearoveryear company pivoted great growth ecommerce consumer health agility delivered notable team also refused let challenges deter launching ambitious healthy financial performance lives mission holistic approach health tumultuous year continuing wellnessadvancing sustainable innovation invest sustainable transformative packaging providing enhanced transparency ingredients used products innovation longterm supporting proactive selfcare encouraging new consumer behaviorhas welcome many periods upheaval since reminder company accomplish founding broad base diversified tackle widest range unmet healthcare solutions created stability investors health needs increased shareholder dividend th consecutive year cid perhaps striking testament power worldclass execution seen core strengths powered performance rebound across medical devices business last year ones served covid pandemic caused many stakeholders well every market environment individuals delay healthcare treatmentfrom unwavering focus execution innovation routine exams important elective surgeries people emergency room visits medical devices business continued prioritizing patient customer needs maintaining product reliability chairmans letterand advancing innovation quickly identified selexipag injection intravenous use treat urgent needs focused efforts supporting pulmonary arterial hypertension darzalex patients training million healthcare faspro treatment newly diagnosed professionals virtual platforms conducting patients light chain amyloidosis also live remote case support securing hope receive approval year ponesimod providing personal protective equipment ppe multiple sclerosis ppm treatment bringing together industry partners schizophrenia developments expanding coverage emerging sites care potentially change lives patients efforts weve developed new families years come capabilities strengthened customer relationships set us even greater cidcidcidour medical devices business made strong performance beyond progress achieving even accelerating key pipeline milestones throughout year cid focus sustainability efforts areas continued invest innovation believe make greatest impact advance critical programs across franchise advance health humanity healthcare throughout including expansion company johnson johnson understands hip knee portfolios highgrowth climate health affect human health market segments enhancements industry longstanding commitment leadingtecnis family intraocular lenses environmental health set new climate goals introduction ofechelon endopath track next years staple line reinforcement launch end honored cerenovus stroke solutions remain recognized global corporate leader incredibly excited great potential climate action water security awarded endtoend digital surgery ecosystem two alist ratings carbon disclosure simultaneously developing three differentiated projectthe third year row tackling robotic programs recently achieved climate change second year row significant milestone thefda clearance work water security velys roboticassisted solution designed use attune total knee system lifeenhancing innovation industry starting unlock full one thing think speaks volumes potential benefits robotic digital performance prospects company technologiesand seems fitting investment innovation midst company helped pioneer sterile years uncertainty johnson johnson surgery years ago poised lead invested alltime high billion research way bringing differentiated cuttingedge new development million solutions stcentury operating room billion acquisitions continued fortify pipeline ensure able cidcidcidin consumer health displayed great agility continue changing trajectory human health finding ways ensure could supply long pandemic among years families worldwide essential products highlights science innovation throughout pandemic innovation didnt stop brands launched nearly new cidcidcidvaccine development one area products deepened commitment worldclass scientists utilized expertise creating inclusive sustainable health pharmaceutical business initiated solutions meet needs consumers one us fda filing ourbcma cart therapy timely example launch nicorette ciltacabtagene autoleucel ciltacel quickmist smarttrack united kingdom treatment relapsed refractory multiple worlds first digitally connected smoking myeloma patients received three cessation option tool developed prior classes therapies filed approval top behavioral scientists connect smokers amivantamab treatment patients support app help track metastatic nonsmall cell lung cancer personalized programs epidermal growth factor receptor exon insertion mutations whose disease progressed platinumbased chemotherapy additionally filed approval uptravi chairmans letter cid innovation doesnt happen cid look back could possibly ignore laboratories also want recognize events last summer forced usas impactful work supply chain colleagues individuals company country driving improvements efficiencies confront reality systemic racism past year gartner research honored johnson society turmoil streets cities johnson number three ranking across across america beyond brought light industries supply chain top index overdue recognition inequalities five spots ranking top simultaneously exacerbated ranking healthcare supply chain disproportionate impact covid top citing commitment continuous communities color improvement putting innovation practice particularly response real change doesnt happen one galvanizing covid pandemic moment dialogue alone requires sustained longterm commitment want powered people purpose make impact meaningful lasting meeting commitments stakeholders started place recognition racism balancing act even times stability public health crisis johnson johnson prosperity fierce headwinds faced chose focus eliminating health inequities throughout sometimes put deeply people color million race held beliefs testand dealing constant health equity platform launched november disruption often felt like fulltime jobim dramatically higher mortality rate communities incredibly proud employees truly color covid pandemic living credo values even face recent example disparity access daunting challenges onceina quality healthcare resultant outcomes century pandemic could excuse patients families communities delay rather call action thats determination put better health within johnson johnson reach everyone work includes use data better understand root causes inequalities cid even pandemics toughest days encourage information sharing effective employees around globe worked tirelessly training methods medical centers clinics provide uninterrupted access medicines local level helping grassroots leaders products use full spectrum frontline workers better prepared expertise support healthcare systems risk positioned care lift overwhelmed surges cases communities hospitalizations billion lives touch every day delivered achieving true diversity clinical trials hiring againeven professional offices boardrooms take time effort personal lives changed ways demanded investment every day brings new opportunity unparalleled resilience creativity inclusive know decades experience science technology innovation cid johnson johnson family companies depends collaboration driven diversity johnson johnson foundation rallied ideas approaches opinions individuals support healthcare professionals including make us better company better citizens million initiative provide doctors world community nurses working front lines pandemic ppe mental health resources critical forms support select number johnson johnson employees call serve even stronger nearly licensed healthcare professionals ranks took advantage companys newly announced benefit weeks paid leave volunteer hardesthit hospitals community health centers chairmans letterin closing time shift theres old saying adversity doesnt build focus healthcare away character reveals without question effectiveness cost covid pandemic shown us much accomplish following moral compass sustainability resiliency value credo witnessed unprecedented levels collaboration public idea companies could right customers patients healthcare professionals private partnerships past employees shareholders also good monthslets use new models world pretty revolutionary concept supercharge efforts combat general robert wood johnson first put values words doubt idea urgent public health challenges fight health humanity must hard work thats together would resonant required turn collective desire us address disparities care since weve showing world plague underserved communities looks like lead purposeespecially measurable meaningful action moments great crisis despite disruption weve navigate last year never confident forge onward im filled optimism future industry company lessons weve learned covid ultimately accelerate progress healthier equitable future alland johnson johnson moment must ensure continue play pivotal role achieving covid pandemic isnt consequential moment world history wakeup call critical profoundly grateful opportunity lead company exceptional employees importance public health national economic societal sincerely security must call action consider postpandemic future opportunity decide bring us alex gorsky chairman chief executive officer new world johnson johnson leave behind owe whose lives livelihoods ravaged virus made enormous personal sacrifices greater good choose wisely note regarding forwardlooking statements letter contains forwardlooking statements relating among things future operating financial performance product development market position business strategy reader cautioned rely statements based current expectations future events important information statements including risks uncertainties factors could cause actual results vary materially assumptions expectations projections expressed forwardlooking statements reader review enclosed annual report fiscal year ended january including sections captioned cautionary note regarding forward looking statements item risk factors johnson johnson undertake update forwardlooking statement result new information future events developments chairmans letter united states securities exchange commission washington dc annual report pursuant section securities exchange act forthefiscalyearendedjanuary transition report pursuant section securities exchange act transition period commissionfilenumber johnson johnson exactnameofregistrantasspecifiedinitscharter newjersey stateofincorporation irsemployeridentificationno onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffices zipcode onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffices registrantstelephonenumberincludingareacode securitiesregisteredpursuanttosectionboftheact titleofeachclass tradingsymbol nameofeachexchangeonwhichregistered commonstockparvalue jnj newyorkstockexchange notesduejanuary jnj newyorkstockexchange notesduemay jnjc newyorkstockexchange notesduenovember jnjbp newyorkstockexchange notesduenovember jnj newyorkstockexchange notesduemay jnj newyorkstockexchange indicatebycheckmarkiftheregistrantisawellknownseasonedissuerasdefinedinruleofthesecurities act yes indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttosectionorsectiondoftheexchange act yes indicatebycheckmarkwhethertheregistranthasfiledallreportsrequiredtobefiledbysectionordoftheexchange actduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtofilesuchreportsandhas beensubjecttosuchfilingrequirementsforthepastdays yes indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryinteractivedatafilerequiredtobesubmitted pursuanttoruleofregulationstduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwas requiredtosubmitsuchfiles yes indicatebycheckmarkwhethertheregistrantisalargeacceleratedfileranacceleratedfileranonacceleratedfilerasmaller reportingcompanyoremerginggrowthcompanyseethedefinitionsoflargeacceleratedfileracceleratedfilersmaller reportingcompanyandemerginggrowthcompanyinruleboftheexchangeact largeacceleratedfiler acceleratedfiler nonacceleratedfiler smallerreportingcompany emerginggrowthcompany ifanemerginggrowthcompanyindicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttosectionaoftheexchange act indicatebycheckmarkwhethertheregistranthasfiledareportonandattestationtoitsmanagementsassessmentofthe effectivenessofitsinternalcontroloverfinancialreportingundersectionbofthesarbanesoxleyactusc bbytheregisteredpublicaccountingfirmthatpreparedorissueditsauditreport yes indicatebycheckmarkwhethertheregistrantisashellcompanyasdefinedinruleboftheexchange act yes theaggregatemarketvalueofthecommonstockheldbynonaffiliatescomputedbyreferencetothepriceatwhichthe commonstockwaslastsoldasofthelastbusinessdayoftheregistrantsmostrecentlycompletedsecondfiscalquarter wasapproximatelybillion onfebruarythereweresharesofcommonstockoutstanding documentsincorporatedbyreference partsiandiii portionsofregistrantsproxystatementforitsannualmeetingofshareholdersfiledwithin daysafterthecloseoftheregistrantsfiscalyeartheproxystatementareincorporatedby referencetothisreportonformkthisreportitem parti business general segmentsofbusiness geographicareas rawmaterials patents trademarks seasonality competition environment regulation employeesandhumancapitalmanagement availableinformation riskfactors b unresolvedstaffcomments properties legalproceedings minesafetydisclosures executiveofficersoftheregistrant partii marketforregistrantscommonequityrelatedstockholdermattersandissuerpurchasesof equitysecurities reserved managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition quantitativeandqualitativedisclosuresaboutmarketrisk financialstatementsandsupplementarydata changesinanddisagreementswithaccountantsonaccountingandfinancialdisclosure controlsandprocedures b otherinformation partiii directorsexecutiveofficersandcorporategovernance executivecompensation securityownershipofcertainbeneficialownersandmanagementandrelatedstockholder matters certainrelationshipsandrelatedtransactionsanddirectorindependence principalaccountantfeesandservices partiv exhibitsandfinancialstatementschedules formksummary signatures exhibitindex cautionary note regarding forwardlooking statements thisannualreportonformkandjohnsonjohnsonsotherpubliclyavailabledocumentscontainforwardlooking statementswithinthemeaningofthesafeharborprovisionsoftheusprivatesecuritieslitigationreformactof managementandrepresentativesofjohnsonjohnsonanditssubsidiariesthecompanyalsomayfromtimeto timemakeforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand reflectmanagementsassumptionsviewsplansobjectivesandprojectionsaboutthefutureforwardlookingstatements maybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandotherwordsof similarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsexpectedoperatingresultsand financialperformanceimpactofplannedacquisitionsanddispositionsthecompanysstrategyforgrowthproduct developmentregulatoryapprovalsmarketpositionandexpenditures becauseforwardlookingstatementsarebasedoncurrentbeliefsexpectationsandassumptionsregardingfutureevents theyaresubjecttouncertaintiesrisksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorknownorunknownrisksor uncertaintiesmaterializethecompanysactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand projectionsexpressedorimpliedinitsforwardlookingstatementsinvestorsarethereforecautionednottorelyonthese forwardlookingstatementsrisksanduncertaintiesincludebutarenotlimitedto risksrelatedtoproductdevelopmentmarketsuccessandcompetition challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologies onwhichthecompanyscontinuedgrowthandsuccessdependincludinguncertaintyofclinicaloutcomesadditional analysisofexistingclinicaldataobtainingregulatoryapprovalshealthplancoverageandcustomeraccessandinitial andcontinuedcommercialsuccess challengestothecompanysabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew andexistingproductsandtechnologiesintheunitedstatesandotherimportantmarkets theimpactofpatentexpirationstypicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand resultingrevenueandmarketsharelosses increasinglyaggressiveandfrequentchallengestothecompanyspatentsbycompetitorsandothersseekingtolaunch competinggenericbiosimilarorotherproductsandincreasedreceptivityofcourtstheunitedstatespatentand trademarkofficeandotherdecisionmakerstosuchchallengespotentiallyresultinginlossofmarketexclusivityand rapiddeclineinsalesfortherelevantproductsoonerthanexpected competitioninresearchanddevelopmentofnewandimprovedproductsprocessesandtechnologieswhichcanresult inproductandprocessobsolescence competitiontoreachagreementwiththirdpartiesforcollaborationlicensingdevelopmentandmarketingagreements forproductsandtechnologies competitionbasedoncosteffectivenessproductperformancetechnologicaladvancesandpatentsattainedby competitorsand allegationsthatthecompanysproductsinfringethepatentsandotherintellectualpropertyrightsofthirdpartieswhich couldadverselyaffectthecompanysabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamages andfutureroyalties risksrelatedtoproductliabilitylitigationandregulatoryactivity productefficacyorsafetyconcernswhetherornotbasedonscientificevidencepotentiallyresultinginproduct withdrawalsrecallsregulatoryactiononthepartoftheunitedstatesfoodanddrugadministrationorinternational counterpartsdecliningsalesreputationaldamageincreasedlitigationexpenseandsharepriceimpact impactincludingdecliningsalesandreputationaldamageofsignificantlitigationorgovernmentactionadversetothe companyincludingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand contractingstrategies impactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedingsincluding patentlitigationproductliabilitypersonalinjuryclaimssecuritiesclassactionsgovernmentinvestigationsemployment andotherlegalproceedings increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin investigationsandprosecutionswhichcarrytheriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimited todebarmentfromgovernmentbusiness johnsonjohnsonannualreport failuretomeetcomplianceobligationsinthemcneilppcincconsentdecreeoranyothercomplianceagreements withgovernmentsorgovernmentagencieswhichcouldresultinsignificantsanctions potentialchangestoapplicablelawsandregulationsaffectingunitedstatesandinternationaloperationsincluding relatingtoapprovalofnewproductslicensingandpatentrightssalesandpromotionofhealthcareproductsaccess toandreimbursementandpricingforhealthcareproductsandservicesenvironmentalprotectionandsourcingofraw materials compliancewithlocalregulationsandlawsthatmayrestrictthecompanysabilitytomanufactureorsellitsproductsin relevantmarketsincludingrequirementstocomplywithmedicaldevicereportingregulationsandotherrequirements suchastheeuropeanunionsmedicaldevicesregulation changesindomesticandinternationaltaxlawsandregulationsincludingchangesrelatedtothetaxcutsandjobsact intheunitedstatesincreasingauditscrutinybytaxauthoritiesaroundtheworldandexposurestoadditionaltax liabilitiespotentiallyinexcessofexistingreservesand issuanceofneworrevisedaccountingstandardsbythefinancialaccountingstandardsboardandregulationsbythe securitiesandexchangecommission risksrelatedtothecompanysstrategicinitiativesandhealthcaremarkettrends pricingpressuresresultingfromtrendstowardhealthcarecostcontainmentincludingthecontinuedconsolidation amonghealthcareprovidersandothermarketparticipantstrendstowardmanagedcaretheshifttowardgovernments increasinglybecomingtheprimarypayersofhealthcareexpensessignificantnewentrantstothehealthcaremarkets seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincreases restrictedspendingpatternsofindividualinstitutionalandgovernmentalpurchasersofhealthcareproductsand servicesduetoeconomichardshipandbudgetaryconstraints challengestothecompanysabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovations suchasdevelopmentcollaborationsstrategicacquisitionslicensingandmarketingagreementsandthepotential heightenedcostsofanysuchexternalarrangementsduetocompetitivepressures thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor divestiturebythecompanymaynotberealizedormaytakelongertorealizethanexpectedand thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe realizedormaytakelongertorealizethanexpected risksrelatedtoeconomicconditionsfinancialmarketsandoperatinginternationally therisksassociatedwithglobaloperationsonthecompanyanditscustomersandsuppliersincludingforeign governmentsincountriesinwhichthecompanyoperates impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch fluctuationsonrevenuesexpensesandresultingmargins potentialchangesinexportimportandtradelawsregulationsandpoliciesoftheunitedstatesandothercountries includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomiessovereignriskpossible impositionofgovernmentalcontrolsandrestrictiveeconomicpoliciesandunstableinternationalgovernmentsandlegal systems theimpactofglobalpublichealthcrisesandpandemicsincludingtheoutbreakofthenovelcoronaviruscovid pandemic changestoglobalclimateextremeweatherandnaturaldisastersthatcouldaffectdemandforthecompanysproducts andservicescausedisruptionsinmanufacturinganddistributionnetworksaltertheavailabilityofgoodsandservices withinthesupplychainandaffecttheoveralldesignandintegrityofthecompanysproductsandoperationsand theimpactofarmedconflictsandterroristattacksintheunitedstatesandotherpartsoftheworldincludingsocialand economicdisruptionsandinstabilityoffinancialandothermarkets risksrelatedtosupplychainandoperations difficultiesanddelaysinmanufacturinginternallythroughthirdpartyprovidersorotherwisewithinthesupplychainthat mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdownsproductshortageswithdrawalsor suspensionsofproductsfromthemarketandpotentialregulatoryaction interruptionsandbreachesofthecompanysinformationtechnologysystemsorthoseofthecompanysvendors whichcouldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsand regulatoryaction johnsonjohnsonannualreport relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing regulatoryrequirementsthatmayadverselyaffectsupplysourcingandpricingofmaterialsusedinthecompanys productsand thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal supplychainincludingthecompanystransactionwithjabilmaynotberealizedormaytakelongertorealizethan expectedincludingduetoanyrequiredapprovalsfromapplicableregulatoryauthoritiesdisruptionsassociatedwiththe announcedglobalsupplychainactionsmayadverselyaffectsupplyandsourcingofmaterialsusedinthecompanys products investorsalsoshouldcarefullyreadtheriskfactorsdescribedinitemaofthisannualreportonformkfora descriptionofcertainrisksthatcouldamongotherthingscausethecompanysactualresultstodiffermateriallyfrom thoseexpressedinitsforwardlookingstatementsinvestorsshouldunderstandthatitisnotpossibletopredictoridentify allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinitematobeacompletestatementofall potentialrisksanduncertaintiesthecompanydoesnotundertaketopubliclyupdateanyforwardlookingstatementthat maybemadefromtimetotimewhetherasaresultofnewinformationorfutureeventsordevelopments johnsonjohnsonannualreport part item business general johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldjohnsonjohnson isaholdingcompanywithoperatingcompaniesconductingbusinessinvirtuallyallcountriesoftheworldthecompanys primaryfocusisproductsrelatedtohumanhealthandwellbeingjohnsonjohnsonwasincorporatedinthestateof newjerseyin theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe companysthreebusinesssegmentsconsumerhealthpreviouslyreferredtoasconsumerpharmaceuticaland medicaldeviceswithinthestrategicparametersprovidedbythecommitteeseniormanagementgroupsatusand internationaloperatingcompaniesareeachresponsiblefortheirownstrategicplansandthedaytodayoperationsof thosecompanieseachsubsidiarywithinthebusinesssegmentsiswithlimitedexceptionsmanagedbyresidentsofthe countrywherelocated segments business thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpharmaceuticalandmedicaldevices additionalinformationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsof segmentsandoperatingresultsunderitemmanagementsdiscussionandanalysisofresultsofoperationsand financialconditionofthisreportandnotesegmentsofbusinessandgeographicareasofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport consumerhealth theconsumerhealthsegmentincludesabroadrangeofproductsfocusedonpersonalhealthcareusedintheskin healthbeautyoverthecountermedicinesbabycareoralcarewomenshealthandwoundcaremarketsmajorbrandsin skinhealthbeautyincludetheaveenocleancleardrcilaboneutrogenaandogxproduct linesoverthecounterotcmedicinesincludethebroadfamilyoftylenolacetaminophenproductssudafed coldfluandallergyproductsbenadrylandzyrtecallergyproductsmotrinibibuprofenproducts nicorettesmokingcessationproductsoutsidetheuszarbeesnaturalsandthepepcidlineofacidreflux productsbabycareincludesthejohnsonsandaveenobabylineofproductsoralcareincludesthe listerineproductlinemajorbrandsinwomenshealthoutsideofnorthamericaarestayfreeandcarefree sanitarypadsandobtamponbrandswoundcarebrandsincludethebandaidbrandadhesivebandagesand neosporinfirstaidproductlinestheseproductsaremarketedtothegeneralpublicandsoldonlineecommerce andtoretailoutletsanddistributorsthroughouttheworld pharmaceutical thepharmaceuticalsegmentisfocusedonsixtherapeuticareasimmunologyegrheumatoidarthritisinflammatory boweldiseaseandpsoriasisinfectiousdiseaseseghivaidsneuroscienceegmooddisorders neurodegenerativedisordersandschizophreniaoncologyegprostatecancerandhematologicmalignancies cardiovascularandmetabolismegthrombosisanddiabetesandpulmonaryhypertensionegpulmonaryarterial hypertensionmedicinesinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealthcare professionalsforprescriptionusekeyproductsinthepharmaceuticalsegmentincluderemicadeinfliximaba treatmentforanumberofimmunemediatedinflammatorydiseasessimponigolimumabasubcutaneoustreatment foradultswithmoderatetosevererheumatoidarthritisactivepsoriaticarthritisactiveankylosingspondylitisand moderatelyactivetoseverelyactiveulcerativecolitissimponiariagolimumabanintravenoustreatmentforadults withmoderatetosevererheumatoidarthritisactivepsoriaticarthritisandactiveankylosingspondylitisstelara ustekinumabatreatmentforadultsandchildrenwithmoderatetosevereplaquepsoriasisforadultswithactivepsoriatic arthritisforadultswithmoderatelytoseverelyactivecrohnsdiseaseandtreatmentofmoderatelytoseverelyactive johnsonjohnsonannualreport ulcerativecolitistremfyaguselkumabatreatmentforadultswithmoderatetosevereplaquepsoriasisedurant rilpivirineprezistadarunavirandprezcobixrezolstadarunavircobicistatantiretroviralmedicinesforthe treatmentofhumanimmunodeficiencyvirushivincombinationwithotherantiretroviralproductsandsymtuza darunavircobicistatemtricitabinetenofoviralafenamideaoncedailysingletabletregimenforthetreatmentofhiv concertamethylphenidatehclextendedreleasetabletsciiatreatmentforattentiondeficithyperactivitydisorder invegasustennaxeplionpaliperidonepalmitateforthetreatmentofschizophreniaandschizoaffectivedisorder inadultsinvegatrinzatrevictapaliperidonepalmitateforthetreatmentofschizophreniainpatientsafterthey havebeenadequatelytreatedwithinvegasustennaforatleastfourmonthsrisperdalconstarisperidone longactinginjectionforthetreatmentofschizophreniaandthemaintenancetreatmentofbipolardisorderinadults zytigaabirateroneacetateatreatmentformetastaticcastrationresistantprostatecancercrpcandmetastatic highriskcastrationsensitiveprostatecancerimbruvicaibrutinibatreatmentforcertainbcellmalignanciesor bloodcancerschronicgraftversushostdiseaseandwaldenstrmsmacroglobulinemiadarzalexdaratumumaba treatmentforrelapsedrefractorymultiplemyelomaerleadaapalutamideanextgenerationandrogenreceptor inhibitorforthetreatmentofpatientswithprostatecancervelcadebortezomibatreatmentformultiplemyeloma mantlecelllymphomaprocriteprexepoetinalfaatreatmentforchemotherapyinducedanemiaandpatients withchronickidneydiseasexareltorivaroxabananoralanticoagulantforthepreventionofdeepveinthrombosis dvtwhichmayleadtopulmonaryembolismpeinpatientsundergoinghiporkneereplacementsurgerytoreducethe riskofstrokeandsystemicembolisminpatientswithnonvalvularatrialfibrillationandforthetreatmentandreductionof riskofrecurrenceofdvtandpeinvokanacanagliflozinforthetreatmentofadultswithtypediabetes invokametvokanametcanagliflozinmetforminhclacombinationtherapyoffixeddosesofcanagliflozinand metforminhydrochlorideforthetreatmentofadultswithtypediabetesandinvokametxrcanagliflozinmetformin hydrochlorideextendedreleaseaoncedailyfixeddosecombinationtherapyofcanagliflozinandmetformin hydrochlorideextendedreleaseforthetreatmentofadultswithtypediabetesopsumitmacitentanasmonotherapy orincombinationindicatedforthelongtermtreatmentofpulmonaryarterialhypertensionpahuptraviselexipag theonlyapprovedoralselectiveipreceptoragonisttargetingaprostacyclinpathwayinpahmanyofthesemedicines weredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesandmaintainactivelifecycle developmentprograms medicaldevices themedicaldevicessegmentincludesabroadrangeofproductsusedintheinterventionalsolutionsorthopaedics surgeryandvisionfieldsmedicaldevicesininterventionalsolutionsincludeelectrophysiologyproductsbiosense webstertotreatcardiovasculardiseasesneurovascularcarecerenovusthattreatshemorrhagicandischemicstroke theorthopaedicsportfoliodepuysynthesiscomprisedofproductsinsupportofhipskneestraumaandspine sportsotherthesurgeryportfoliosethiconincludeadvancedandgeneralsurgeryofferingssolutionsthatfocuson breastaestheticsmentorandearnoseandthroatacclarentproceduresandjohnsonjohnsonvisionproducts suchasacuvuebranddisposablecontactlensesandophthalmicproductsrelatedtocataractandlaserrefractive surgerytheseproductsaredistributedtowholesalershospitalsandretailersandusedpredominantlyintheprofessional fieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics geographic areas johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing theproductsmadeandsoldintheinternationalbusinessincludemanyofthosedescribedaboveundersegmentsof businessconsumerhealthpharmaceuticalandmedicaldeviceshowevertheprincipalmarketsproducts andmethodsofdistributionintheinternationalbusinessvarywiththecountryandtheculturetheproductssoldin internationalbusinessincludethosedevelopedintheusandbysubsidiariesabroad investmentsandactivitiesinsomecountriesoutsidetheusaresubjecttohigherrisksthancomparableusactivities becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomies restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertainties johnsonjohnsonannualreportraw materials rawmaterialsessentialtothecompanysbusinessaregenerallyreadilyavailablefrommultiplesourceswherethereare exceptionsthetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe financialresultsofthecompany patents thecompanyssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere possibletheyownorarelicensedunderasignificantnumberofpatentsintheusandothercountriesrelatingtotheir productsproductusesformulationsandmanufacturingprocesseswhichintheaggregatearebelievedtobeofmaterial importancetothecompanyintheoperationofitsbusinessesthecompanyssubsidiariesfacepatentchallengesfrom thirdpartiesincludingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsofthecompanys keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductssignificantlegal proceedingsandclaimsinvolvingthecompanyspatentandotherintellectualpropertyaredescribedinnotelegal proceedingsintellectualpropertyofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport salesofthecompanyslargestproductstelaraustekinumabaccountedforapproximatelyofthecompanys totalrevenuesforfiscalaccordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompany janssenbiotechincawhollyownedsubsidiaryofjohnsonjohnsonownspatentsspecificallyrelatedtostelara thelatestexpiringunitedstatespatentexpiresinthelatestexpiringeuropeanpatentexpiresin salesofthecompanyssecondlargestproductdarzalexdaratumumabanddarzalexfasprodaratumumab andhyaluronidasefihjaccountedforapproximatelyofthecompanystotalrevenuesforfiscal accordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompanygenmabasownspatents relatedtodarzalexandjanssenbiotechinchasanexclusivelicensetothosepatentsthelatestexpiringlicensed unitedstatespatentexpiresinthelatestexpiringlicensedeuropeanpatentexpiresinjanssenbiotechinc ownsaseparatepatentportfoliorelatedtodarzalexfaspro salesofthecompanysthirdlargestproductimbruvicaibrutinibaccountedforapproximatelyofthe companystotalrevenuesforfiscalaccordinglypatentsrelatedtothisproductarebelievedtobematerialtothe companypharmacyclicsllcanabbviecompanyownsthepatentsrelatedtoimbruvicaandjanssenbiotechinc hasanexclusivelicensetothosepatentsthepharmacyclicspatentsandtheirexpirationdatesarelistedintheapproved drugproductswiththerapeuticequivalenceevaluationsorangebookpharmacyclicsllcandjanssenbiotechinc haveenteredintoconfidentialsettlementagreementswithcertaingenericcompaniesgrantinglicensestomarkettheir genericibrutinibproductsintheunitedstatesbeforetheexpirationofcertainpatents trademarks thecompanyssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection forthesetrademarksbyallavailablemeansthesetrademarksareprotectedbyregistrationintheusandothercountries wheresuchproductsaremarketedthecompanyconsidersthesetrademarksintheaggregatetobeofmaterial importanceintheoperationofitsbusinesses seasonality worldwidesalesdonotreflectanysignificantdegreeofseasonalityhoweverspendinghasbeenheavierinthefourth quarterofeachyearthaninotherquartersthisreflectsincreasedspendingdecisionsprincipallyforadvertisingand researchanddevelopmentactivity competition inalloftheirproductlinesthecompanyssubsidiariescompetewithcompaniesbothlocallyandgloballycompetition existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolvedcompetitionin researchbothinternallyandexternallysourcedinvolvingthedevelopmentandtheimprovementofnewandexisting productsandprocessesisparticularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotecting theunderlyingintellectualpropertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareas ofitsbusinessthecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvesignificant expendituresforadvertisingandpromotion johnsonjohnsonannualreport environment thecompanyissubjecttoavarietyofusandinternationalenvironmentalprotectionmeasuresthecompanybelieves thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulationsthecompanys compliancewiththeserequirementsdidnotchangeduringthepastyearandisnotexpectedtohaveamaterialeffect uponitscapitalexpenditurescashflowsearningsorcompetitiveposition regulation thecompanysbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperations areconductedandthegeneraltrendistowardincreasinglystringentregulationandenforcementthecompanyissubject tocostlyandcomplexusandforeignlawsandgovernmentalregulationsandanyadverseregulatoryactionmay materiallyadverselyaffectthecompanysfinancialconditionandbusinessoperationsintheusthedrugdeviceand cosmeticindustrieshavelongbeensubjecttoregulationbyvariousfederalandstateagenciesprimarilyastoproduct safetyefficacymanufacturingadvertisinglabelingandsafetyreportingtheexerciseofbroadregulatorypowersbythe usfoodanddrugadministrationtheusfdacontinuestoresultinincreasesintheamountsoftestingand documentationrequiredforusfdaapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseof productintroductionsimilartrendsarealsoevidentinmajormarketsoutsideoftheusthenewmedicaldevice regulatoryframeworkandthenewprivacyregulationsineuropeandinothercountriesareexamplesofsuchincreased regulation theregulatoryagenciesunderwhosepurviewthecompanyoperateshaveadministrativepowersthatmaysubjectitto actionssuchasproductwithdrawalsrecallsseizureofproductsandothercivilandcriminalsanctionsinsomecasesthe companyssubsidiariesmaydeemitadvisabletoinitiateproductrecalls theusfdaandregulatoryagenciesaroundtheglobearealsoincreasingtheirenforcementactivitiesiftheusfda weretoconcludethatwearenotincompliancewithapplicablelawsorregulationsorthatanyofourdrugsormedical devicesareineffectiveorposeanunreasonablehealthrisktheusfdacouldbansuchproductsdetainorseize adulteratedormisbrandedproductsorderarecallrepairreplacementorrefundofsuchproductsrefusetogrant pendingapplicationsformarketingauthorizationorrequirecertificatesofforeigngovernmentsforexportsandorrequire ustonotifyhealthprofessionalsandothersthattheproductspresentunreasonablerisksofsubstantialharmtothepublic healththeusfdamayalsoassesscivilorcriminalpenaltiesagainstusourofficersoremployeesandimpose operatingrestrictionsonacompanywidebasisorenjoinandorrestraincertainconductresultinginviolationsof applicablelawtheusfdamayalsorecommendprosecutiontotheusdepartmentofjusticeanyadverseregulatory actiondependingonitsmagnitudemayrestrictusfromeffectivelymarketingandsellingourproductsandlimitourability toobtainfutureclearancesorapprovalsandcouldresultinasubstantialmodificationtoourbusinesspracticesand operationsequivalentenforcementmechanismsexistindifferentcountriesinwhichweconductbusiness thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudyinvestigationandregulationby governmentalagenciesandlegislativebodiesaroundtheworldintheusattentionhasbeenfocusedbystates regulatoryagenciesandcongressondrugpricesandprofitsandprogramsthatencouragedoctorstowriteprescriptions forparticulardrugsortorecommenduseorpurchaseparticularmedicaldeviceslawsandregulationshavebeen enactedtorequireadherencetostrictcompliancestandardsandpreventfraudandabuseinthehealthcareindustrythere isincreasedfocusoninteractionsandfinancialrelationshipsbetweenhealthcarecompaniesandhealthcareproviders varioustransparencylawsandregulationsrequiredisclosuresofpaymentsandothertransfersofvaluemadetophysicians andteachinghospitalsandbeginningwithdisclosuresintocertainnonphysicianpractitionersfederalandforeign lawsgoverninginternationalbusinesspracticesrequirestrictcompliancewithantibriberystandardsandcertain prohibitionswithrespecttopaymentstoanyforeigngovernmentofficialpayershavebecomeamorepotentforceinthe marketplaceandincreasedattentionisbeingpaidtodrugandmedicaldevicepricingappropriatedrugandmedical deviceutilizationandthequalityandcostsofhealthcaregenerally usgovernmentagenciescontinueeffortstorepealmodifyorinvalidateprovisionsofthepatientprotectionand affordablecareacttheacawhichpassedinforexamplefederallegislationrepealedtheacasindividual mandatetaxpenaltyaswellasthetaxongenerousemployersponsoredhealthcareplansthecenterformedicare medicaidservicescmsbeganpermittingstatestoimposeworkrequirementsonpersonscoveredbymedicaid expansionplanscertainfederalsubsidiestoinsurershaveendedandcertainshortterminsuranceplansnotofferingthe fullarrayofacabenefitshavebeenallowedtoextendindurationsomeofthesechangesarebeingchallengedinus courtsandsotheirlongtermimpactremainsuncertaintheacahasalsobeensubjecttojudicialchallengeinnovember theussupremecourtheardargumentintexasvazarwhichchallengestheconstitutionalityoftheaca pendingresolutionofthelitigationalloftheacabuttheindividualmandatetobuyhealthinsuranceremainsineffectthe johnsonjohnsonannualreportusgovernmentalsocontinuestoproposeandimplementchangestothemedicarepartdbenefitincludingthesizeof manufacturerdiscountsinthecoveragegapandcatastrophicphasesofthebenefitthereareanumberofadditionalbills pendingincongressandhealthcarereformproposalsatthestatelevelthatwouldaffectdrugpricinginthemedicareand medicaidprogramsthischangingfederallandscapehasbothpositiveandnegativeimpactsontheushealthcare industrywithmuchremaininguncertainastohowvariousprovisionsoffederallawandpotentialmodificationorrepealof theselawswillultimatelyaffecttheindustry inadditionbusinesspracticesinthehealthcareindustryhavecomeunderincreasedscrutinyparticularlyintheusby governmentagenciesandstateattorneysgeneralandresultinginvestigationsandprosecutionscarrytheriskofsignificant civilandcriminalpenalties furtherthecompanyreliesonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexare subjecttoincreasingregulatoryrequirementsandmaybefacedwithunexpectedchangessuchasthoseresultingfrom thecovidpandemicandbrexitthatmayaffectsourcingsupplyandpricingofmaterialsusedinthecompanys productstheseprocessesalsoaresubjecttocomplexandlengthyregulatoryapprovals theglobalregulatorylandscapeisalsosubjecttochangeasthecovidpandemiccontinuestoaffecttheusand globaleconomiestheusfdaandotherhealthauthoritieshaveshiftedresourcesandprioritiestomeetthemany challengespresentedbythepandemicpandemicrelateddisruptionscouldnegativelyimpacttheprocessingofregulatory submissionsandslowagencyreviewtimesnecessaryfortheapprovalorclearanceofnewdrugsanddevicesthe durationandseverityofthecovidpandemicisunpredictableanddifficulttoassess employees human capital management asofjanuaryanddecemberthenumberofemployeeswereapproximately employees fulltimeequivalentftepositions employeeisdefinedasanindividualworkingfulltimeorparttimeexcludingfixedtermemployeesinternsandcoopemployees employeedatamaynotincludefullpopulationfrommorerecentlyacquiredcompaniesandindividualsonlongtermdisabilityare excludedcontingentworkerscontractorsandsubcontractorsarealsoexcluded fterepresentsthetotalnumberoffulltimeequivalentpositionsanddoesnotreflectthetotalnumberofindividualemployeesas someworkparttime employees region percentages asiapacific emea latin america north america strategy thecompanybelievesthatitsemployeesarecriticaltoitscontinuedsuccessandareanessentialelementofitslong termstrategymanagementisresponsibleforensuringthatitspoliciesandprocessesreflectandreinforcethecompanys desiredcorporatecultureincludingpoliciesandprocessesrelatedtostrategyriskmanagementandethicsand compliancethecompanyshumancapitalmanagementstrategyisbuiltonthreefundamentalfocusareas attractingandrecruitingthebesttalent johnsonjohnsonannualreport developingandretainingtalent empoweringandinspiringtalent underpinningthesefocusareasareongoingeffortstocultivateandfosteraculturebuiltondiversityequityandinclusion deiinnovationhealthwellbeingandsafetywherethecompanysemployeesareencouragedtosucceedboth professionallyandpersonallywhilehelpingthecompanyachieveitsbusinessgoals cultureandemployeeengagement atjohnsonjohnsonemployeesareguidedbyourcredowhichsetsforththecompanysresponsibilitiestopatients consumerscustomershealthcareprofessionalsemployeescommunitiesandshareholdersemployeesworldwideare furtherguidedbythecompanyscodeofbusinessconductwhichsetsbasicrequirementsforbusinessconductand servesasafoundationforthecompanypoliciesproceduresandguidelinesallofwhichprovideadditionalguidanceon expectedemployeebehaviorsineverymarketwhereitoperatesthecompanyconductsglobalsurveysthatofferits employeestheabilitytoprovidefeedbackandvaluableinsighttohelpaddresspotentialhumanresourcesrisksandidentify opportunitiestoimproveinofglobalemployeesacrosscountriesparticipatedinourcredosurveywhich isofferedinlanguages growthanddevelopment tocontinuetoleadinthechanginghealthcarelandscapeitiscrucialthatthecompanycontinuetoattractandretaintop talentthecompanybelievesthatitsemployeesmustbeequippedwiththerightknowledgeandskillsandbeprovided withopportunitiestogrowanddevelopintheircareersaccordinglyprofessionaldevelopmentprogramsandeducational resourcesareavailabletoallemployeesthecompanysobjectiveistofosteralearningculturethathelpsshapeeach personsuniquecareerpathwhilecreatingarobustpipelineoftalenttodeliveronthecompanyslongtermstrategiesin furtheranceofthisobjectivethecompanydeploysaglobalapproachtoensuredevelopmentisforeveryoneregardlessof wheretheyareontheircareerjourneyinofemployeesinmanagerandabovejobcategoriestookadvantage ofcareeropportunitiesbymovingacrossfunctionscountryorbusinesssegmentlinesincludingupwardpromotionor lateraltransferandexcludingemployeesintheresearchanddevelopmentorganizationsthecompanysvoluntary turnoverratewas diversityequityandinclusiondei thecompanyiscommittedtoworkplacediversityandtocultivatingfosteringandadvancingacultureofequityand inclusionenablingemployeestoperformattheirbestwhilebeingthemselvesisfundamentaltothecompanyscontinued successthecompanysdeivisionisbeyourselfchangetheworldthecompanysdeistrategyfocusesonthreepillars thatreflectthestrategicprioritiesidentifiedtoenablethecompanytoaddressthechallengesandopportunitiespresented bythisevolvingunderstandingofdiversity acceleratethecompanyseffortstoadvanceacultureofinclusionandinnovation buildadiverseworkforceforthefuture enhancebusinessresultsandreputation thecompanysdeistrategyisguidedbyinternalandexternalinsightsglobalbestpracticesandcontinualemployee feedbackwhichremindthecompanythatwhilediversitychangesbylocationinclusionisthesameeverywhere compensationandbenefits aspartofthecompanystotalrewardsphilosophythecompanyofferscompetitivecompensationandbenefitstoattract andretaintoptalentthecompanyiscommittedtofairnessandequitabletreatmentinitscompensationandbenefitsfor employeesatalllevelsthecompanyobserveslegalminimumwageprovisionsandexceedsthemwherepossiblethe companystotalrewardsofferingsincludeanarrayofprogramstosupportitsemployeesfinancialphysicalandmental wellbeingincludingannualperformanceincentiveopportunitiespensionandretirementsavingsprogramshealthand welfarebenefitspaidtimeoffleaveprogramsflexibleworkschedulesandemployeeassistanceprograms healthwellnessandsafety thecompanysinvestmentinemployeehealthwellbeingandsafetyisbuiltonitsconvictionthatadvancinghealthfor humanitystartswithadvancingthehealthofitsemployeeswiththerightawarenessfocuspracticesandtoolsthe johnsonjohnsonannualreportcompanyensuresthatallitsemployeesaroundtheworldaswellastemporarycontractorsandvisitorstothecompanys sitescanworksafelythecompanyhascontinuouslyexpandedhealthandwellbeingprogramsthroughoutthecompany andacrosstheglobeincorporatingnewthinkingandtechnologiestokeepitsofferingsbestinclassandtohelp employeesachievetheirpersonalmindandbodyhealthgoalstheprogramsandpracticesthecompanyadvancescovers threecoredimensionshealthyeatinghealthymovementandhealthymind available information thecompanysmaincorporatewebsiteaddressiswwwjnjcomallofthecompanyssecfilingsarealsoavailableonthe companyswebsiteatwwwinvestorjnjcomseccfmassoonasreasonablypracticableafterhavingbeenelectronically filedorfurnishedtothesecallsecfilingsarealsoavailableatthesecswebsiteatwwwsecgov investorsandthepublicshouldnotethatthecompanyalsoannouncesinformationat wwwfactsaboutourprescriptionopioidscomandwwwfactsabouttalccomweusethesewebsitestocommunicatewith investorsandthepublicaboutourproductslitigationandothermattersitispossiblethattheinformationweposttothese websitescouldbedeemedtobematerialinformationthereforeweencourageinvestorsandothersinterestedinthe companytoreviewtheinformationpostedtothesewebsitesinconjunctionwithwwwjnjcomthecompanyssecfilings pressreleasespublicconferencecallsandwebcasts inadditiontheamendedandrestatedcertificateofincorporationbylawsthewrittenchartersoftheauditcommittee thecompensationbenefitscommitteethenominatingcorporategovernancecommitteetheregulatory compliancecommitteeandthesciencetechnologysustainabilitycommitteeoftheboardofdirectorsandthe companysprinciplesofcorporategovernancecodeofbusinessconductforemployeescodeofbusiness conductethicsformembersoftheboardofdirectorsandexecutiveofficersandothercorporategovernance materialsareavailableatwwwinvestorjnjcomgovcfmonthecompanyswebsiteandwillbeprovidedwithoutchargeto anyshareholdersubmittingawrittenrequestasprovidedabovetheinformationonwwwjnjcom wwwfactsaboutourprescriptionopioidscomandwwwfactsabouttalccomisnotandwillnotbedeemedapartofthisreport orincorporatedintoanyotherfilingsthecompanymakeswiththesec item risk factors aninvestmentinthecompanyscommonstockordebtsecuritiesinvolvesrisksanduncertaintiesthecompanyseeksto identifymanageandmitigateriskstoourbusinessbutuncertaintiesandrisksaredifficulttopredictandmanyareoutside ofthecompanyscontrolandcannotthereforebeeliminatedinadditiontotheotherinformationinthisreportandthe companysotherfilingswiththesecinvestorsshouldconsidercarefullythefactorssetforthbelowinvestorsshouldbe awarethatitisnotpossibletopredictoridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacomplete discussionofallpotentialrisksoruncertaintiesifknownorunknownrisksoruncertaintiesmaterializethecompanys businessresultsofoperationsorfinancialconditioncouldbeadverselyaffectedpotentiallyinamaterialway risks related business industry operations thecompanysbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould adverselyaffectthecompanysearnings thecompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarketsthecompanys businessescompetewithcompaniesofallsizesonthebasisofcosteffectivenesstechnologicalinnovationsintellectual propertyrightsproductperformancerealorperceivedproductadvantagespricingandavailabilityandrateof reimbursementthecompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisitions collaborationsandlicensingagreementswiththirdpartiescompetitionforrightstoproductcandidatesandtechnologies mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsforthecompanycompetitors developmentofmoreeffectiveorlesscostlyproductsandortheirabilitytosecurepatentandotherintellectualproperty rightsandsuccessfullymarketproductsaheadofthecompanycouldnegativelyimpactsalesofthecompanysexisting productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct development forthecompanyspharmaceuticalbusinesseslossofpatentexclusivityforaproductoftenisfollowedbyasubstantial reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproductforthecompanysmedicaldevice businessestechnologicalinnovationproductqualityreputationandcustomerserviceareespeciallyimportantto johnsonjohnsonannualreport competitivenessdevelopmentbyothercompaniesofneworimprovedproductsprocessesandtechnologiescould threatentomakethecompanysproductsortechnologieslessdesirablelesseconomicalorobsoletethecompanys consumerhealthbusinessesfaceintensecompetitionfromotherbrandedproductsandretailersprivatelabelbrandsifthe companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproductsthiscouldadverselyaffect revenuesandprofitabilityofthoseproducts interruptionsanddelaysinmanufacturingoperationscouldadverselyaffectthecompanysbusinesssales andreputation thecompanysmanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplexhighquality componentsandmaterialsthecompanyssubsidiariesoperatemanufacturingfacilitiesaswellassourcingfrom hundredsofsuppliersaroundtheworldthecompanyhasinthepastandmayinthefuturefaceunanticipated interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychainmanufacturingdisruptionscanoccur formanyreasonsincludingregulatoryactionproductionqualitydeviationsorsafetyissueslabordisputessitespecific incidentssuchasfiresnaturaldisasterssuchashurricanesandothersevereweathereventsrawmaterialshortages politicalunrestterroristattacksandepidemicsorpandemicssuchdelaysanddifficultiesinmanufacturingcanresultin productshortagesdeclinesinsalesandreputationalimpactaswellassignificantremediationandrelatedcostsassociated withaddressingtheshortage thecompanyreliesonthirdpartiestomanufacturecertainofourproductsanyfailurebyorlossofathird partymanufacturercouldresultindelaysandincreasedcostswhichmayadverselyaffectourbusiness thecompanyreliesonthirdpartiestomanufacturecertainofourproductswedependonthesethirdparty manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneedstoproduceproducts ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat acceptablepriceshoweverwecannotguaranteethatthesethirdpartymanufacturerswillbeabletomeetournearterm orlongtermmanufacturingrequirementswhichcouldresultinlostsalesandhaveanadverseeffectonourbusiness otherrisksassociatedwithourrelianceonthirdpartiesincludingthecompanysstrategicpartnershipwithjabilinthe medicaldevicessegmenttomanufacturetheseproductsincluderelianceonthethirdpartyforregulatorycomplianceand qualityassurancemisappropriationofthecompanysintellectualpropertylimitedabilitytomanageourinventorypossible breachofthemanufacturingagreementbythethirdpartyandthepossibleterminationornonrenewalofthemanufacturing agreementbythethirdpartyatatimethatiscostlyorinconvenientforusmoreoverifanyofourthirdpartymanufacturers sufferanydamagetofacilitieslosebenefitsundermaterialagreementsexperiencepoweroutagesencounterfinancial difficultiesareunabletosecurenecessaryrawmaterialsfromtheirsuppliersorsufferanyotherreductioninefficiencythe companymayexperiencesignificantbusinessdisruptionintheeventofanysuchdisruptionthecompanywouldneedto seekandsourceotherqualifiedthirdpartymanufacturerslikelyresultinginfurtherdelaysandincreasedcostswhichcould affectourbusinessadversely counterfeitversionsofourproductscouldharmourpatientsandhaveanegativeimpactonourrevenues earningsreputationandbusiness ourindustrycontinuestobechallengedbythevulnerabilityofdistributionchannelstoillegalcounterfeitingandthe presenceofcounterfeitproductsinagrowingnumberofmarketsandovertheinternetthirdpartiesmayillegallydistribute andsellcounterfeitversionsofourproductswhichdonotmeetourrigorousmanufacturingandtestingstandardsto distributorsandpatientscounterfeitproductsmaybevisuallyindistinguishablefromtheauthenticversioncounterfeit medicinesposearisktopatienthealthandsafetybecauseoftheconditionsunderwhichtheyaremanufacturedoftenin unregulatedunlicenseduninspectedandunsanitarysitesaswellasthelackofregulationoftheircontents theindustrysfailuretomitigatethethreatofcounterfeitmedicinescouldadverselyimpactourbusinessandreputationby impactingpatientconfidenceinourauthenticproductspotentiallyresultinginlostsalesproductrecallsandanincreased threatoflitigationinadditiondiversionofourproductsfromtheirauthorizedmarketintootherchannelsmayresultin reducedrevenuesandnegativelyaffectourprofitability thecovidpandemichasadverselyimpactedcertainaspectsofthecompanysbusinessandcould causedisruptionsorfutureimpacttothecompanysbusinessresultsofoperationsandfinancial condition wearesubjecttorisksassociatedwithglobalhealthcrisesandpandemicsincludingtheglobaloutbreakofthenovel coronavirusanditsmutationscovidthecovidpandemichasadverselyimpactedandisexpectedtocontinue toadverselyimpactcertainaspectsofthecompanysbusinessresultsofoperationsandfinancialconditionincluding johnsonjohnsonannualreportlowersalesandreducedcustomerdemandandusageofcertainofourproductsthespreadofcovidhascaused thecompanytomodifyitsbusinesspracticesincludinginstitutingremoteworkformanyofthecompanysemployees andthecompanymaytakefurtheractionsasmayberequiredbygovernmentauthoritiesorasthecompanydetermines areinthebestinterestsofourpatientscustomersemployeesandbusinesspartnersthecompanycontinuestomonitor thesituationandwhilewehaverobustbusinesscontinuityplansinplaceacrossourglobalsupplychainnetworktohelp mitigatetheimpactofcovidtheseeffortsmaynotcompletelypreventourbusinessfrombeingadverselyaffected andfutureimpactsremainuncertain whiletheusandothercountrieshavebegunorwillbegintoreopentheireconomiestheextenttowhichcovidwill impactthecompanysfutureoperationswilldependonmanyfactorswhichcannotbepredictedwithconfidence includingthedurationoftheoutbreakanyresurgenceincovidinfectionscouldresultintheimpositionofnew mandatesandprolongedrestrictivemeasuresimplementedinordertocontrolthespreadofthediseasethecontinued globalspreadofcovidcouldadverselyimpactthecompanysoperationsincludingamongotherthingsour manufacturingoperationssupplychainincludingthirdpartysupplierssalesandmarketingandclinicaltrialoperations anyofthesefactorscouldadverselyaffectthecompanysbusinessfinancialresultsandglobaleconomicconditions generally wealsofaceuncertaintiesrelatedtooureffortstodevelopacovidvaccinecandidateincludinguncertaintiesrelated totheriskthatourdevelopmentprogramsmaynotbesuccessfulcommerciallyviableorreceiveapprovaloremergency useauthorizationfromregulatoryauthoritiesrisksassociatedwithclinicaltrialdataincludingfurtheranalysesofexisting preclinicalorclinicaltrialdatathatmaybeinconsistentwiththedatausedforselectionofthejnjvaccine candidateanddoselevelforthephaseensembletrialtheriskthatclinicaltrialdataaresubjecttodiffering interpretationsandassessmentsincludingduringthepeerreviewpublicationprocessinthescientificcommunity generallyandbyregulatoryauthoritiesdisruptionsintherelationshipsbetweenusourthirdpartysuppliersandexternal manufacturerstheriskthatothercompaniesmayproducesuperiororcompetitiveproductstheriskthatdemandforany productswemaydevelopmaynolongerexistrisksrelatedtotheavailabilityofrawmaterialstomanufactureanysuch productstheriskthatwemaynotbeabletorecoupcostsassociatedwithourrdandmanufacturingeffortsandrisks associatedwithanychangesinthewayweapproachorprovideadditionalresearchfundingforpotentialdrug developmentrelatedtocovidtheriskthatwemaynotbeabletocreateorscaleupmanufacturingcapacityona timelybasisthatwemayexperiencemanufacturingdelaysonceamanufacturingsiteisactivatedorhaveaccessto logisticsorsupplychannelscommensuratewithglobaldemandforanypotentialapprovedvaccineorproductcandidate whichwouldnegativelyimpactourabilitytosupplytheestimatednumbersofdosesofourvaccinecandidatewithinthe projectedtimeperiodsindicatedandotherchallengesandrisksassociatedwiththepaceofourvaccinedevelopment programandpricingandaccesschallengesforsuchproductsincludingintheus inadditiontotheextentthecovidpandemicadverselyaffectsourbusinessandfinancialresultsitmayalsohavethe effectofheighteningmanyoftheotherrisksdescribedinthisriskfactorssectionandthoseincorporatedbyreference hereinincludingrisksrelatingtothecompanyseffectivetaxrateasaresultofchangesinconsumptionaswellas changesinlawsrelatingtosupplyofthecompanysproductsgiventhatdevelopmentsconcerningthecovid pandemichavebeenconstantlyevolvingadditionalimpactsandrisksmayariseincludinglitigationthatarenotpresently knowntothecompany risk related government regulation legal proceedings globalsalesinthecompanyspharmaceuticalandmedicaldevicessegmentsmaybenegatively impactedbyhealthcare reformsandincreasingpricingpressures salesofthecompanyspharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby thirdpartypayerssuchasgovernmenthealthcareprogramsprivateinsuranceplansandmanagedcareorganizationsas partofvariouseffortstocontainhealthcarecoststhesepayersareputtingdownwardpressureonpricesatwhich productswillbereimbursedintheusincreasedpurchasingpowerofentitiesthatnegotiateonbehalfofmedicare medicaidandprivatesectorbeneficiariesinpartduetocontinuedconsolidationamonghealthcareproviderscould resultinfurtherpricingpressuresinadditionincreasedpoliticalscrutinycouldresultinadditionalpricingpressures outsidetheusnumerousmajormarketsincludingtheeuunitedkingdomandjapanhavepervasivegovernment involvementinfundinghealthcareandinthatregarddirectlyorindirectlyimposepricecontrolslimitaccesstoor reimbursementforthecompanysproductsorreducethevalueofitsintellectualpropertyprotection johnsonjohnsonannualreport thecompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpenses finesandreputationaldamage intheordinarycourseofbusinessjohnsonjohnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuits involvingvariousissuessuchaspatentdisputesproductliabilityandclaimsthattheirproductsalesmarketingandpricing practicesviolatevariousantitrustunfairtradepracticesandorconsumerprotectionlawsthecompanysmoresignificant legalproceedingsaredescribedinnotelegalproceedingsundernotestotheconsolidatedfinancialstatements includedinitemofthisreportlitigationingeneralandsecuritiesderivativeactionclassactionandmultidistrict litigationinparticularcanbeexpensiveanddisruptivesomeofthesemattersmayincludethousandsofplaintiffsmay involvepartiesseekinglargeandorindeterminateamountsincludingpunitiveorexemplarydamagesandmayremain unresolvedforseveralyearsforexamplethecompanyisadefendantinnumerouslawsuitsarisingoutoftheuseofbody powderscontainingtalcprimarilyjohnsonsbabypowderandthecompanyssalemanufacturingandmarketingof opioidswhilethecompanybelievesithassubstantialdefensesinthesemattersitisnotfeasibletopredicttheultimate outcomeoflitigationthecompanycouldinthefutureberequiredtopaysignificantamountsasaresultofsettlementsor judgmentsinthesematterspotentiallyinexcessofaccrualsincludingmatterswherethecompanycouldbeheldjointly andseverallyliableamongotherdefendantstheresolutionoforincreaseinaccrualsforoneormoreofthesemattersin anyreportingperiodcouldhaveamaterialadverseeffectonthecompanysresultsofoperationsandcashflowsforthat periodthecompanydoesnotpurchasethirdpartyproductliabilityinsurancehoweverthecompanyutilizesawholly ownedcaptiveinsurancecompanysubjecttocertainlimits productreliabilitysafetyandeffectivenessconcernscanhavesignificantnegativeimpactson salesandresultsofoperationsleadtolitigationandcausereputationaldamage concernsaboutproductsafetywhetherraisedinternallyorbylitigantsregulatorsorconsumeradvocatesandwhetheror notbasedonscientificevidencecanresultinsafetyalertsproductrecallsgovernmentalinvestigationsregulatoryaction onthepartoftheusfoodanddrugadministrationoritscounterpartinothercountriesprivateclaimsandlawsuits paymentoffinesandsettlementsdecliningsalesandreputationaldamagethesecircumstancescanalsoresultin damagetobrandimagebrandequityandconsumertrustinthecompanysproductsproductrecallshaveinthepast andcouldinthefuturepromptgovernmentinvestigationsandinspectionstheshutdownofmanufacturingfacilities continuedproductshortagesandrelatedsalesdeclinessignificantremediationcostsreputationaldamagepossiblecivil penaltiesandcriminalprosecution thecompanyfacessignificantregulatoryscrutinywhichimposessignificantcompliancecosts andexposesthecompanytogovernmentinvestigationslegalactionsandpenalties likeothercompaniesinthehealthcareindustrythecompanyissubjecttoextensiveregulationinvestigationsandlegal actionbynationalstateandlocalgovernmentagenciesintheusandothercountriesinwhichtheyoperateregulatory issuesregardingcompliancewithcurrentgoodmanufacturingpracticescgmpandcomparablequalityregulationsin foreigncountriesbymanufacturersofdrugsdevicesandconsumerproductscanleadtofinesandpenaltiesproduct recallsproductshortagesinterruptionsinproductiondelaysinnewproductapprovalsandlitigationinadditionthe marketingpricingandsaleofthecompanysproductsaresubjecttoregulationinvestigationsandlegalactionsincluding underthefederalfooddrugandcosmeticactthemedicaidrebateprogramfederalandstatefalseclaimsactsstate unfairtradepracticesactsandconsumerprotectionlawsscrutinyofhealthcareindustrybusinesspracticesby governmentagenciesandstateattorneysgeneralintheusandanyresultinginvestigationsandprosecutionscarryrisk ofsignificantcivilandcriminalpenaltiesincludingbutnotlimitedtodebarmentfromparticipationingovernment healthcareprogramsanysuchdebarmentcouldhaveamaterialadverseeffectonthecompanysbusinessandresultsof operationsthemostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin notelegalproceedingsgovernmentproceedingsundernotestotheconsolidatedfinancialstatementsincluded initemofthisreport changesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpactthecompanys operatingresults changesintaxlawsorregulationsaroundtheworldcouldnegativelyimpactthecompanyseffectivetaxrateandresults ofoperationsachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthecompanysdeferredtax assetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawisenactedthischange wouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementofearningsthecompany closelymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothestatutorytaxratemay occuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarterandyearinwhichthe lawchangeisenacted johnsonjohnsonannualreportseenoteonincometaxesforadditionalinformation thecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddisputes withmanytaxauthoritiesinconnectionwiththeorganizationforeconomiccooperationanddevelopmentbase erosionandprofitshiftingbepsprojectcompaniesarerequiredtodisclosemoreinformationtotaxauthoritieson operationsaroundtheworldwhichmayleadtogreaterauditscrutinyofprofitsearnedinothercountriesthecompany regularlyassessesthelikelyoutcomesofitstaxauditsanddisputestodeterminetheappropriatenessofitstaxreserves howeveranytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothecompanysexpectationswhich couldresultintaxliabilitiesinexcessofreserves risks related intellectual property thecompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto thecompanysbusinesses thecompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsrelatingtoitsproductsand manufacturingprocessestheserightsareessentialtothecompanysbusinessesandmateriallyimportanttothe companysresultsofoperationspublicpolicybothwithinandoutsidetheushasbecomeincreasinglyunfavorable towardintellectualpropertyrightsthecompanycannotbecertainthatitwillobtainadequatepatentprotectionfornew productsandtechnologiesintheunitedstatesandotherimportantmarketsorthatsuchprotectionsoncegrantedwill lastaslongasoriginallyanticipated competitorsroutinelychallengethevalidityorextentofthecompanysownedorlicensedpatentsandproprietaryrights throughlitigationinterferencesoppositionsandotherproceedingssuchasinterpartesreviewiprproceedingsbefore theunitedstatespatenttrademarkofficeusptotheseproceedingsabsorbresourcesandcanbeprotractedas wellasunpredictableinadditionchallengesthatthecompanysproductsinfringethepatentsofthirdpartiescouldresult intheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionandsalesofthe productsinquestion thecompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand biosimilarversionsofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering thoseproductsintheusmanufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay challengethevalidityorclaimnoninfringementofinnovatorproductsthroughtheabbreviatednewdrugapplicationor andaprocesswiththefdaandrelatedandalitigationthebiologicspricecompetitionandinnovationactbpcia enactedinwhichcreatedanewregulatorypathwayfortheapprovalbythefdaofbiosimilaralternativesto innovatordevelopedbiologicalproductsalsocreatedmechanismsforbiosimilarapplicantstochallengethepatentson theinnovatorbiologicstheiprprocesswiththeusptoisalsobeingusedbycompetitorstochallengepatentsasserted inlitigation intheeventthecompanyisnotsuccessfulindefendingitspatentsagainstsuchchallengesorupontheatrisklaunch despitependingpatentinfringementlitigationbythegenericorbiosimilarfirmofitsproductthecompanycanlosea majorportionofrevenuesforthereferencedproductinaveryshortperiodoftimecurrentlegalproceedingsinvolvingthe companyspatentsandotherintellectualpropertyrightsaredescribedinnotelegalproceedingsintellectual propertyofthenotestotheconsolidatedfinancialstatementsincludedinitemofthisreport risksrelatedtoproductdevelopmentregulatoryapprovalandcommercialization significantchallengesordelaysinthecompanysinnovationanddevelopmentofnewproducts technologiesandindicationscouldhaveanadverseimpactonthecompanyslongtermsuccess thecompanyscontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiated productsandservicesthataddresstheevolvinghealthcareneedsofpatientsprovidersandconsumersdevelopmentof successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhenthecompanysexistingproducts losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivitynewproductsintroduced withinthepastfiveyearsaccountedforapproximatelyofsalesthecompanycannotbecertainwhenor whetheritwillbeabletodeveloplicenseorotherwiseacquirecompaniesproductsandtechnologieswhetherparticular productcandidateswillbegrantedregulatoryapprovalandifapprovedwhethertheproductswillbecommercially successful johnsonjohnsonannualreport thecompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaborations acquisitionsjointventuresandlicensingorotherarrangementswiththirdpartiesinallofthesecontextsdevelopingnew productsparticularlypharmaceuticalandbiotechnologyproductsandmedicaldevicesrequiressignificantinvestmentof resourcesovermanyyearsonlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially viableproductstheprocessdependsonmanyfactorsincludingtheabilitytodiscernpatientsandhealthcareproviders futureneedsdeveloppromisingnewcompoundsstrategiesandtechnologiesachievesuccessfulclinicaltrialresults secureeffectiveintellectualpropertyprotectionobtainregulatoryapprovalsonatimelybasisandifandwhentheyreach themarketsuccessfullydifferentiatethecompanysproductsfromcompetingproductsandapproachestotreatment newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue toproductandpricecompetitionchangesincustomerpreferencesorhealthcarepurchasingpatternsresistanceby healthcareprovidersoruncertaintyoverthirdpartyreimbursementevenfollowinginitialregulatoryapprovalthesuccess ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulationsaswellas marketentryofcompetitiveproducts risk related financial economic market conditions thecompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally thecompanysextensiveoperationsandbusinessactivityoutsidetheusareaccompaniedbycertainfinancial economicandpoliticalrisksincludingthoselistedbelow foreigncurrencyexchangeinfiscalapproximatelyofthecompanyssalesoccurredoutsideoftheuswith approximatelyineuropeinthewesternhemisphereexcludingtheusandintheasiapacificandafrica regionchangesinnonuscurrenciesrelativetotheusdollarimpactthecompanysrevenuesandexpenseswhile thecompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflows unhedgedexposurescontinuetobesubjecttocurrencyfluctuationsinadditiontheweakeningorstrengtheningofthe usdollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe companysnonusbusinessactivityaretranslatedintousdollars inflationandcurrencydevaluationrisksthecompanyfaceschallengesinmaintainingprofitabilityofoperationsin economiesexperiencinghighinflationratesthecompanyhasaccountedforoperationsinargentinabeginninginthe fiscalthirdquarterofandvenezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassed whilethecompanystrivestomaintainprofitmarginsintheseareasthroughcostreductionprogramsproductivity improvementsandperiodicpriceincreasesitmightexperienceoperatinglossesasaresultofcontinuedinflationin additiontheimpactofcurrencydevaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchange fluctuationscouldnegativelyimpactthecompanysoperatingresults illegalimportationofpharmaceuticalproductstheillegalimportationofpharmaceuticalproductsfromcountrieswhere governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffectthecompanyssalesand profitabilityintheusandothercountriesinwhichthecompanyoperateswiththeexceptionoflimitedquantitiesof prescriptiondrugsforpersonaluseforeignimportsofpharmaceuticalproductsareillegalundercurrentuslaw howeverthevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower pricedimportshasgrownsignificantly antibriberyandotherregulationsthecompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational businesspracticeswithrespecttopaymentstogovernmentofficialsthoselawsincludetheusforeigncorrupt practicesactfcpawhichprohibitsuspubliclytradedcompaniesfrompromisingofferingorgivinganythingofvalue toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingthecompanyobtain orretainbusinessorgainanyimproperadvantagethecompanysbusinessisheavilyregulatedandthereforeinvolves significantinteractionwithforeignofficialsalsoinmanycountriesoutsidetheusthehealthcareproviderswho prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare governmententitiesthereforethecompanysinteractionswiththeseprescribersandpurchasersaresubjecttoregulation underthefcpainadditiontotheusapplicationandenforcementofthefcpavariousjurisdictionsinwhichthe companyoperateshavelawsandregulationsincludingtheukbriberyactaimedatpreventingandpenalizing corruptandanticompetitivebehaviorenforcementactivitiesundertheselawscouldsubjectthecompanytoadditional administrativeandlegalproceedingsandactionswhichcouldincludeclaimsforcivilpenaltiescriminalsanctionsand administrativeremediesincludingexclusionfromhealthcareprograms johnsonjohnsonannualreportotherlegalsocialandpoliticalrisksotherrisksinherentinconductingbusinessgloballyinclude protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimportexportlicensing requirements compliancewithlocalregulationsandlawsincludinginsomecountriesregulatoryrequirementsrestrictingthe companysabilitytomanufactureorsellitsproductsintherelevantmarket diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdictions potentialnationalizationorexpropriationofthecompanysforeignassets politicalorsocialupheavalseconomicinstabilityrepressionorhumanrightsissuesand geopoliticaleventsincludingnaturaldisastersdisruptionstomarketsduetowararmedconflictterrorismepidemicsor pandemics failuretomaintainasatisfactorycreditratingcouldadverselyaffectourliquiditycapitalposition borrowingcostsandaccesstocapitalmarkets wecurrentlymaintaininvestmentgradecreditratingswithmoodysinvestorsserviceandstandardpoorsratings servicesratingagenciesroutinelyevaluateusandtheirratingsofourlongtermandshorttermdebtarebasedona numberoffactorsanydowngradeofourcreditratingsbyacreditratingagencywhetherasaresultofouractionsor factorswhicharebeyondourcontrolcanincreasethecostofborrowingunderanyindebtednesswemayincurreduce marketcapacityforourcommercialpaperorrequirethepostingofadditionalcollateralunderourderivativecontracts therecanbenoassurancethatwewillbeabletomaintainourcreditratingsandanyadditionalactualoranticipated changesordowngradesinourcreditratingsincludinganyannouncementthatourratingsareunderreviewfora downgrademayhaveanegativeimpactonourliquiditycapitalpositionandaccesstocapitalmarkets risks ourbusinessdependsonourabilitytorecruitandretaintalentedhighlyskilledemployeesandadiverse workforce ourcontinuedgrowthrequiresustorecruitandretaintalentedemployeesrepresentingdiversebackgroundsexperiences andskillsetsthemarketforhighlyskilledworkersandleadersinourindustryisextremelycompetitiveandourabilityto competedependsonourabilitytohiredevelopandmotivatehighlyskilledpersonnelinallareasofourorganization maintainingourbrandandreputationaswellasadiverseequitableandinclusiveworkenvironmentenablesustoattract toptalentifwearelesssuccessfulinourrecruitingeffortsorifwecannotretainhighlyskilledworkersandkeyleaders ourabilitytodevelopanddeliversuccessfulproductsandservicesmaybeadverselyaffectedinadditioneffective successionplanningisimportanttoourlongtermsuccessanyunsuccessfulimplementationofoursuccessionplansor failuretoensureeffectivetransferofknowledgeandsmoothtransitionsinvolvingkeyemployeescouldadverselyaffectour businessfinancialconditionorresultsofoperations aninformationsecurityincidentincludingacybersecuritybreachcouldhaveanegativeimpacttothe companysbusinessorreputation tomeetbusinessobjectivesthecompanyreliesonbothinternaltechnologyitsystemsandnetworksandthoseof thirdpartiesandtheirvendorstoprocessandstoresensitivedataincludingconfidentialresearchbusinessplans financialinformationintellectualpropertyandpersonaldatathatmaybesubjecttolegalprotectionandensurethe continuityofthecompanyssupplychaintheextensiveinformationsecurityandcybersecuritythreatswhichaffect companiesgloballyposearisktothesecurityandavailabilityofthesesystemsandnetworksandtheconfidentiality integrityandavailabilityofthecompanyssensitivedatathecompanycontinuallyassessesthesethreatsandmakes investmentstoincreaseinternalprotectiondetectionandresponsecapabilitiesaswellasensurethecompanysthird partyprovidershaverequiredcapabilitiesandcontrolstoaddressthisrisktodatethecompanyhasnotexperiencedany materialimpacttothebusinessoroperationsresultingfrominformationorcybersecurityattackshoweverbecauseofthe frequentlychangingattacktechniquesalongwiththeincreasedvolumeandsophisticationoftheattacksthereisthe potentialforthecompanytobeadverselyimpactedthisimpactcouldresultinreputationalcompetitiveoperationalor otherbusinessharmaswellasfinancialcostsandregulatoryactionthecompanymaintainscybersecurityinsurancein theeventofaninformationsecurityorcyberincidenthoweverthecoveragemaynotbesufficienttocoverallfinancial legalbusinessorreputationallosses johnsonjohnsonannualreport climatechangeorlegalregulatoryormarketmeasurestoaddressclimatechangemaynegativelyaffect ourbusinessandresultsofoperations climatechangeresultingfromincreasedconcentrationsofcarbondioxideandothergreenhousegasesintheatmosphere couldpresentriskstoouroperationsincludinganadverseimpactonglobaltemperaturesweatherpatternsandthe frequencyandseverityofextremeweatherandnaturaldisastersnaturaldisastersandextremeweatherconditionssuch asahurricanetornadoearthquakewildfireorfloodingmayposephysicalriskstoourfacilitiesanddisrupttheoperation ofoursupplychaintheimpactsofthechangingclimateonwaterresourcesmayresultinwaterscarcitylimitingourability toaccesssufficienthighqualitywaterincertainlocationswhichmayincreaseoperationalcosts concernoverclimatechangemayalsoresultinneworadditionallegalorregulatoryrequirementsdesignedtoreduce greenhousegasemissionsandormitigatetheeffectsofclimatechangeontheenvironmentifsuchlawsorregulations aremorestringentthancurrentlegalorregulatoryobligationswemayexperiencedisruptioninoranincreaseinthecosts associatedwithsourcingmanufacturinganddistributionofourproductswhichmayadverselyaffectourbusinessresults ofoperationsorfinancialcondition item b unresolved staff comments notapplicable item properties thecompanyssubsidiariesoperatemanufacturingfacilitiesoccupyingapproximatelymillionsquarefeetoffloor spacethemanufacturingfacilitiesareusedbytheindustrysegmentsofthecompanysbusinessapproximatelyas follows squarefeet segment inthousands consumerhealth pharmaceutical medicaldevices worldwidetotal withintheusfivefacilitiesareusedbytheconsumerhealthsegmentfivebythepharmaceuticalsegmentandby themedicaldevicessegmentoutsideoftheusfacilitiesareusedbytheconsumerhealthsegmentbythe pharmaceuticalsegmentandbythemedicaldevicessegment thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollows squarefeet geographicarea numberoffacilities inthousands unitedstates europe westernhemisphereexcludingus africaasiaandpacific worldwidetotal inadditiontothemanufacturingfacilitiesdiscussedabovethecompanymaintainsnumerousofficeandwarehouse facilitiesthroughouttheworldresearchfacilitiesarealsodiscussedinitemmanagementsdiscussionandanalysisof resultsofoperationsandfinancialconditionofthisreport thecompanyssubsidiariesgenerallyseektoownratherthanleasetheirmanufacturingfacilitiesalthoughsome principallyinnonuslocationsareleasedofficeandwarehousefacilitiesareoftenleasedthecompanyalsoengages contractmanufacturers thecompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition mcneilppcincnowjohnsonjohnsonconsumerincmcneilppccontinuestooperateunderaconsentdecree signedinwiththefdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationsandrequires mcneilppctoremediatethefacilitiesitoperatesinlancasterpennsylvaniafortwashingtonpennsylvaniaandlas johnsonjohnsonannualreportpiedraspuertoricotheconsentdecreefollowingfdainspectionsmcneilppcreceivednotificationsfromthe fdathatallthreemanufacturingfacilitiesareinconformitywithapplicablelawsandregulationsandcommercial productionrestartedin undertheconsentdecreeafterreceivingnoticefromthefdaofbeingincompliancewithapplicablelawsand regulationseachofthethreefacilitiesissubjecttoafiveyearauditperiodbyathirdpartycgmpexpertathirdparty expertcontinuedtoreassessthesitesatvarioustimesthroughmcneilppcisawaitingfdainspectionsofthe facilitieswhichhavebeendelayedduetocovid segmentinformationonadditionstopropertyplantandequipmentiscontainedinnotesegmentsofbusinessand geographicareasofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport item legal proceedings theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinnotelegal proceedingsofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport inadditionjohnsonjohnsonanditssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthe comprehensiveenvironmentalresponsecompensationandliabilityactcommonlyknownassuperfundand comparablestatelocalorforeignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation item mine safety disclosures notapplicable johnsonjohnsonannualreport executive officers registrant listedbelowaretheexecutiveofficersofthecompanytherearenofamilyrelationshipsbetweenanyoftheexecutive officersandthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto whichtheexecutiveofficerwasselectedattheannualmeetingoftheboardofdirectorstheexecutiveofficersare electedbytheboardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualifiedoruntil earlierresignationorremoval informationwithregardtothedirectorsofthecompanyincludinginformationforalexgorskywhoisalsoanexecutive officerisincorporatedhereinbyreferencetothematerialcaptioneditemelectionofdirectorsintheproxystatement name age position joaquinduato vicechairmanexecutivecommitteea memberexecutivecommitteeexecutivevicepresidentchiefhuman petermfasolophd resourcesofficerb chairmanboardofdirectorschairmanexecutivecommitteechiefexecutive alexgorsky officer memberexecutivecommitteeexecutivevicepresidentworldwidechairman ashleymcevoy medicaldevicesc memberexecutivecommitteeexecutivevicepresidentworldwidechairman thibautmongon consumerhealthd memberexecutivecommitteeexecutivevicepresidentglobalcorporate michaelesneed affairsandchiefcommunicationofficere paulusstoffelsmd vicechairmanexecutivecommitteechiefscientificofficerf memberexecutivecommitteeexecutivevicepresidentworldwidechairman jenniferltaubert pharmaceuticalsg michaelhullmann memberexecutivecommitteeexecutivevicepresidentgeneralcounselh memberexecutivecommitteeexecutivevicepresidentchiefglobalsupply kathrynewengel chainofficeri memberexecutivecommitteeexecutivevicepresidentchieffinancial josephjwolk officerj mrjduatojoinedthecompanyinwithjanssenfarmaceuticasaspainasubsidiaryofthecompanyandheldexecutive positionsofincreasingresponsibilityinthepharmaceuticalsectorinhewasnamedcompanygroupchairman pharmaceuticalsandinhewasnamedworldwidechairmanpharmaceuticalsinmrduatobecameamemberofthe executivecommitteeandwasnamedexecutivevicepresidentworldwidechairmanpharmaceuticalsinjulymrduatowas promotedtovicechairmanoftheexecutivecommitteewithresponsibilityforthecompanyspharmaceuticalandconsumerhealth sectorssupplychaininformationtechnologyglobalservicesandthehealthwellnessgroups b drpmfasolojoinedthecompanyinasvicepresidentworldwidehumanresourcesforcordiscorporationasubsidiary ofthecompanyandwassubsequentlynamedvicepresidentglobaltalentmanagementforthecompanyheleftjohnson johnsonintojoinkohlbergkravisrobertscoaschieftalentofficerdrfasoloreturnedtothecompanyinasthe vicepresidentglobalhumanresourcesandinhebecameamemberoftheexecutivecommitteeinaprilhewas namedexecutivevicepresidentchiefhumanresourcesofficerdrfasolohasresponsibilityforglobaltalentrecruitingdiversity compensationbenefitsemployeerelationsandallaspectsofthehumanresourcesagendaforthecompany c msamcevoyjoinedthecompanyinasassistantbrandmanagerofmcneilconsumerhealthasubsidiaryofthecompany advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedcompanygroupchairmanvisioncarein followedbycompanygroupchairmanconsumermedicaldevicesininjulymsmcevoywaspromotedtoexecutive vicepresidentworldwidechairmanmedicaldevicesandbecameamemberoftheexecutivecommitteemsmcevoyhas responsibilityforthesurgeryorthopaedicsinterventionalsolutionsandeyehealthbusinessesacrossethicondepuysynthes biosensewebsterandjohnsonjohnsonvision mrtmongonjoinedthecompanyinasdirectorofmarketingforthevisioncaregroupinfranceandsubsequentlyheld generalmanagementpositionsascountrymanagerfrancebelgiumandnorthafricamanagingdirectorlatinamericaand presidentasiapacificmrmongontransitionedtothepharmaceuticalsectorinastheglobalcommercialstrategyleaderfor theneurosciencetherapeuticareabeforejoiningtheconsumerhealthsectorascompanygroupchairmanasiapacificin hewaspromotedtoexecutivevicepresidentandworldwidechairmanconsumerhealthandbecameamemberoftheexecutive committeemrmongonhasresponsibilityfortheglobaldevelopmentofjohnsonjohnsonshealthandwellnessproductsand solutionsinbeautyotcoralcarebabycarewomenshealthandwoundcare johnsonjohnsonannualreporte mrmesneedjoinedthecompanyinasmarketingassistantforpersonalproductscompanyasubsidiaryofthecompany andgainedincreasedresponsibilitiesinexecutivepositionsacrosstheglobalenterpriseinmrsneedwasappointed companygroupchairmanconsumernorthamericafollowedbycompanygroupchairmanvisioncarefranchiseinin hebecamethevicepresidentglobalcorporateaffairsandchiefcommunicationsofficermrsneedwasappointed executivevicepresidentglobalcorporateaffairsandchiefcommunicationsofficerinjanuaryandbecameamemberofthe executivecommitteeinjulyleadingthecompanysglobalmarketingcommunicationdesignandphilanthropyfunctions f drpstoffelsrejoinedthecompanyinwiththeacquisitionoftibotecvirconvwherehewaschiefexecutiveofficerofvirco nvandchairmanoftibotecnvinhewasappointedcompanygroupchairmanglobalvirologyinheassumedthe roleofcompanygroupchairmanpharmaceuticalsdrstoffelswasappointedglobalheadresearchdevelopment pharmaceuticalsinandinbecameworldwidechairmanpharmaceuticalsindrstoffelswasappointedchief scientificofficerandbecameamemberoftheexecutivecommitteeindrstoffelswasnamedexecutivevicepresident chiefscientificofficerindrstoffelswaspromotedtovicechairmanoftheexecutivecommitteechiefscientificofficerhe isresponsibleforthecompanysinnovationagendaacrossthepharmaceuticalmedicaldevicesandconsumerhealthsectors productsafetystrategyandthecompanysglobalpublichealthstrategy g msjltaubertjoinedthecompanyinasworldwidevicepresidentatjohnsonjohnsonpharmaceuticalservicesa subsidiaryofthecompanysheheldseveralexecutivepositionsofincreasingresponsibilityinthepharmaceuticalsectoruntil whenshewasappointedcompanygroupchairmannorthamericapharmaceuticalsandinbecamecompanygroup chairmantheamericaspharmaceuticalsinjulymstaubertwaspromotedtoexecutivevicepresidentworldwide chairmanpharmaceuticalsandbecameamemberoftheexecutivecommitteemstauberthasresponsibilityfortheimmunology infectiousdiseasesneuroscienceoncologycardiovascularandmetabolismandpulmonaryhypertensionbusinessesthroughout janssen h mrmhullmannjoinedthecompanyinasacorporateattorneyinthelawdepartmenthewasappointedcorporate secretaryinandservedinthatroleuntilduringthattimehealsoheldvariousmanagementpositionsinthelaw departmentinhewasnamedgeneralcounselmedicaldevicesanddiagnosticsandwasappointedvicepresidentgeneral counselandbecameamemberoftheexecutivecommitteeininaprilmrullmannwasnamedexecutivevice presidentgeneralcounselmrullmannhasworldwideresponsibilityforlegalgovernmentaffairspolicyglobalsecurityaviation healthcarecomplianceglobalbrandprotectionandprivacy mskewengeljoinedthecompanyinasprojectengineerandengineeringsupervisoratjanssenasubsidiaryofthe companyduringhertenurewiththecompanyshehasheldavarietyofstrategicleadershipandexecutivepositionsacrossthe globalenterpriseinroleswithinoperationsqualityengineeringnewproductsinformationtechnologyandothertechnicaland businessfunctionsinmswengelbecamethefirstchiefqualityofficerofthecompanyinshewaspromotedtovice presidentjohnsonjohnsonsupplychaininjulyshewaspromotedtoexecutivevicepresidentchiefglobalsupplychain officerandbecameamemberoftheexecutivecommittee j mrjjwolkjoinedthecompanyinasfinancemanagerbusinessdevelopmentfororthomcneilasubsidiaryofthe companyandthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrossthecompanys subsidiariesinpharmaceuticalsmedicaldevicesandsupplychainfromtoheservedasvicepresidentfinanceand chieffinancialofficerofthejanssenpharmaceuticalcompaniesofjohnsonjohnsoninmrwolkbecamethevice presidentinvestorrelationsinjulyhewasappointedexecutivevicepresidentchieffinancialofficerandbecameamember oftheexecutivecommitteemrwolkplaysastrategicroleintheoverallmanagementofthecompanyandleadsthedevelopment andexecutionofthecompanysgloballongtermfinancialstrategy johnsonjohnsonannualreport part ii item market registrants common equity related stockholder matters issuer purchases equity securities asoffebruarytherewererecordholdersofcommonstockofthecompanyadditionalinformation calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisreportnotecommon stockstockoptionplansandstockcompensationagreementsofthenotestoconsolidatedfinancialstatements includedinitemanditemsecurityownershipofcertainbeneficialownersandmanagementandrelated stockholdermattersequitycompensationplaninformation issuer purchases equity securities thefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbythecompanyduringthefiscalfourth quarterofcommonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneeds ofthecompanyscompensationprogramstherepurchasesbelowalsoincludethestockforstockoptionexercisesthat settledinthefiscalfourthquarter totalnumberof maximumnumberor sharesorunits approximatedollar purchasedaspart valueofsharesorunits totalnumber ofpublicly thatmayyetbe ofshares avgprice announcedplans purchasedunderthe fiscalperiod purchased paidpershare orprograms plansorprograms septemberthrough october octoberthrough november novemberthroughjanuary total duringthefiscalfourthquarterofthecompanyrepurchasedanaggregateofsharesofjohnsonjohnson commonstockinopenmarkettransactionsallofwhichwerepurchasedinopenmarkettransactionsaspartofasystematicplanto meettheneedsofthecompanyscompensationprograms item reserved johnsonjohnsonannualreportitem managements discussion analysis results operations financial condition organization business segments description company business segments johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpreviouslyreferredtoasconsumer pharmaceuticalandmedicaldevicestheconsumerhealthsegmentincludesabroadrangeofproductsusedinthebaby careoralcareskinhealthbeautyoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsthese productsaremarketedtothegeneralpublicandsoldonlineecommerceandtoretailoutletsanddistributorsthroughout theworldthepharmaceuticalsegmentisfocusedonsixtherapeuticareasincludingimmunologyinfectiousdiseases neuroscienceoncologypulmonaryhypertensionandcardiovascularandmetabolicdiseasesproductsinthissegment aredistributeddirectlytoretailerswholesalershospitalsandhealthcareprofessionalsforprescriptionusethemedical devicessegmentincludesabroadrangeofproductsusedintheorthopaedicsurgeryinterventionalsolutions cardiovascularandneurovascularandeyehealthfieldstheseproductsaredistributedtowholesalershospitalsand retailersandusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe consumerhealthpharmaceuticalandmedicaldevicesbusinesssegments inallofitsproductlinesthecompanycompeteswithothercompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotectingtheunderlyingintellectual propertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareasofitsbusinessthe competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentand maintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertising andpromotion managementsobjectives withourcredoasthefoundationthecompanyspurposeistoblendheartscienceandingenuitytoprofoundly changethetrajectoryofhealthforhumanitythecompanyiscommittedtobringingitsfullbreadthanddepthtoensure healthforpeopletodayandforfuturegenerationsunitedaroundthiscommonambitionthecompanyispoisedtofulfillits purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompetes thecompanyisbroadlybasedinhumanhealthcareandiscommittedtocreatingvaluebydevelopingaccessiblehigh qualityinnovativeproductsandservicesnewproductsintroducedwithinthepastfiveyearsaccountedforapproximately ofsalesinbillionwasinvestedinresearchanddevelopmentandbillionspenton acquisitionsreflectingmanagementscommitmenttocreatelifeenhancinginnovationsandtocreatevaluethrough partnershipsthatwillprofoundlychangethetrajectoryofhealthforhumanity acriticaldriverofthecompanyssuccessisthediverseemployeesworldwideemployeesareempoweredand inspiredtoleadwiththecompanysourcredoandpurposeasguidesthisallowseveryemployeetousethecompanys reachandsizetoadvancethecompanyspurposeandtoalsoleadwithagilityandurgencyleveragingtheextensive resourcesacrosstheenterpriseenablesthecompanytoinnovateandexecutewithexcellencethisensuresthe companycanremainfocusedonaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpact ultimatelydeliveringvaluetoitspatientsconsumersandhealthcareprofessionalsemployeescommunitiesand shareholders johnsonjohnsonannualreport snoillib ni snoillib ni srallod ni research acquisicidons net dividends paid development cash acquired per share results operations analysisofconsolidatedsales fordiscussiononresultsofoperationsandfinancialconditionpertainingtothefiscalyearsandseethe companysannualreportonformkforthefiscalyearendeddecemberitemmanagementsdiscussion andanalysisofresultsofoperationsandfinancialcondition inworldwidesalesincreasedtobillionascomparedtoanincreaseofinthesesales changesconsistedofthefollowing salesincreasedecreasedueto volume price currency total thenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasanegativeimpactofinand anegativeimpactofin salesbyuscompanieswerebillioninandbillioninthisrepresentsincreasesofin andinsalesbyinternationalcompanieswerebillioninandbillioninthisrepresents adecreaseofinandanincreaseofin thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively insalesbycompaniesineuropeachievedgrowthofascomparedtotheprioryearwhichincluded operationalgrowthofandapositivecurrencyimpactofsalesbycompaniesinthewesternhemisphere excludingtheusexperiencedasalesdeclineofascomparedtotheprioryearwhichincludedoperational growthofoffsetbyanegativecurrencyimpactofsalesbycompaniesintheasiapacificafricaregion experiencedasalesdeclineofascomparedtotheprioryearincludinganoperationaldeclineofpartiallyoffset byapositivecurrencyimpactof theresultsbenefitedfromtheinclusionofardweekseenotetotheconsolidatedfinancialstatementsfor annualclosingdatedetailsthecompanyestimatedthatthefiscalyearsalesgrowthratewasenhancedby approximatelywhiletheadditionalweekaddedafewdaystosalesitalsoaddedafullweeksworthofoperating coststhereforethenetearningsimpactwasnegligible inthecompanyutilizedthreewholesalersdistributingproductsforallthreesegmentsthatrepresented approximatelyandofthetotalconsolidatedrevenuesinthecompanyhadthreewholesalers distributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenues johnsonjohnsonannualreport sales geographic region billions sales segment billions europe western hemisphere ex us consumer health pharmaceutical asiapacific africa us medical devices notevaluesmayhavebeenrounded analysis sales business segments consumerhealthsegment consumerhealthsegmentsalesinwerebillionanincreaseoffromwhichincluded operationalgrowthandanegativecurrencyimpactofusconsumerhealthsegmentsaleswerebillionan increaseofinternationalsaleswerebillionadecreaseofwhichincludedanoperationaldeclineof andanegativecurrencyimpactofinacquisitionsanddivestitureshadanetnegativeimpactofonthe operationalsalesgrowthoftheworldwideconsumerhealthsegment majorconsumerhealthfranchisesales change dollarsinmillions vs otc skinhealthbeauty oralcare babycare womenshealth woundcareother totalconsumerhealthsales previouslyreferredtoasconsumer previouslyreferredtoasbeauty johnsonjohnsonannualreport theotcfranchisesalesofbillionincreasedascomparedtotheprioryeargrowthwasprimarilyattributable tosalesfromtylenoldrivenbycovidstockingdemandzyrtecduetocompetitorproductoutofstockand pepcidduetocompetitiveproductwithdrawalbothintheusandincreasedconsumptioninantismokingaids internationalsaleswerenegativelyimpactedbycovidandlowincidenceofcoughandflu theskinhealthbeautyfranchisesaleswerebillioninadecreaseofascomparedtotheprioryearthe declinewasprimarilyduetonegativecovidrelatedimpactsandskurationalizationpartiallyoffsetbygrowthin ecommerceandnewproductinnovation theoralcarefranchisesalesofbillionincreasedascomparedtotheprioryearprimarilyattributabletosalesof listerinemouthwashduetousecommerceandclubchannelgrowthincreasedstockingdemandrelatedto covidandnewproductlaunchesinasiapacific thebabycarefranchisesaleswerebillioninadecreaseofcomparedtotheprioryearthedeclinewas primarilyduetocovidrelatedimpactsskurationalizationandthebabycenterdivestitureintheuspartiallyoffset bystrengthinaveenobaby thewomenshealthfranchisesaleswerebillioninadecreaseofascomparedtotheprioryearthe declinewasprimarilydrivenbycovidimpacts thewoundcareotherfranchisesaleswerebillioninanincreaseofascomparedtotheprioryear growthwasduetostrongperformanceofneosporinandbandaidbrandadhesivebandagesandcovid relateddemandintheasiapacificregion johnsonjohnsonannualreportpharmaceutical segment pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandanegativecurrencyimpactofussaleswerebillionanincreaseofinternational saleswerebillionanincreaseofwhichincludedoperationalgrowthandanegativecurrencyimpactof inacquisitionsanddivestitureshadanetnegativeimpactofontheoperationalsalesgrowthofthe worldwidepharmaceuticalsegmentadjustmentstopreviousreserveestimatespositivelyimpactedthepharmaceutical segmentoperationalgrowthbyapproximatelyinbothfiscalyearsand majorpharmaceutical therapeuticareasales change dollarsinmillions vs totalimmunology remicade simponisimponiaria stelara tremfya otherimmunology totalinfectiousdiseases edurantrilpivirine prezistaprezcobixrezolstasymtuza otherinfectiousdiseases totalneuroscience concertamethylphenidate invegasustennaxeplioninvegatrinzatrevicta risperdalconsta otherneuroscience totaloncology darzalex erleada imbruvica velcade zytigaabirateroneacetate otheroncology totalpulmonaryhypertension opsumit uptravi otherpulmonaryhypertension totalcardiovascularmetabolismother xarelto invokanainvokamet procriteprex totalpharmaceuticalsales certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthanornotmeaningful johnsonjohnsonannualreport previouslyincludedinotheroncology inclusiveoftracleerwhichwaspreviouslydisclosedseparately immunologyproductssaleswerebillioninrepresentinganincreaseofascomparedtotheprioryear drivenbystronguptakeofstelaraustekinumabincrohnsdiseaseandulcerativecolitisandstrengthintremfya guselkumabinpsoriasisthiswaspartiallyoffsetbycovidrelateddemandandlowersalesofremicade infliximabduetoincreaseddiscountsrebatesandbiosimilarcompetition thepatentsforremicadeinfliximabincertaincountriesineuropeexpiredinfebruarybiosimilarversionsof remicadehavebeenintroducedincertainmarketsoutsidetheunitedstatesresultinginareductioninsalesof remicadeinthosemarketsadditionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninsalesof remicadeinmarketsoutsidetheunitedstatesintheunitedstatesabiosimilarversionofremicadewas introducedinandadditionalcompetitorscontinuetoenterthemarketcontinuedinfliximabbiosimilarcompetitionin theusmarketwillresultinafurtherreductioninussalesofremicade infectiousdiseaseproductssaleswerebillioninrepresentinganincreaseofascomparedtotheprior yearprimarilyduetostrongsalesofsymtuzaandjulucathiswaspartiallyoffsetbylowersalesofprezista andprezcobixrezolstaduetoincreasedcompetitionandlossofexclusivityofprezistaincertaincountries outsidetheus neuroscienceproductssaleswerebillionrepresentinganincreaseofascomparedtotheprioryear paliperidonelongactinginjectablesgrowthdrivenbysalesofinvegasustennaxeplionpaliperidonepalmitate andinvegatrinzatrevictafromnewpatientstartsandpersistencethegrowthwaspartiallyoffsetbymigration fromrisperdalconstarisperidoneanddeclinesinconcertamethylphenidateduetocompetitiveentrants oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearcontributorstothegrowthwerestrongsalesofdarzalexdaratumumabdrivenbypatientuptakeinalllinesof therapyandthelaunchofasubcutaneousformulationintheusandeuimbruvicaibrutinibduetomarketgrowth globallyandmaintainingstrongshareandthecontinuedgloballaunchuptakeandsharegainsoferleada apalutamideadditionallythegrowthwasnegativelyimpactedbydecliningsalesofzytigaabirateroneacetateand velcadebortezomibduetogenericcompetition pulmonaryhypertensionproductsachievedsalesofbillionrepresentinganincreaseofascomparedtothe prioryearsalesgrowthofopsumitmacitentananduptraviselexipagwereduetocontinuedsharegainsand marketgrowthadditionallysalesoftracleerbosentanwerenegativelyimpactedbygenericsandmigrationto opsumit cardiovascularmetabolismotherproductssaleswerebillionadeclineofascomparedtotheprioryearsales growthofinvokanainvokametcanagliflozinwereduetomarketgrowthandfavorablechannelmixdynamicsin theusandstrengthintheeuropeanregionpartiallyoffsetbyussharedeclinesduetocompetitivepressuresthe growthofxareltorivaroxabanwasduetodemandgrowthpartiallyoffsetbyhigherrebateslowersalesof procriteprexepoetinalfawereduetobiosimilarcompetition johnsonjohnsonannualreportduringthecompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand additionalindicationsforexistingdrugsasfollows productnamechemical us eu us eu name indication approval approval filing filing amivantamab treatmentofpatientswithmetastaticnonsmallcelllung cancerwithegfrexoninsertionmutations darzalexdaratumumab combinationregimenfornewlydiagnosedtransplant eligiblepatientswithmultiplemyeloma darzalexdaratumumab combinationwithcarfilzomibanddexamethasoneforpatients withrelapsedrefractorymultiplemyeloma darzalexfaspro subcutaneousformulationofdaratumumabinthetreatment daratumumaband ofpatientswithmultiplemyeloma hyaluronidase erleadaapalutamide treatmentofmetastaticcastrationsensitiveprostatecancer imbruvicaibrutinib incombinationwithrituximabfortreatmentofchronic lymphocyticleukemia invokanacanagliflozin treatmentofdiabetickidneydisease rilpivirineandcabotegravir formonthlyinjectabletwodrugregimenfortreatmentof hiv paliperidonepamitatemonth treatmentofschizophrenia ponesimod treatmentofadultswithrelapsedmultiplesclerosis simponiariagolimumab treatmentofpolyarticularjuvenileidiopathicarthritisand juvenilepsoriaticarthritis sirturobedaquiline combinationtherapytotreatchildrenwithpulmonary multidrugresistanttuberculosis spravatoesketamine rapidreductionofdepressivesymptomsinadultswith majordepressivedisorderwhohaveactivesuicidalideation withintent stelaraustekinumab treatmentofpediatricpatientswithmoderatetosevere plaquepsoriasis tremfyaguselkumab treatmentofadultswithactivepsoriaticarthritis uptraviiv pulmonaryarterialhypertension xareltorivaroxaban newindicationtoexpanduseinpatientswithperipheral arterydisease zabdenoadzebovand preventiveebolavaccine mvabeamvabnfilo johnsonjohnsonannualreport medicaldevicessegment themedicaldevicessegmentsalesinwerebillionadecreaseoffromwhichincludedan operationaldecreaseofandanegativecurrencyimpactofussaleswerebillionadecreaseof ascomparedtotheprioryearinternationalsaleswerebillionadecreaseofascomparedtotheprior yearwithanoperationaldecreaseofandanegativecurrencyimpactofinthenetimpactof acquisitionsanddivestituresonthemedicaldevicessegmentworldwideoperationalsalesgrowthwasanegativeof whichthedivestitureofadvancedsterilizationproductsasphadanimpactofapproximatelygrowthwas negativelyimpactedbycovidandassociateddeferralofmedicalprocedures majormedicaldevicesfranchisesales change dollarsinmillions vs surgery advanced general orthopaedics hips knees trauma spinesportsother vision contactlensesother surgical interventionalsolutions totalmedicaldevicessales certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation includesspecialtysurgerywhichwaspreviouslydisclosedseparately previouslyreferredtoasspineother thesurgeryfranchisesaleswerebillioninadecreaseoffromthedeclineinadvancedsurgery wasprimarilydrivenbythenegativeimpactofcovidandcompetitivepressuresintheusthiswaspartiallyoffsetby thesuccessofnewproductsoutsidetheusandtherecoveryofanisolatedsupplydisruptionintheprioryearrelatedto surgiflothedeclineingeneralsurgerywasprimarilydrivenbythenegativeimpactofcovidandtheasp divestiture theorthopaedicsfranchisesaleswerebillioninadecreaseoffromthedeclineinhipswas drivenbythenegativeimpactofcovidpartiallyoffsetbyaleadershippositionintheanteriorapproachstrongmarket demandfortheactisstemandenablingtechnologieskinciseandvelyshipnavigationthedeclineinknees wasdrivenbythenegativeimpactofcovidthedeclineintraumawasdrivenbythenegativeimpactofcovid partiallyoffsetbystrengthfromnewproductsthedeclineinspinesportsotherwasdrivenbythenegativeimpactof covidpartiallyoffsetbytheuptakeofnewproducts thevisionfranchisesaleswereofbillioninadecreaseoffromthecontactlensesother operationaldeclinewasduetothenegativeimpactofcovidthesurgicaloperationaldeclinewasprimarilydrivenby thenegativeimpactofcovidandcompetitivepressuresintheus theinterventionalsolutionsfranchiseachievedsalesofbillioninanincreaseoffromgrowthin theelectrophysiologybusinesswasdrivenbyatrialfibrillationproceduregrowthcoupledwithstrengthfromnewproducts andmarketrecoveryoffsettingnegativeimpactsfromcovid johnsonjohnsonannualreportanalysisofconsolidatedearningsbeforeprovisionfortaxesonincome consolidatedearningsbeforeprovisionfortaxesonincomewasbillionandbillionfortheyearsand respectivelyasapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomewasand inandrespectively earnings provision taxes dollars billions percentages chart percent total sales costofproductssoldandsellingmarketingandadministrativeexpenses cost products sold selling markecidng administracidve dollars billions percentages chart percent total sales costofproductssoldincreasedasapercenttosalesdrivenby medicaldeviceidlecapacitycostsassociatedwithcovidrelatedproductionslowdowns establishmentofobsolescencereservesandfixedcostdeleveragingassociatedwiththeimpactofcovidinthe medicaldevicesbusiness supplychaincostsassociatedwiththedevelopmentofthecovidvaccineinthepharmaceuticalbusiness partiallyoffsetby favorablemixwithinthepharmaceuticalbusiness favorableproductmixwithahigherpercentageofsalescomingfromthepharmaceuticalbusiness johnsonjohnsonannualreport theintangibleassetamortizationexpenseincludedincostofproductssoldwasbillionandbillionfortheyears andrespectively sellingmarketingandadministrativeexpensesdecreasedasapercenttosalesdrivenby leveraginginthepharmaceuticalandconsumerhealthbusinesses portfolioandinvestmentoptimizationincludingexecutionoftheongoingskurationalizationprogramintheconsumer healthbusiness favorablesegmentmixwithahigherpercentageofsalescomingfromthepharmaceuticalbusiness partiallyoffsetby thenegativeimpactonsalesresultingfromcovidinthemedicaldevicesbusiness researchanddevelopmentexpense researchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillions amount ofsales amount ofsales consumerhealth pharmaceutical medicaldevices totalresearchanddevelopmentexpense percentincreasedecreaseovertheprioryear asapercenttosegmentsales researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsupfrontpaymentsanddevelopmentalmilestones improvingexistingproductsaswellasensuringproductefficacyandregulatorycompliancepriortolaunchthecompany remainscommittedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovative products researchanddevelopmentincreasedasapercenttosalesprimarilydrivenby segmentmixdrivenbyahigherpercentageofsalesgeneratedbythepharmaceuticalbusinessversustheprioryear thenegativecovidimpactonmedicaldevicessales increasedinvestmentinthemedicaldevicesbusinessrelatedtoroboticsanddigitalprograms portfolioprogressionincludingthecovidvaccineinthepharmaceuticalbusinessnetofgovernmental reimbursements researchfacilitiesarelocatedintheusbelgiumbrazilchinafrancegermanyindiaisraelthenetherlandspoland singaporeswedenswitzerlandandtheunitedkingdomwithadditionalrdsupportinoverothercountries inprocessresearchanddevelopmentiprdinfiscalyearthecompanyrecordedaniprdchargeof billionprimarilyrelatedtoapartialimpairmentduetotimingandprogressionofoneofthedigitalsurgeryplatforms acquiredwiththeaurishealthacquisitioninthefiscalyearthecompanyrecordedaniprdchargeofbillion fortheremainingintangibleassetvaluerelatedtothedevelopmentprogramofalaninvestigationaldrugforthe treatmentofrespiratorysyncytialvirusrsvandhumanmetapneumovirushmpvacquiredwiththeacquisitionof aliosbiopharmainctheimpairmentchargewasbasedonadditionalinformationincludingclinicaldatawhichbecame availableandledtothecompanysdecisiontoabandonthedevelopmentofal otherincomeexpensenetotherincomeexpensenetistheaccountwherethecompanyrecordsgainsand lossesrelatedtothesaleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnsoninnovation jjdcincjjdcunrealizedgainsandlossesoninvestmentsgainsandlossesondivestiturescertaintransactional currencygainsandlossesacquisitionrelatedcostslitigationaccrualsandsettlementsaswellasroyaltyincome johnsonjohnsonannualreportotherincomeexpensenetforthefiscalyearwasunfavorablebybillionascomparedtotheprioryear primarilyduetothefollowing dollarsinbillionsincomeexpense change litigationexpense acquisitionandintegrationrelated unrealizedgainslossesonsecurities equitystepupgainrelatedtodrcilabo divestituregains restructuringrelated totalotherincomeexpensenet litigationexpenseprimarilyassociatedwithtalcrelatedreservesandcertainsettlementsbillionlitigationexpense primarilyrelatedtotheagreementinprincipletosettleopioidlitigationbillion isprimarilydrivenbyacontingentconsiderationreversalofapproximatelybillionrelatedtothetimingofcertain developmentalmilestonesassociatedwiththeaurishealthacquisition includedthedivestitureofasp interestincomeexpensethefiscalyearincludednetinterestexpenseofmillionascomparedtoincomeof millioninthefiscalyearthiswasprimarilyduetoreducedinterestincomeresultingfromlowerratesofinterest earnedoncashbalancesandahigheraveragedebtbalancethiswaspartiallyoffsetbyaloweraveragedebtinterestrate andahigheraveragecashbalancecashcashequivalentsandmarketablesecuritiestotaledbillionattheendof andaveragedbillionascomparedtothecashcashequivalentsandmarketablesecuritiestotalof billionandbillionaveragecashbalanceinthetotaldebtbalanceattheendofwasbillion withanaveragedebtbalanceofbillionascomparedtobillionattheendofandanaveragedebt balanceofbillioninthefiscalthirdquarterofthecompanyissuedapproximatelybillionofcommercial paperwithapproximatelybillionoutstandingatyearendinthefiscalthirdquarterofthecompanyissued seniorunsecurednotesforatotalofbillion incomebeforetaxbysegment incomelossbeforetaxbysegmentofbusinesswereasfollows percentof incomebeforetax segmentsales segmentsales dollarsinmillions consumerhealth pharmaceutical medicaldevices total lessnetexpensenotallocatedtosegments earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetails amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense consumerhealthsegmentintheconsumerhealthsegmentlossbeforetaxasapercentofsaleswas versusincomebeforetaxofinthedecreaseintheincomebeforetaxasapercentofsaleswasprimarily drivenbythefollowing higherlitigationexpenseofbillioninvsbillioninprimarilyassociatedwithtalcrelatedreserves andcertainsettlements johnsonjohnsonannualreport thefiscalyearincludedagainofbillionrelatedtothecompanyspreviouslyheldequityinvestmentindr cilabo partiallyoffsetby portfolioandinvestmentoptimizationincludingexecutionoftheongoingskurationalizationprogram pharmaceuticalsegmentinthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswas versusintheincreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythefollowing lowerlitigationexpenseofbillioninvsbillioninprimarilyrelatedtotheagreementinprincipleto settleopioidlitigationofwhichbillionisinandbillionisin aninprocessresearchanddevelopmentchargeofbillioninfiscalrelatedtoalios loweracquisitionandintegrationrelatedcostsinfiscal leveraginginsellingmarketingandadministrativeexpense medicaldevicessegmentinthemedicaldevicessegmentincomebeforetaxasapercenttosaleswas versusinthedecreaseintheincomebeforetaxasapercenttosaleswasprimarilydrivenbythefollowing againofbillionrelatedtotheaspdivestiturerecordedinthefiscal idlecapacitycostsassociatedwithcovidrelatedproductionslowdownsinfiscal establishmentofobsolescencereservesandfixedcostdeleveragingassociatedwiththeimpactofcovidinfiscal thenegativeimpactofcovidonsalesinfiscal aninprocessresearchanddevelopmentchargeofbillioninfiscalprimarilyrelatedtotheaurishealth acquisition partiallyoffsetby acontingentconsiderationreversalofapproximatelybillioninfiscalrelatedtothetimingofcertain developmentalmilestonesassociatedwiththeaurishealthacquisition litigationexpensewasbillioninvsbillionin restructuringinthefiscalsecondquarterofthecompanyannouncedplanstoimplementactionsacrossits globalsupplychainthatareintendedtoenablethecompanytofocusresourcesandincreaseinvestmentsincritical capabilitiestechnologiesandsolutionsnecessarytomanufactureandsupplyitsproductportfolioofthefutureenhance agilityanddrivegrowththecompanyexpectsthesesupplychainactionswillincludeexpandingitsuseofstrategic collaborationsandbolsteringitsinitiativestoreducecomplexityimprovingcostcompetitivenessenhancingcapabilities andoptimizingitsnetworkdiscussionsregardingspecificfutureactionsareongoingandaresubjecttoallrelevant consultationrequirementsbeforetheyarefinalizedintotalthecompanyexpectstheseactionstogenerateapproximately tobillioninannualpretaxcostsavingsthatwillbesubstantiallydeliveredbythecompanyexpectsto recordpretaxrestructuringchargesofapproximatelytobillionthecompanyestimatesthatapproximately ofthecumulativepretaxcostswillresultincashoutlaysinthecompanyrecordedapretaxchargeof billionwhichisincludedonthefollowinglinesoftheconsolidatedstatementofearningsbillionin restructuringbillioninotherincomeexpenseandbillionincostofproductssoldtotalprojectcostsof approximatelybillionhavebeenrecordedsincetherestructuringwasannounced seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtotherestructuringprograms provisionfortaxesonincometheworldwideeffectiveincometaxratewasinandin duringthefiscalfirstquarteroftheinternalrevenueservicepublishedfinalregulationsaddressingthe requirementsfortaxdeductibilityofsettlementpaymentsthecompanyrecordedapretaxreserveforbillioninthe fiscalyearbasedontheagreementinprincipletosettleopioidlitigationandrecordedanadditionalpretax billioninthefiscalthirdquarterofuponwhichaneffectiverateofhasbeenapplied fordiscussionrelatedtothefiscalprovisionfortaxesrefertonotetotheconsolidatedfinancialstatements johnsonjohnsonannualreportliquidity capital resources liquiditycashflows cashandcashequivalentswerebillionattheendofascomparedtobillionattheendof theprimarysourcesandusesofcashthatcontributedtothebilliondecreasewere dollarsinbillions qcashandcashequivalentsbalance cashgeneratedfromoperatingactivities netcashusedbyinvestingactivities netcashusedbyfinancingactivities effectofexchangerateandrounding qcashandcashequivalentsbalance inadditionthecompanyhadbillioninmarketablesecuritiesattheendoffiscalyearandbillionatthe endoffiscalyearseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncashcash equivalentsandmarketablesecurities cashflowfromoperationsofbillionwastheresultof dollarsinbillions netearnings noncashexpensesandotheradjustmentsprimarilyfordepreciationandamortizationstockbased compensationassetwritedownsandcreditlossesandaccountsreceivableallowancespartiallyoffsetbythe deferredtaxprovisionandnetgainonsaleofassetsbusinesses decreaseinaccountsreceivable anincreaseinaccountspayableandaccruedliabilitiesandothercurrentandnoncurrentliabilities anincreaseininventoriesandothercurrentandnoncurrentassets contingentconsiderationreversalrelatedtothetimingofcertaindevelopmentalmilestonesassociatedwiththe aurishealthacquisitionandrounding cashflowfromoperations investingactivitiesuseofbillionofcashwasprimarilyusedfor dollarsinbillions primarilyrelatedtotheacquisitionsofmomentabermekimabandrelatedassetsfromxbiotechincaswellasthe acquisitionofalloutstandingsharesinverbsurgicalinc additionstopropertyplantandequipment netpurchasesofinvestments creditsupportagreementsactivitynet proceedsfromthedisposalofassetsbusinessesnet otherprimarilylicensesandmilestones netcashusedforinvestingactivities financingactivitiesuseofbillionofcashwasprimarilyusedfor dollarsinbillions dividendstoshareholders repurchaseofcommonstock netproceedsfromshortandlongtermdebt proceedsfromstockoptionsexercisedemployeewithholdingtaxonstockawardsnet creditsupportagreementsactivitynet netcashusedforfinancingactivities asofjanuarythecompanysnotespayableandlongtermdebtwasinexcessofcashcashequivalentsand marketablesecuritiesasofjanuarythenetdebtpositionwasbillionascomparedtotheprioryearof billiontherewasanincreaseinthenetdebtpositionduetoincreasedborrowingsinthefiscalthirdquarterof johnsonjohnsonannualreport thedebtbalanceattheendofwasbillionascomparedtobillioninconsideringrecentmarket conditionsandtheongoingcovidcrisisthecompanyhasevaluateditsoperatingcashflowsandliquidityprofile anddoesnotforeseeanysignificantincrementalriskthecompanyanticipatesthatoperatingcashflowstheabilityto raisefundsfromexternalsourcesborrowingcapacityfromexistingcommittedcreditfacilitiesandaccesstothe commercialpapermarketswillcontinuetoprovidesufficientresourcestofundoperatingneedsincludingthetalclitigation andagreementinprincipletosettleopioidlitigationofwhichthemajoritymaybepaidoverthenexttwotothreeyearsin additionthecompanymonitorstheglobalcapitalmarketsonanongoingbasisandfromtimetotimemayraisecapital whenmarketconditionsarefavorableinthefiscalthirdquarterofthecompanyissuedapproximatelybillionof commercialpaperwithapproximatelybillionoutstandingatyearendinthefiscalthirdquarterofthecompany issuedseniorunsecurednotesforatotalofbillionforadditionaldetailsonborrowingsseenotetothe consolidatedfinancialstatementsthenetproceedsfromthisofferingwereusedtofundthemomentapharmaceuticals incacquisitionwhichclosedonoctoberandforgeneralcorporatepurposesadditionallyasaresultofthetax cutsandjobsacttcjathecompanyhasaccesstoitscashoutsidetheusatasignificantlyreducedcost thefollowingtablesummarizesthecompanysmaterialcontractualobligationsandtheiraggregatematuritiesasof januarytosatisfytheseobligationsthecompanyintendstousecashfromoperations tax intereston legislation debt debt dollarsinmillions tcja obligations obligations total total fortaxmattersseenotetotheconsolidatedfinancialstatementsthetabledoesnotincludeactivityrelatedto businesscombinationsorthecompanysapproximatebillionincontractualsupplycommitmentsassociatedwithits developmentofacovidvaccine financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosses onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthejanuarymarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthejanuarymarketrateswoulddecrease theunrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflows thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegain orlossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhave noimpactonfutureanticipatedcashflows thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditratingthecounterpartiesto thesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremotethecompanyenteredintocreditsupportagreements csawithcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsand nettingagreementsseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncreditsupport agreements thecompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate riskthefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrateswhilefloating johnsonjohnsonannualreportratesecuritiesmayproducelessincomethanpredictedifinterestratesfallabasispointschangeinspreadon thecompanysinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash equivalentsandcurrentmarketablesecuritiesbyapproximatelymillion thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankslondoninterbankofferedratesliborsecuredovernightfinancingratesofrswapcurveor otherapplicablemarketrateasallowedplusapplicablemarginscommitmentfeesundertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelytheincreasein borrowingswastheissuanceofnotesinwhenmarketconditionswerefavorableinnetdebtcashand currentmarketablesecuritiesnetofdebtwasbillioncomparedtonetdebtofbillionintotaldebt representedoftotalcapitalshareholdersequityandtotaldebtinandoftotalcapitalin shareholdersequitypershareattheendofwascomparedtoatyearend asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatements dividends thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein andpersharein onjanuarytheboardofdirectorsdeclaredaregularcashdividendofpersharepayableonmarch toshareholdersofrecordasoffebruary information criticalaccountingpoliciesandestimates managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompanys consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosures actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards theextenttowhichcovidimpactsthecompanysbusinessandfinancialresultswilldependonnumerousevolving factorsincludingbutnotlimitedtothemagnitudeanddurationofcovidtheextenttowhichitwillimpactworldwide macroeconomicconditionsincludinginterestratesemploymentratesandhealthinsurancecoveragethespeedofthe anticipatedrecoveryandgovernmentalandbusinessreactionstothepandemicthecompanyassessedcertain accountingmattersthatgenerallyrequireconsiderationofforecastedfinancialinformationincontextwiththeinformation reasonablyavailabletothecompanyandtheunknownfutureimpactsofcovidasofjanuaryandthroughthe dateofthisreporttheaccountingmattersassessedincludedbutwerenotlimitedtothecompanysallowancefor doubtfulaccountsandcreditlossesinventoryandrelatedreservesaccruedrebatesandassociatedreservesandthe carryingvalueofthegoodwillandotherlonglivedassetswhiletherewasnotamaterialimpacttothecompanys consolidatedfinancialstatementsasofandfortheyearendedjanuarythecompanysfutureassessmentofthe magnitudeanddurationofcovidaswellasotherfactorscouldresultinmaterialimpactstothecompanys consolidatedfinancialstatementsinfuturereportingperiods revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa contractwiththecustomeraresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthe companysglobalpaymenttermsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentives tradepromotionscouponsproductreturnsanddiscountstocustomersareaccountedforasvariableconsiderationand recordedasareductioninsales johnsonjohnsonannualreport productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarkets servedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof wholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerhealthandpharmaceuticalsegmentsarealmostexclusivelynotresalablesales returnsforcertainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompany infrequentlyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhas beenapproximatelyofannualnettradesalesduringthefiscalyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsofcertain productswhichareincludedinsalestocustomersforallyearspresentedprofitsharepaymentswerelessthanof thetotalrevenuesandareincludedinsalestocustomers inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered basedontherelativesellingpriceupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover theperformanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaborations reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchanges toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact belowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedjanuaryanddecember johnsonjohnsonannualreportconsumerhealthsegment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatdecemberrecordedasacontra asset pharmaceutical segment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatdecemberrecordedasa contraasset includesadjustments johnsonjohnsonannualreport medicaldevicessegment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatdecemberrecordedasa contraasset incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilities thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromits internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximatelybillion undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates duringthefiscalfirstquarteroftheinternalrevenueservicepublishedfinalregulationsaddressingthe requirementsfortaxdeductibilityofsettlementpaymentsthecompanyrecordedapretaxreserveforbillioninfiscal basedontheagreementinprincipletosettleopioidlitigationandrecordedanadditionalpretaxbillioninthe fiscalthirdquarterofuponwhichaneffectiverateofhasbeenapplied seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimated johnsonjohnsonannualreportthecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimated seenotesandtotheconsolidatedfinancialstatementsforfurtherinformationregardingproductliabilityandlegal proceedings longlivedandintangibleassetsthecompanyassesseschangesbothqualitativelyandquantitativelyineconomic conditionsandmakesassumptionsregardingestimatedfuturecashflowsinevaluatingthevalueofthecompanys propertyplantandequipmentgoodwillandintangibleassetsastheseassumptionsandestimatesmaychangeovertime itmayormaynotbenecessaryforthecompanytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreaseshealthcare costtrendratesandattritionratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsonthese rates stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsovertheserviceperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandexpected dividendyieldpriortofiscalforperformanceshareunitsthefairmarketvaluewascalculatedforeachofthethree componentgoalsatthedateofgrantoperationalsalesadjustedoperationalearningspershareandrelativetotal shareholderreturnbeginninginfiscalforperformanceshareunitsthefairmarketvalueiscalculatedforthetwo componentgoalsatthedateofgrantadjustedoperationalearningspershareandrelativetotalshareholderreturnthefair valuesfortheearningspersharegoalofeachperformanceshareunitwasestimatedonthedateofgrantusingthefair marketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidontheperformanceshare unitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeachperformanceshareunit wasestimatedonthedateofgrantusingthemontecarlovaluationmodelseenotetotheconsolidatedfinancial statementsforadditionalinformation newaccountingpronouncements refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofjanuary economicandmarketfactors covidconsiderationsandbusinesscontinuity thecompanyhasconsideredvariousinternalandexternalfactorsinassessingthepotentialimpactofcovidonits businessandfinancialresultsbaseduponinformationavailableatthistimeasfollows operatingmodelthecompanyhasadiversifiedbusinessmodelacrossthehealthcareindustrywithflexibilitydesigned intoitsmanufacturingresearchanddevelopmentclinicaloperationsandcommercialcapabilities supplychainthecompanycontinuestoleverageitsglobalmanufacturingfootprintanddualsourcecapabilitieswhile closelymonitoringandmaintainingcriticalinventoryatmajordistributioncentersawayfromhighriskareastoensure adequateandeffectivedistribution businesscontinuitytherobustactivebusinesscontinuityplansacrossthecompanysnetworkhavebeeninstrumental inpreparingthecompanyforeventslikecovidandtheabilitytomeetthemajorityofpatientandconsumerneeds remainsuninterrupted workforcethecompanyhasputproceduresinplacetoprotectitsessentialworkforceinmanufacturingdistribution commercialandresearchoperationswhileensuringappropriateremoteworkingprotocolshavebeenestablishedfor otheremployees liquiditythecompanyshighqualitycreditratingallowsthecompanysuperioraccesstothefinancialcapitalmarkets fortheforeseeablefutureinthefiscalthirdquarterofthecompanyissuedapproximatelybillionof commercialpaperwithapproximatelybillionoutstandingatyearendforadditionalliquidityadditionallyinthe fiscalthirdquarterofthecompanyissuedseniorunsecurednotesforatotalofbillionthenetproceeds fromthisofferingwereusedtofundthemomentapharmaceuticalsincacquisitiononoctoberandforgeneral corporatepurposes johnsonjohnsonannualreport domesticandforeignlegislationthecompanywillcontinuetoassessandevaluatetheongoinggloballegislative effortstocombatthecovidimpactoneconomiesandthesectorsinwhichitparticipatescurrentlytherecent legislativeactsputinplacearenotexpectedtohaveamaterialimpactonthecompanysoperations infiscalthecompanyenteredintoaseriesofcontractmanufacturingarrangementsforvaccineproductionwith thirdpartycontractmanufacturingorganizationsthesearrangementsprovidethecompanywithfuturesupplemental commercialcapacityforvaccineproductionandpotentiallytransferablerightstosuchproductionifcapacityisnot requiredamountspaidandcontractuallyobligatedtobepaidtothesecontractmanufacturingorganizationsof approximatelybillionarereflectedintheprepaidexpensesandotherotherassetsaccruedliabilitiesandother liabilitiesaccountsinthecompanysconsolidatedbalancesheetuponexecutionofeachagreementadditionallythe companyhasenteredintocertainvaccinedevelopmentcostsharingarrangementswithgovernmentrelatedorganizations thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymakers consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcerns thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheusthe weightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproducts prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin argentinabeginninginthefiscalthirdquarterofandvenezuelaashighlyinflationaryasthepriorthreeyear cumulativeinflationratesurpassedthisdidnothaveamaterialimpacttothecompanysresultsintheperiodin thefaceofincreasingcoststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms productivityimprovementsandperiodicpriceincreases injunetheunitedkingdomukheldareferenduminwhichvotersapprovedanexitfromtheeuropeanunion eucommonlyreferredtoasbrexittheukofficiallyexitedtheeuonjanuaryhowevertherewasa transitionperiodtoallowtimetoagreethetermsofanewtradedealondecembertheukeuandthe europeanatomicenergycommunityeuratomsignedtheeuuktradeandcooperationagreementtcaoverthe lastfewyearsbrexithascreatedglobalpoliticalandeconomicuncertaintyandhasledtovolatilityinexchangeratesand interestratesadditionalcostcontainmentbythirdpartypayorsandchangesinregulationswhiletheukandeuhave nowagreedonafuturetradeandcooperationagreementitisstillunclearwhattheultimatefinancialtraderegulatoryand legalimplicationsthewithdrawaloftheukfromtheeuwillhavehoweverthecompanycurrentlydoesnotbelievethat theseandotherrelatedeffectswillhaveamaterialimpactonthecompanysconsolidatedfinancialpositionoroperating resultsasofjanuarythebusinessofthecompanysuksubsidiariesrepresentedlessthanofthe companysconsolidatedassetsandlessthanofthecompanysfiscaltwelvemonthsrevenues thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandnetincomebyapproximatelymillion governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlawswhichmayincludeincreasingor decreasingexistingstatutorytaxratesachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe companysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis enactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementof earningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothe statutorytaxratemayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter andyearinwhichthelawchangeisenacted thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare products changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaying medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompanys businesses johnsonjohnsonannualreportthecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefiled abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththefdaorotherwisechallenged thecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmanyofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericorbiosimilar versionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarketshareand revenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangible assetthereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplace legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuchestimatesandjudgmentscanbe affectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtintheproceedingsare unsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsarein earlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindisputeproceduralorjurisdictionalissues theuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachievecomprehensivemultiparty settlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerouspartiesinvolvedtothe extentadverseverdictshavebeenrenderedagainstthecompanythecompanydoesnotrecordanaccrualuntilalossis determinedtobeprobableandcanbereasonablyestimated inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceedings commonstock thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompany johnsonjohnsonannualreport item quantitative qualitative disclosures market risk theinformationcalledforbythisitemisincorporatedhereinbyreferencetoitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesfinancingandmarketrisk ofthisreportandnotesummaryofsignificantaccountingpoliciesfinancialinstrumentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport item financial statements supplementary data indextoauditedconsolidatedfinancialstatements consolidatedbalancesheets consolidatedstatementsofearnings consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflows notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporting johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated balance sheets atjanuaryanddecember dollarsinmillionsexceptshareandpershareamountsnote assets currentassets cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccounts inventoriesnotesand prepaidexpensesandotherreceivables assetsheldforsalenote totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherassets totalassets liabilitiesandshareholdersequity currentliabilities loansandnotespayablenote accountspayable accruedliabilities accruedrebatesreturnsandpromotions accruedcompensationandemployeerelatedobligations accruedtaxesonincomenote totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand longtermtaxespayablenote otherliabilities totalliabilities commitmentsandcontingenciesnote shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshares commonstockparvaluepersharenoteauthorizedsharesissued shares accumulatedothercomprehensiveincomelossnote retainedearnings lesscommonstockheldintreasuryatcostnotesharesandshares totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements earnings dollarsandsharesinmillionsexceptpershareamountsnote salestocustomers costofproductssold grossprofit sellingmarketingandadministrativeexpenses researchanddevelopmentexpense inprocessresearchanddevelopmentnote interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearnings netearningspersharenotesand basic diluted averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements comprehensive income dollarsinmillionsnote netearnings othercomprehensiveincomelossnetoftax foreigncurrencytranslation securities unrealizedholdinggainlossarisingduringperiod reclassificationstoearnings netchange employeebenefitplans priorservicecreditcostnetofamortization gainlossnetofamortization effectofexchangerates netchange derivativeshedges unrealizedgainlossarisingduringperiod reclassificationstoearnings netchange othercomprehensiveincomeloss comprehensiveincome thetaxeffectsinothercomprehensiveincomeforthefiscalyearsandrespectivelyforeigncurrency translationmillionmillionandmillionemployeebenefitplansmillionmillionandmillion derivativeshedgesmillionmillionandmillion seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements equity dollarsinmillionsnote accumulated common stock treasury retained comprehensive issued stock total earnings incomeloss amount amount balancedecember cumulativeadjustment netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary seenotetoconsolidatedfinancialstatementsforadditionaldetailsontheeffectofcumulativeadjustmentstoretainedearnings seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements cash flows dollarsinmillionsnote cashflowsfromoperatingactivities netearnings adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities depreciationandamortizationofpropertyandintangibles stockbasedcompensation assetwritedowns contingentconsiderationreversal netgainonsaleofassetsbusinesses deferredtaxprovision creditlossesandaccountsreceivableallowances changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestitures decreaseincreaseinaccountsreceivable increaseininventories increaseinaccountspayableandaccruedliabilities increaseinothercurrentandnoncurrentassets increasedecreaseinothercurrentandnoncurrentliabilities netcashflowsfromoperatingactivities cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestments salesofinvestments creditsupportagreementsactivitynet otherprimarilylicensesandmilestones netcashusedbyinvestingactivities cashflowsfromfinancingactivities dividendstoshareholders repurchaseofcommonstock proceedsfromshorttermdebt repaymentofshorttermdebt proceedsfromlongtermdebtnetofissuancecosts repaymentoflongtermdebt proceedsfromtheexerciseofstockoptionsemployeewithholdingtaxonstockawardsnet creditsupportagreementsactivitynet netcashusedbyfinancingactivities effectofexchangeratechangesoncashandcashequivalents decreaseincreaseincashandcashequivalents cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalized incometaxes supplementalscheduleofnoncashinvestingandfinancingactivities treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceedsemployee withholdingtaxonstockawards conversionofdebt acquisitions fairvalueofassetsacquired fairvalueofliabilitiesassumedandnoncontrollinginterests netcashpaidforacquisitionsnote seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport notes consolidated financial statements summary significant accounting policies principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminatedcolumnsandrowswithintablesmaynotaddduetorounding percentageshavebeencalculatedusingactualnonroundedfigures descriptionofthecompanyandbusinesssegments thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpreviouslyreferredtoasconsumer pharmaceuticalandmedicaldevicestheconsumerhealthsegmentincludesabroadrangeofproductsusedinthebaby careoralcareskinhealthbeautyoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsthese productsaremarketedtothegeneralpublicandsoldonlineecommerceandtoretailoutletsanddistributorsthroughout theworldthepharmaceuticalsegmentisfocusedonsixtherapeuticareasincludingimmunologyinfectiousdiseases neuroscienceoncologypulmonaryhypertensionandcardiovascularandmetabolicdiseasesproductsinthissegment aredistributeddirectlytoretailerswholesalershospitalsandhealthcareprofessionalsforprescriptionusethemedical devicessegmentincludesabroadrangeofproductsusedintheorthopaedicsurgeryinterventionalsolutions cardiovascularandneurovascularandeyehealthfieldswhicharedistributedtowholesalershospitalsandretailersand usedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics newaccountingstandards recentlyadoptedaccountingstandards asucollaborativearrangements thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdateclarifiestheinteraction betweenasccollaborativearrangementsandascrevenuefromcontractswithcustomerstheupdate clarifiesthatcertaintransactionsbetweenparticipantsinacollaborativearrangementshouldbeaccountedforunderasc whenthecounterpartyisacustomerinadditiontheupdateprecludesanentityfrompresentingconsiderationfroma transactioninacollaborativearrangementasrevenueifthecounterpartyisnotacustomerforthattransactionthe adoptionofthisstandarddidnothaveamaterialimpactonthecompanysconsolidatedfinancialstatements asufinancialinstrumentscreditlosses thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdateintroducesthecurrent expectedcreditlossceclmodelwhichrequiresanentitytomeasurecreditlossesforcertainfinancialinstrumentsand financialassetsincludingtradereceivablesunderthisupdateoninitialrecognitionandateachreportingperiodanentity isrequiredtorecognizeanallowancethatreflectstheentityscurrentestimateofcreditlossesexpectedtobeincurred overthelifeofthefinancialinstrumenttheadoptionofthisstandarddidnothaveamaterialimpactonthecompanys consolidatedfinancialstatements asucompensationdefinedbenefitplans thecompanyadoptedthisstandardinthefiscalyearendedthisstandardrevisedthefinancialstatementnote disclosurerequirementsofascfordefinedbenefitplansponsorstheadoptionofthisstandardhadnoimpact onthecompanysconsolidatedfinancialstatementsseenotetotheconsolidatedfinancialstatementsfordefined benefitplandisclosures johnsonjohnsonannualreportaccountingstandardsadoptedinthefiscalwithacumulativeeffecttotheopening balanceofretainedearnings thefollowingtablesummarizesthecumulativeeffectadjustmentsmadetotheopeningbalanceofretainedearnings uponadoptionoftheseaccountingstandardsin cumulativeeffect adjustmentincrease decreaseto dollarsinmillions retainedearnings asurevenuefromcontractswithcustomers asufinancialinstruments asuincometaxesintraentitytransfers total recentlyissuedaccountingstandards notadoptedasofjanuary thecompanyassessestheadoptionimpactsofrecentlyissuedaccountingstandardsbythefinancialaccounting standardsboardonthecompanysfinancialstatementsaswellasmaterialupdatestopreviousassessmentsifanyfrom thecompanysannualreportonformkforthefiscalyearendeddecembertherewerenonewmaterial accountingstandardsissuedinfiscalthatimpactedthecompany cashequivalents thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastaninvestmentgradecreditratingthecompanyinvestsitscashprimarilyingovernment securitiesandobligationscorporatedebtsecuritiesmoneymarketfundsandreverserepurchaseagreementsrras rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonths fromthedateofpurchaseareclassifiedasmarketablesecurities investments investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare reportedinearningsinvestmentsclassifiedasavailableforsaledebtsecuritiesarecarriedatestimatedfairvaluewith unrealizedgainsandlossesrecordedasacomponentofaccumulatedothercomprehensiveincomeavailableforsale securitiesavailableforcurrentoperationsareclassifiedascurrentassetsotherwisetheyareclassifiedaslongterm managementdeterminestheappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeof purchaseandreevaluatessuchdeterminationateachbalancesheetdatethecompanyreviewsitsinvestmentsfor impairmentandadjuststheseinvestmentstofairvaluethroughearningsasrequired propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheassets buildingandbuildingequipment years landandleaseholdimprovements years machineryandequipment years johnsonjohnsonannualreport thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflows revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer aresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthecompanysglobalpayment termsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentivestradepromotionscoupons productreturnsanddiscountstocustomersareaccountedforasvariableconsiderationandrecordedasareductionin salestheliabilityisrecognizedwithinaccruedrebatesreturnsandpromotionsontheconsolidatedbalancesheet productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarkets servedasignificantportionoftheliabilityrelatedtorebatesisfromthesaleofthecompanyspharmaceuticalproducts withintheusprimarilythemanagedcaremedicareandmedicaidprogramswhichamountedtobillionand billionasofjanuaryanddecemberrespectivelythecompanyevaluatesmarketconditionsfor productsorgroupsofproductsprimarilythroughtheanalysisofwholesalerandotherthirdpartysellthroughandmarket researchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerhealthandpharmaceuticalsegmentsarealmostexclusivelynotresalablesales returnsforcertainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompany infrequentlyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhas beenapproximatelyofannualnettradesalesduringeachofthefiscalyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsforcertain productswhichareincludedinsalestocustomersforallyearspresentedprofitsharepaymentswerelessthanof thetotalrevenuesandareincludedinsalestocustomers seenotetotheconsolidatedfinancialstatementsforfurtherdisaggregationofrevenue shippingandhandling shippingandhandlingcostsincurredwerebillionbillionandbillioninfiscalyearsand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresented johnsonjohnsonannualreportinventories inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed annuallyforimpairmentthecompanycompleteditsannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpoint theintangibleassetwillbewrittenofforpartiallyimpaired intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstruments asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instruments leases thecompanydetermineswhetheranarrangementisaleaseatcontractinceptionbyestablishingifthecontractconveys therighttocontroltheuseofidentifiedpropertyplantorequipmentforaperiodoftimeinexchangeforconsideration rightofuserouassetsandleaseliabilitiesforoperatingleasesareincludedinotherassetsaccruedliabilitiesand otherliabilitiesontheconsolidatedbalancesheettherouassetsrepresenttherighttouseanunderlyingassetforthe leasetermandleaseliabilitiesrepresentanobligationtomakeleasepaymentsarisingfromtheleasecommitmentsunder financeleasesarenotsignificantandareincludedinpropertyplantandequipmentloansandnotespayableandlong termdebtontheconsolidatedbalancesheet rouassetsandleaseliabilitiesarerecognizedattheleasecommencementdatebasedonthepresentvalueofall minimumleasepaymentsovertheleasetermthecompanyusesitsincrementalborrowingratebasedontheinformation availableatcommencementdateindeterminingthepresentvalueofleasepaymentswhentheimplicitrateisnotreadily determinableleasetermsmayincludeoptionstoextendorterminatetheleasetheseoptionsareincludedinthelease termwhenitisreasonablycertainthatthecompanywillexercisethatoptionoperatingleaseexpenseisrecognizedona straightlinebasisovertheleasetermthecompanyhaselectedthefollowingpolicyelectionsonadoptionuseof portfolioapproachonleasesofassetsundermasterserviceagreementsexclusionofshorttermleasesonthebalance sheetandnotseparatingleaseandnonleasecomponents thecompanyprimarilyhasoperatingleaseforspacevehiclesmanufacturingequipmentanddataprocessingequipment therouassetpertainingtooperatingleaseswasbillionandbillioninandrespectivelythelease liabilitywasbillionandbillioninandrespectivelytheoperatingleasecostswerebillion billionandbillioninandrespectivelycashpaidforamountsincludedinthemeasurementof leaseliabilitieswerebillionandbillioninandrespectively productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially johnsonjohnsonannualreport determinedestimateswhereapplicabletheaccrualsareadjustedperiodicallyasadditionalinformationbecomes availablethecompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecosts areprobableandcanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany thecompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated thecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimated researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredinaccordancewithascresearchand developmentupfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment collaborationsareexpensedasincurreduptothepointofregulatoryapprovalpaymentsmadetothirdpartiessubsequent toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproductamounts capitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulatedamortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopment amountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesaregenerallyreflectedasareductionof researchanddevelopmentexpensebecausetheperformanceofcontractdevelopmentservicesisnotcentraltothe companysoperationsingeneraltheincomestatementpresentationforthesecollaborationsisasfollows naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproductprofitsharepaymentsreceived salestocustomers royaltiesmilestonespaidtocollaborativepartnerpost costofproductssold regulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartnerorgovernmententity milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidated researchanddevelopmentexpense thecompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding xareltocodevelopedwithbayerhealthcareagandimbruvicadevelopedincollaborationandcomarketed withpharmacyclicsllcanabbviecompany separatelythecompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingdarzalex licensedfromgenmabas advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninfiscalyearsandrespectively johnsonjohnsonannualreportincometaxes incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition intheunitedstatesenactedintolawnewustaxlegislationtheustaxcutsandjobsacttcjathislaw includedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcodeincludingareductionofthestatutory corporatetaxratefromtoeffectiveonjanuarythetcjaincludedaprovisionforataxonall previouslyundistributedearningsofuscompanieslocatedinforeignjurisdictionsundistributedearningsintheformof cashandcashequivalentsweretaxedatarateofandallotherearningsweretaxedatarateofthistaxis payableoveryearsandwillnotaccrueinterestthesepaymentsbeganinandwillcontinuethroughthe remainingbalanceattheendofthewasapproximatelybillionofwhichbillionisclassifiedasnoncurrent andreflectedaslongtermtaxespayableonthecompanysbalancesheetthebalanceofthisaccountisrelatedto receivablesfromtaxauthoritiesnotexpectedtobereceivedinthenextmonths thetcjaalsoincludesprovisionsforataxonglobalintangiblelowtaxedincomegiltigiltiisdescribedasthe excessofausshareholderstotalnetforeignincomeoveradeemedreturnontangibleassetsasprovidedbythetcja injanuarythefasbissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe taxeffectsofgiltiintheperiodthetaxliabilityisgeneratedieperiodcostorprovidefordeferredtaxassetsand liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofgiltiinclusioninfutureyears uponreversaliedeferredmethodinthecompanyelectedtoaccountforgiltiunderthedeferredmethod thedeferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseas giltiisincurredinfutureperiods thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromits internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximatelybillion undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimates thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxeswithholdingtaxes depreciationamortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresults mayormaynotdifferfromthoseestimates thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued theextenttowhichcovidimpactsthecompanysbusinessandfinancialresultswilldependonnumerousevolving factorsincludingbutnotlimitedtothemagnitudeanddurationofcovidtheextenttowhichitwillimpactworldwide johnsonjohnsonannualreport macroeconomicconditionsincludinginterestratesemploymentratesandhealthinsurancecoveragethespeedofthe anticipatedrecoveryandgovernmentalandbusinessreactionstothepandemicthecompanyassessedcertain accountingmattersthatgenerallyrequireconsiderationofforecastedfinancialinformationincontextwiththeinformation reasonablyavailabletothecompanyandtheunknownfutureimpactsofcovidasofjanuaryandthroughthe dateofthisreporttheaccountingmattersassessedincludedbutwerenotlimitedtothecompanysallowancefor doubtfulaccountsandcreditlossesinventoryandrelatedreservesaccruedrebatesandassociatedreservesandthe carryingvalueofthegoodwillandotherlonglivedassetswhiletherewasnotamaterialimpacttothecompanys consolidatedfinancialstatementsasofandforthefiscalyearendedjanuarythecompanysfutureassessmentof themagnitudeanddurationofcovidaswellasotherfactorscouldresultinmaterialimpactstothecompanys consolidatedfinancialstatementsinfuturereportingperiods annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks andthereforeincludesadditionalshippingdaysaswasthecaseinfiscalyearandwillbethecaseagaininfiscal year reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation cash cash equivalents current marketable securities attheendofthefiscalyearandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof estimated cash current carrying unrecognized fair cash marketable dollarsinmillions amount gain value equivalents securities cash nonussovereignsecurities usreverserepurchaseagreements corporatedebtsecurities moneymarketfunds timedeposits subtotal usgovtsecurities othersovereignsecurities corporatedebtsecurities subtotalavailableforsale totalcashcashequivalentsandcurrentmarketable securities johnsonjohnsonannualreport cash current carrying cash marketable dollarsinmillions amount equivalents securities cash nonussovereignsecurities usreverserepurchaseagreements otherreverserepurchaseagreements corporatedebtsecurities moneymarketfunds timedeposits subtotal govtsecurities corporatedebtsecurities subtotalavailableforsale totalcashcashequivalentsandcurrentmarketablesecurities heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearnings availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother comprehensiveincome attheendoffiscalyearthecarryingamountwasthesameastheestimatedfairvalue fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinputs thecontractualmaturitiesoftheavailableforsaledebtsecuritiesatjanuaryareasfollows cost fair dollarsinmillions basis value duewithinoneyear dueafteroneyearthroughfiveyears dueafterfiveyearsthroughtenyears totaldebtsecurities thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastaninvestmentgradecreditrating inventories attheendoffiscalyearsandinventorieswerecomprisedof dollarsinmillions rawmaterialsandsupplies goodsinprocess finishedgoods totalinventories seenotetotheconsolidatedfinancialstatementsfordetailsonassetsheldforsaleandtherelateddivestituresforthefiscal yearendeddecembertherewerenoassetsheldforsaleatjanuary johnsonjohnsonannualreport property plant equipment attheendoffiscalyearsandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillions landandlandimprovements buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet seenotetotheconsolidatedfinancialstatementsfordetailsonassetsheldforsaleandtherelateddivestituresforthefiscal yearendeddecembertherewerenoassetsheldforsaleatjanuary thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinfiscalyearsandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestinfiscalyearsandwas billionbillionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulated depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearnings intangible assets goodwill attheendoffiscalyearsandthegrossandnetamountsofintangibleassetswere dollarsinmillions intangibleassetswithdefinitelives patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelives trademarks purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelives totalintangibleassetsnet themajorityiscomprisedofcustomerrelationships infiscalyearthecompanycompletedmultipleacquisitionsandrecordedinprocessresearchanddevelopmentintangible assetsofbillionfrommomentapharmaceuticalsincbillionforbermekimabandcertainrelatedassetsfromxbiotechinc andbillionfromtheacquisitionofalloutstandingsharesinverbsurgicalinc johnsonjohnsonannualreportgoodwillasofjanuaryanddecemberasallocatedbysegmentofbusinesswasasfollows dollarsinmillions consumerhealth pharmaceutical medicaldevices total goodwillatdecember goodwillrelatedtoacquisitions currencytranslationother goodwillatdecember goodwillrelatedtoacquisitions currencytranslationother goodwillatjanuary theweightedaverageamortizationperiodforpatentsandtrademarksisyearstheweightedaverageamortization periodforcustomerrelationshipsandotherintangibleassetsisyearstheamortizationexpenseofamortizableassets includedincostofproductssoldwasbillionbillionandbillionbeforetaxforthefiscalyearsended januarydecemberanddecemberrespectivelyintangibleassetwritedownsareincludedin otherincomeexpensenet theestimatedamortizationexpenseforapprovedproductsbeforetaxforthefivesucceedingyearsisapproximately dollarsinmillions seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures fair value measurements thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthirdpartypurchasesofmaterials denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedges additionallythecompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate borrowingsthesederivativesaredesignatedasfairvaluehedgesthecompanyusescrosscurrencyinterestrateswaps andforwardforeignexchangecontractsdesignatedasnetinvestmenthedgesadditionallythecompanyusesforward foreignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilitiestheseforwardforeign exchangecontractsarenotdesignatedashedgesandthereforechangesinthefairvaluesofthesederivativesare recognizedinearningstherebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilities thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesthecompanymaintainscreditsupportagreementscsawithcertainderivative counterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsandnettingagreementsasof januarythetotalamountofcashcollateralpaidbythecompanyunderthecsaamountedtobillionnet relatedtonetinvestmentandcashflowhedgesonanongoingbasisthecompanymonitorscounterpartycreditratings thecompanyconsiderscreditnonperformancerisktobelowbecausethecompanyprimarilyentersintoagreements withcommercialinstitutionsthathaveatleastaninvestmentgradecreditratingrefertothetableonsignificantfinancial assetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercial institutionsasofjanuarythecompanyhadnotionalamountsoutstandingforforwardforeignexchange contractsandcrosscurrencyinterestrateswapsofbillionandbillionrespectivelyasofdecember thecompanyhadnotionalamountsoutstandingforforwardforeignexchangecontractsandcrosscurrencyinterest rateswapsofbillionandbillionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction johnsonjohnsonannualreport thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivatives areexpectedtobehighlyeffectiveforeignexchangecontractsdesignatedascashflowhedgesareaccountedforunder theforwardmethodandallgainslossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen thehedgeditemimpactsearningschangesinthefairvalueofthesederivativesarerecordedinaccumulatedother comprehensiveincomeuntiltheunderlyingtransactionaffectsearningsandarethenreclassifiedtoearningsinthesame accountasthehedgedtransaction gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccurtheeffectofwhichareimmaterialforthe fiscalyearsendedjanuaryanddecembergainsandlossesonnetinvestmenthedgeareaccounted throughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincometheportionexcludedfrom effectivenesstestingisrecordedthroughinterestincomeexpenseusingthespotmethodonanongoingbasisthe companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesofhedgeditemsifand whenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinued thecompanydesignateditseurodenominatednotesissuedinmaywithduedatesrangingfromtoas anetinvestmenthedgeofthecompanysinvestmentsincertainofitsinternationalsubsidiariesthatusetheeuroastheir functionalcurrencyinordertoreducethevolatilitycausedbychangesinexchangerates asofjanuarythebalanceofdeferrednetgainonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexcluding interestratecontractsnetinvestmenthedgestheamountultimatelyrealizedinearningsmaydifferasforeignexchange rateschangerealizedgainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative thefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendedjanuary anddecembernetoftax january december costof interest costof interest products rd income income products rd income income dollarsinmillions sales sold expense expense expense sales sold expense expense expense theeffectsoffairvaluenetinvestment andcashflowhedging gainlossonnetinvestment hedgingrelationship crosscurrencyinterestrateswaps contracts amountofgainorlossrecognizedin incomeonderivativeamount excludedfromeffectivenesstesting amountofgainorlossrecognizedin aoci gainlossoncashflowhedging relationship forwardforeignexchange contracts amountofgainorlossreclassified fromaociintoincome amountofgainorlossrecognizedin aoci crosscurrencyinterestrateswaps contracts amountofgainorlossreclassified fromaociintoincome amountofgainorlossrecognizedin aoci johnsonjohnsonannualreportthefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsendedjanuary anddecember locationofgainloss gainloss recognizedinincomeon recognizedin dollarsinmillions derivative incomeonderivative derivativesnotdesignatedashedginginstruments january december foreignexchangecontracts otherincomeexpense thefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendedjanuaryanddecember gainloss gainloss locationofgainorlossreclassified reclassifiedfrom recognizedin fromaccumulatedothercomprehensive accumulatedoci accumulatedoci incomeintoincome intoincome january december january december dollarsinmillions debt interestincomeexpense crosscurrencyinterestrateswaps interestincomeexpense thecompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily determinablefairvaluesthecompanymeasuresequityinvestmentsthatdonothavereadilydeterminablefairvaluesat costminusimpairmentifanyplusorminuschangesresultingfromobservablepricechangesinorderlytransactionsfor theidenticalorasimilarinvestmentofthesameissuer thefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsforthefiscalyearsendedjanuary anddecember january changesinfairvalue december reflectedinnet sales noncurrentother dollarsinmillions carryingvalue income purchasesother carryingvalue assets equityinvestmentswithreadily determinablevalue equityinvestmentswithoutreadily determinablevalue december changesinfairvalue december reflectedinnet sales noncurrentother dollarsinmillions carryingvalue income purchasesother carryingvalue assets equityinvestmentswithreadily determinablevalue equityinvestmentswithoutreadily determinablevalue recordedinotherincomeexpense otherincludesimpactofcurrency forthefiscalyearsendedjanuaryanddecemberforequityinvestmentswithoutreadilydeterminable marketvaluesmillionandmillionrespectivelyofthechangesinfairvaluereflectedinnetincomeweretheresult ofimpairmentsthereweremillionandmillionrespectivelyofchangesinfairvaluereflectedinnetincomedue tochangesinobservableprices fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbased measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilityin accordancewithascathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevelswithinthe hierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand johnsonjohnsonannualreport subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelanddebtsecuritieswhich areclassifiedaslevelthecompanyholdsacquisitionrelatedcontingentliabilitiesbaseduponcertainregulatoryand commercialeventswhichareclassifiedaslevelwhosevaluesaredeterminedusingdiscountedcashflow methodologiesorsimilartechniquesforwhichthedeterminationoffairvaluerequiressignificantjudgmentorestimations thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilities levelsignificantotherobservableinputs levelsignificantunobservableinputs thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofthefiscalyearendedjanuary anddecemberwereasfollows dollarsinmillions level level level total total derivativesdesignatedashedginginstruments assets forwardforeignexchangecontracts interestratecontracts total liabilities forwardforeignexchangecontracts interestratecontracts total derivativesnotdesignatedashedginginstruments assets forwardforeignexchangecontracts liabilities forwardforeignexchangecontracts availableforsaleotherinvestments equityinvestments debtsecurities otherliabilities contingentconsideration grosstonetderivativereconciliation dollarsinmillions totalgrossassets creditsupportagreementcsa totalnetasset totalgrossliabilities creditsupportagreementcsa totalnetliabilities johnsonjohnsonannualreportsummarizedinformationaboutchangesinliabilitiesforcontingentconsiderationisasfollows dollarsinmillions beginningbalance changesinestimatedfairvalue additions payments endingbalance assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofequityinvestmentsofmillionwhichareclassified aslevelandcontingentconsiderationofmillionclassifiedaslevel includesmillionofnoncurrentassetsasofdecember includescrosscurrencyinterestrateswapsandinterestrateswaps classifiedasnoncurrentotherassets classifiedascashequivalentsandcurrentmarketablesecurities includesmillionmillionprimarilyrelatedtoaurishealthandmillionclassifiedasnoncurrentotherliabilitiesas ofjanuarydecemberanddecemberrespectivelyincludesmillionandmillionclassifiedas currentliabilitiesasofjanuaryanddecemberrespectively ongoingfairvalueadjustmentamountsarerecordedprimarilyinresearchanddevelopmentexpensethecompanyrecordeda contingentconsiderationreversalofmillioninrelatedtothetimingofcertaindevelopmentalmilestonesassociatedwith theaurishealthacquisitionthereversalofthecontingentconsiderationwasrecordedinotherincomeandexpense seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowings thecomponentsoflongtermdebtareasfollows effective effective dollarsinmillions rate rate zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue notesdue notesdue notesdue notesduebeurobeuro notesdue debenturesdue notesdue notesdue notesduemmeurommeuro notesdue mmgbpmmgbp notesdue notesdue notesdue notesdue notesdue notesduemmeurommeuro notesdue notesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue debenturesdue notesdue debenturesdue notesdue notesdue notesdue notesdue notesdue notesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt johnsonjohnsonannualreport weightedaverageeffectiverate translationrateatjanuary translationrateatdecember theexcessofthefairvalueoverthecarryingvalueofdebtwasbillionattheendoffiscalyearandbillionattheend offiscalyear inthefiscalthirdquarterofthecompanyissuedseniorunsecurednotesforatotalofbillion fairvalueofthelongtermdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerpricesand significantotherobservableinputs thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankslondoninterbankofferedratesliborsecuredovernightfinancingratesofrswapcurveor otherapplicablemarketrateasallowedplusapplicablemarginscommitmentfeesundertheagreementsarenotmaterial throughoutfiscalyearthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket shorttermborrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendof fiscalyearofwhichbillionisthecurrentportionofthelongtermdebtandtheremainderiscommercialpaper andlocalborrowingsbyinternationalsubsidiaries throughoutfiscalyearthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket shorttermborrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendof fiscalyearofwhichbillionisthecurrentportionofthelongtermdebtandtheremainderprincipallyrepresents localborrowingbyinternationalsubsidiaries aggregatematuritiesoflongtermdebtobligationscommencinginare dollarsinmillions income taxes theprovisionfortaxesonincomeconsistsof dollarsinmillions currentlypayable ustaxes internationaltaxes totalcurrentlypayable deferred ustaxes internationaltaxes totaldeferred provisionfortaxesonincome includesbillionofdeferredtaxexpensefortheadoptionofthedeferredmethodtoaccountforgilti johnsonjohnsonannualreport acomparisonofincometaxexpenseattheusstatutoryrateofinfiscalyearsandtothe companyseffectivetaxrateisasfollows dollarsinmillions us international earningsbeforetaxesonincome taxrates usstatutoryrate internationaloperations ustaxesoninternationalincome taxbenefitsoncapitalloss taxbenefitsonsharebasedcompensation tcjaandrelatedimpacts allother effectiverate forallperiodspresentedthecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentivesinternational operationsreflectstheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheusparticularlyireland switzerlandandpuertoricowhichisafavorableimpactontheeffectivetaxrateascomparedwiththeusstatutoryratethe andamountsincludetheimpactofthenewtaxlegislationenactmentinswitzerlandwhichisfurtherdescribedbelow includestheimpactofthegiltitaxtheforeignderivedintangibleincomedeductionandotherforeignincomethatistaxableunder theustaxcode representsimpactofadjustmentstobalancesoriginallyrecordedaspartofthetcjaprovisionaltaxchargefurther informationprovidedbelow certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation thefiscalyeartaxratedecreasedbycomparedtothefiscalyeartaxratewhichwasprimarilydrivenby thefollowingitemsinfiscalyearswitzerlandenactedthefederalactontaxreformandahvfinancingtraf whichbecameeffectiveonjanuarythefederaltransitionalprovisionsoftrafallowcompaniesundercertain conditionstoadjustthetaxbasisincertainassetstofairvalueiestepuptobedepreciatedandamortizedresulting inanincrementalswisstaxdeductionoverthetransitionalperiod trafalsoprovidesforparameterswhichenabletheswisscantonstoestablishlocalizedtaxratesandregulationsfor companiesthenewcantonaltaxparametersincludefavorabletaxbenefitsforpatentsandadditionalresearchand developmenttaxdeductionsthecantonaltransitionalprovisionsoftrafallowedcompaniestoelecteithertaxbasis stepupsimilartothefederaltransitionbenefitoralternativestatutorytaxrateforaperiodnottoexceedyearsthe companycurrentlyhasoperationslocatedinvariousswisscantonsduringthefiscalyearasdescribedinfurther detailbelowthecompanyrecordedtheimpactsofthetrafthatwereenactedinthatperiod duringthefiscalyearthefinalcantonwherethecompanymaintainssignificantoperationsenactedtraf legislationadditionallythecompanyreceivedrulingsfromtheswissfederalandcantonaltaxauthoritiesintheremaining jurisdictionswhereithassignificantoperationstheserulingsresultedinthecompanyrevisingitsestimateonthetax basisadjustmentiestepupforitsassetsandasaresultthecompanyrecordedadditionaldeferredtaxbenefitsin thecompanyrecognizedanetbenefitinthefiscalyearforswisstaxreformofapproximatelybillionor benefittothecompanysannualeffectivetaxratecomprisedofthefollowingitems approximatelybilliontaxbenefitrelatingtotheremeasurementofswissdeferredtaxassetsandliabilitiesforthe changeinthefederalandcantonaltaxrateswhereenactmentoccurredinthefiscalyearthisbenefithasbeen reflectedasinternationaloperationsonthecompanyseffectivetaxratereconciliation amilliondeferredtaxassetrelatedtotheestimatedvalueofafederaltaxbasisstepupofthecompanysswiss subsidiariesassetsasdescribedabovethisbenefithasbeenreflectedasinternationaloperationsonthecompanys effectivetaxratereconciliation johnsonjohnsonannualreport approximatelybillionofusdeferredtaxexpenserelatingtothegiltideferredtaxliabilityresultingfromthe remeasurementoftheswissdeferredtaxassetsandliabilitiesinthefiscalyearthisbenefithasbeenreflectedas ustaxoninternationalincomeonthecompanyseffectivetaxratereconciliation thecompanydoesnotexpecttoreceivefuturerulingsregardingthetransitionalprovisionsoftraf alsointhefiscalfourthquarterofthecompanyrecognizedacapitallossoncertainusaffiliatesrelatedtothe previouslyimpairedbookvalueofcertainintangibleswhichreducedthetaxratebyapproximatelywhichis reflectedasataxbenefitsoncapitallossontheeffectivetaxratereconciliationinadditioninthefiscalyearthe companyhadlowerincomeinhighertaxjurisdictionsprimarilydrivenby theimpactoftheaccrualoflitigationcostsrelatedtotalcforbillionwhichreducedtheusearningsbefore taxesataneffectivetaxrateof theaccrualofadditionallegalcostsincludinganadditionalbillionassociatedwitharevisedagreementin principletosettleopioidlitigationataneffectivetaxrateof thecompanyalsogeneratedadditionaltaxbenefitsfromstockbasedcompensationthatwereeitherexercisedorvested reducedthecontingentconsiderationliabilityrelatedtotheaurishealthacquisitionseenoteandreversalofsomeof itsunrecognizedtaxbenefitsduetothecompletionofseveralyearsoftaxexaminationsincertainjurisdictionsduringthe fiscalyear thefiscalyeartaxratedecreasedbycomparedtothefiscalyeartaxrateinadditiontotheimpactof trafdiscussedinmoredetailbelowtheprimarydriversofthenetdecreasewereasfollows thecompanyreorganizedtheownershipstructureofcertainwhollyownedinternationalsubsidiariesinthefiscal fourthquarterofwhichresultedinareductionofcertainwithholdingandlocaltaxesthatithadpreviously recognizedaspartoftheprovisionaltaxcutsandjobsacttcjataxchargeinthefiscalyearandfinalizedin thefiscalyearfollowingthecompletionofthisrestructuringandapprovalbytheapplicablelocalauthorities thecompanyreversedadeferredtaxliabilityofbillionandarelateddeferredtaxassetofbillionforus foreigntaxcreditsforanetdeferredtaxbenefitofbilliondecreasingtheannualeffectivetaxratebythis benefithasbeenreflectedastcjaandrelatedimpactsonthecompanyseffectivetaxratereconciliation theimpactoftheagreementinprincipletosettleopioidlitigationforbillionseenotetotheconsolidated financialstatementswhichreducedtheusearningsbeforetaxesataneffectivetaxrateofanddecreased thecompanysannualeffectivetaxratebyapproximately indecemberoffiscalyeartheustreasuryissuedfinalforeigntaxcreditregulationswhichresultedinthe companyrevisingtheamountofforeigntaxcreditsthatwereinitiallyrecordedinthefiscalyearaspartofthe provisionaltcjataxchargeasaresultthecompanyrecordedanincreaseddeferredtaxassetrelatedtothese foreigntaxcreditsofapproximatelybillionortotheannualeffectivetaxratethisbenefithasbeen reflectedastcjaandrelatedimpactsonthecompanyseffectivetaxratereconciliation thecompanyreassesseditsuncertaintaxpositionsrelatedtothecurrentirsauditandincreaseditsunrecognized taxbenefitbybillionliabilitywhichincreasedtheannualeffectivetaxratebyapproximatelyseesectionon unrecognizedtaxbenefitsforadditionalinformationasthesepositionswererelatedtouncertaintaxregarding internationaltransferpricingthisexpensehasbeenclassifiedasinternationaloperationsonthecompanys effectivetaxratereconciliationsubsequenttodecemberthecompanyreceivedandagreedtonoticesof proposedadjustmentsnopasfromtheirsthecompanybelievesitisadequatelyreservedforpotential exposures therewereseveralonetimetaximpactsthatresultedinacumulativenettaxbenefittotheannualeffectivetax rateoftheseitemsincludedthelifescandivestituretheadjustmenttotheprovisionaltcjataxcharge andtheaccelerationofcertaintaxdeductionsaspartofthetaxreturn moreincomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsascomparedto asdescribedabovefortheswisstaxlegislationinthefiscalyearthecompanyrecordedanettaxexpenseof billionwhichincreasedtheeffectivetaxrateforthefiscalyearbyapproximatelythisnettaxexpense relatedtofederalandcertaincantonalenactmentsinthefiscalyearconsistingofthefollowingprovisions approximatelybilliontaxexpenserelatingtotheremeasurementofswissdeferredtaxassetsandliabilitiesfor thechangeinthefederalandcantonaltaxrateswhereenactmentoccurredbydecemberthisexpense hasbeenreflectedasinternationaloperationsonthecompanyseffectivetaxratereconciliation johnsonjohnsonannualreport abilliondeferredtaxassetrelatedtotheestimatedvalueofafederaltaxbasisstepupofthecompanysswiss subsidiariesassetsthisbenefithasbeenreflectedasinternationaloperationsonthecompanyseffectivetaxrate reconciliation approximatelymillionofusdeferredtaxexpenserelatingtothegiltideferredtaxliabilityresultingfromthe remeasurementoftheswissdeferredtaxassetsandliabilitiesandthenewdeferredtaxassetforthefederalstepup thisbenefithasbeenreflectedasustaxoninternationalincomeonthecompanyseffectivetaxrate reconciliation inthefiscalyearthecompanycompleteditsfullassessmentandfinalizedtheaccountingfortheimpactofthe tcjathecompanyrecordednetadjustmentstotheabovecomponentsoftheprovisionalchargeofapproximately billiontheserevisionswerebasedonupdatedestimatesandadditionalanalysisbymanagementaswellasapplying interpretativeguidanceissuedbytheusdepartmentoftreasurytothefactsandcircumstancesthatexistedasofthe tcjaenactmentdatethischargewasprimarilyrelatedtoadditionaldeferredtaxliabilitiesforforeignlocaland withholdingtaxesfortheremainingbalanceofundistributedforeignearningsasofdecemberthatwerenot providedforintheprovisionalcharge asdescribedinnoteinthefiscalyearthecompanyelectedtotreatgiltiasaperiodexpenseunderthe deferredmethodandrecordedadeferredtaxcostofapproximatelybillioninthefiscalyearrelatedtofactsand circumstancesthatexistedonthedateoftcjaenactmentduringthecompanyreorganizedtheownership structureofcertainforeignsubsidiarieswhichresultedinareductionofcertainforeignwithholdingtaxesthatithad recognizedaspartoftheprovisionaltcjataxchargeinthefourthquarteroffollowingthecompletionofthis restructuringandasaresultofclarificationbyswisstaxauthoritiesregardingtheapplicabilityofwithholdingtaxto repatriationofcertainearningsthecompanyreversedadeferredtaxliabilityofbillionandarelateddeferredtax assetofbillionforusforeigntaxcreditsforanetdeferredtaxbenefitofbillionthisbenefithasbeenreflected astcjaandrelatedimpactsonthecompanyseffectivetaxratereconciliation temporarydifferencesandcarryforwardsattheendoffiscalyearsandwereasfollows deferredtax deferredtax dollarsinmillions asset liability asset liability employeerelatedobligations stockbasedcompensation depreciationamortization nondeductibleintangibles internationalrdcapitalizedfortax reservesliabilities incomereportedfortaxpurposes netoperatinglosscarryforwardinternational undistributedforeignearnings globalintangiblelowtaxedincome miscellaneousinternational miscellaneousus totaldeferredincometaxes certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation thecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenetlossesthecompanybelievesthatitis morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxassets johnsonjohnsonannualreportthefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits dollarsinmillions beginningofyear increasesrelatedtocurrentyeartaxpositions increasesrelatedtopriorperiodtaxpositions decreasesrelatedtopriorperiodtaxpositions settlements lapseofstatuteoflimitations endofyear theunrecognizedtaxbenefitsofbillionatjanuaryifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits inprogresswithanumberoftaxauthoritieswithrespecttotheunitedstatestheinternalrevenueserviceirshas completeditsauditforthetaxyearsthroughasofdecemberthecompanyclassifiedunrecognizedtax benefitsandrelatedinterestofapproximatelybillionasacurrentliabilityontheaccruedtaxesonincomelineofthe consolidatedbalancesheetinthefiscalyearthecompanymadeitsfinalpaymentsforapproximatelybillion totheustreasuryrelatedtothefinalsettlementoftaxauditliability inothermajorjurisdictionswherethecompanyconductsbusinesstheyearsthatremainopentotaxauditgobacktothe yearthecompanybelievesitispossiblethattaxauditsmaybecompletedoverthenexttwelvemonthsbytaxing authoritiesinsomejurisdictionsoutsideoftheunitedstateshoweverthecompanyisnotabletoprovideareasonably reliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxpositions thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilities exceptaspreviouslynotedonamountsrelatedtothecurrentunitedstatesirsauditinterestexpenseandpenalties relatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompanyrecognizedaftertaxinterest expenseofmillionmillionandmillioninfiscalyearsandrespectivelythetotalamountof accruedinterestwasmillionandmillioninfiscalyearsandrespectively employee related obligations attheendoffiscalandfiscalemployeerelatedobligationsrecordedontheconsolidatedbalancesheets dollarsinmillions pensionbenefits postretirementbenefits postemploymentbenefits deferredcompensation totalemployeeobligations lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheets johnsonjohnsonannualreport pensions benefit plans thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependents manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant intheusnonunionpensionbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployees compensationduringthelastfiveyearsbeforeretirementandthenumberofyearsofservicethefinalaveragepay formulauspensionbenefitsforemployeeshiredafterarecalculatedusingadifferentformulabasedonemployee compensationovertotalyearsofservicetheretirementvalueformula injanuarythecompanyannouncedthateffectiveonjanuaryalleligibleusnonunionemployees regardlessofhiredatewillearnbenefitsundertheretirementvalueformulathisamendmentdoesnotaffectthebenefits accruedunderthefinalaveragepayformulaforservicebeforejanuarytheimpactofthischangedecreasesthe pboasofjanuarybyapproximatelybillionandisincludedintheamendmentslineinthechangein benefitobligation internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchasedundergroup contractsorreservesareprovided thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture inandthecompanyuseddecemberanddecemberrespectivelyasthemeasurement dateforallusandinternationalretirementandotherbenefitplans netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponents retirementplans otherbenefitplans dollarsinmillions servicecost interestcost expectedreturnonplanassets amortizationofpriorservicecost recognizedactuariallossesgains curtailmentsandsettlements netperiodicbenefitcost unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgains andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheaccumulatedpostretirementbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridor areamortizedovertheaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheaverageremainingfutureserviceofplan participantsatthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedover theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment johnsonjohnsonannualreportthefollowingtablerepresentstheweightedaverageactuarialassumptions retirementplans otherbenefitplans worldwidebenefitplans netperiodicbenefitcost servicecostdiscountrate interestcostdiscountrate rateofincreaseincompensationlevels expectedlongtermrateofreturnonplanassets benefitobligation discountrate rateofincreaseincompensationlevels thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitiesthecompanys methodologyindeterminingserviceandinterestcostusesdurationspecificspotratesalongthatyieldcurvetotheplans liabilitycashflows theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsources longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividuals healthcareplans healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate johnsonjohnsonannualreport thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatfiscalyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplans otherbenefit retirementplans plans dollarsinmillions changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontributions amendments actuarialgainslosses divestituresacquisitions curtailmentssettlementsrestructuring benefitspaidfromplan effectofexchangerates projectedbenefitobligationendofyear changeinplanassets planassetsatfairvaluebeginningofyear actualreturnonplanassets companycontributions planparticipantcontributions settlements divestituresacquisitions benefitspaidfromplanassets effectofexchangerates planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowing noncurrentassets currentliabilities noncurrentliabilities totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowing netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffects accumulatedbenefitobligationsendofyear injanuarythecompanyannouncedthateffectiveonjanuaryalleligibleusnonunionemployeesregardlessofhire datewillearnbenefitsundertheretirementvalueformulathisamendmentdoesnotaffectthebenefitsaccruedunderthefinal averagepayformulaforservicebeforejanuary theactuariallossesforretirementplansinandwasprimarilyrelatedtodecreasesindiscountrates inthecompanyofferedavoluntarylumpsumpaymentoptionforcertaineligibleformeremployeeswhoarevestedparticipants oftheusqualifieddefinedbenefitpensionplanthedistributionofthelumpsumswascompletedbytheendoffiscalthe amountdistributedinwasapproximatelymillion johnsonjohnsonannualreportotherbenefit retirementplans plans dollarsinmillions amountsrecognizedinnetperiodicbenefitcostandothercomprehensive income netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerates totallossincomerecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticeas fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunded inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplans nonqualifiedplans fundedplans unfundedplans dollarsinmillions planassets projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillions projectedfuturebenefitpayments retirementplans otherbenefitplans thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamounts donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillions projectedfuturecontributions eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicles johnsonjohnsonannualreport separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretirees durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplans permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefunds thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareasfollows percentof target planassets allocation worldwideretirementplans equitysecurities debtsecurities totalplanassets determinationoffairvalueofplanassets theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquoted marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilities equityordebtpricesforeignexchangeratesandcreditcurves whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thenetassetvaluenavisbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthen dividedbythenumberofsharesoutstanding afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentfundscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamountheld ondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenavprovidedby theadministratorofthefundthenavisaquotedpriceinamarketthatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarketon whichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified aslevelleveldebtinstrumentsarepricedbasedonunobservableinputs equitysecuritiesequitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallequitysecuritiesareclassifiedwithinlevelofthevaluationhierarchy commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorassetsin thelevelcategoryhaveaquotedmarketprice johnsonjohnsonannualreport otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipstheseinvestmentvehiclesarevalued usingthenavprovidedbythefundadministratorotherassetsthatareexchangelistedandactivelytradedare classifiedaslevelwhileinactivelytradedassetsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprices significant inactive significant investments marketsfor observable unobservable measuredat identicalassets inputs inputs netasset level level level value totalassets dollarsinmillions shortterminvestmentfunds governmentandagencysecurities debtinstruments equitysecurities commingledfunds otherassets investmentsatfairvalue theactivityforthelevelassetsisnotsignificantforallyearspresented thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberanddecemberrespectivelyandusshortterminvestmentfundslevel ofmillionatdecember thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember savings plan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninfiscalyearsandrespectively capital treasury stock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousands shares amount balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary aggregatesharesofcommonstockissuedwereapproximatelysharesattheendoffiscalyears johnsonjohnsonannualreport cashdividendspaidwerepershareinfiscalyearcomparedwithdividendsofpershareinfiscalyear andpershareinfiscalyear onjanuarytheboardofdirectorsdeclaredaregularcashdividendofpersharepayableonmarch toshareholdersofrecordasoffebruary ondecemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstockthissharerepurchase programwascompletedasofseptember accumulated comprehensive income loss componentsofothercomprehensiveincomelossconsistofthefollowing total gainloss accumulated foreign gainloss employee currency benefit derivatives comprehensive dollarsinmillions translation securities plans hedges incomeloss december cumulativeadjustmenttoretainedearnings netchanges december netchanges december netchanges january pertheadoptionofasufinancialinstruments amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome detailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet employeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditionaldetails gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthehedged transactionseenoteforadditionaldetails international currency translation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyears orwhereasubstantialportionofitscashflowsarenotinthelocalcurrencyforthemajorityofthecompanyssubsidiaries thelocalcurrencyisthefunctionalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulated othercomprehensiveincometheothercurrentandnoncurrentassetslinewithinthestatementofcashflowsincludes theimpactofforeigncurrencytranslationthisequityaccountincludestheresultsoftranslatingcertainbalancesheet assetsandliabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighly inflationaryeconomiesargentinaandvenezuelathetranslationofbalancesheetaccountsforhighlyinflationary economiesarereflectedintheoperatingresults arollforwardofthechangesduringfiscalyearsandforforeigncurrencytranslationadjustmentsis includedinnote johnsonjohnsonannualreportnetcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninfiscalyearsandrespectively earnings per share thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended januarydecemberanddecember inmillionsexceptpershareamounts basicnetearningspershare averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplans lesssharesrepurchasedundertreasurystockmethod convertibledebtshares adjustedaveragesharesoutstandingdiluted dilutednetearningspershare thedilutednetearningspersharecalculationforfiscalyearexcludedmillionsharesrelatedtostockoptionsas theexercisepriceoftheseoptionswasgreaterthantheiraveragemarketvalueasofjanuarythecompanydid nothaveconvertibledebt thedilutednetearningspersharecalculationforfiscalyearexcludedaninsignificantnumberofsharesrelatedto stockoptionsastheexercisepriceoftheseoptionswasgreaterthantheaveragemarketvalueofthecompanysstock thedilutednetearningspersharecalculationforfiscalyearincludedthedilutiveeffectofconvertibledebtthatwas offsetbytherelatedreductionininterestexpenseofmillionaftertax thedilutednetearningspersharecalculationforfiscalyearincludedallsharesrelatedtostockoptionsasthe exercisepriceofalloptionswaslessthantheaveragemarketvalueofthecompanysstockthedilutednetearningsper sharecalculationforfiscalyearincludedthedilutiveeffectofconvertibledebtthatwasoffsetbytherelated reductionininterestexpenseofmillionaftertax common stock stock option plans stock compensation agreements atjanuarythecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontractsunder thecompanyslongtermincentiveplanandthelongtermincentiveplanthelongtermincentive planexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthelong termincentiveplanunderthelongtermincentiveplanthecompanymayissueuptomillionsharesof commonstockplusanysharescanceledexpiredforfeitedornotissuedfromthelongtermincentiveplan subsequenttoaprilsharesavailableforfuturegrantsunderthelongtermincentiveplanwere millionattheendoffiscalyear thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforfiscalyearsandrespectivelythetotalincometaxbenefitrecognizedintheincome statementforsharebasedcompensationcostswasmillionmillionandmillionforfiscalyears andrespectivelythecompanyalsorecognizedadditionalincometaxbenefitsofmillionmillion andmillionforfiscalyearsandrespectivelyforwhichoptionswereexercisedorrestrictedshares werevestedthetotalunrecognizedcompensationcostwasmillionmillionandmillionforfiscalyears andrespectivelytheweightedaverageperiodforthiscosttoberecognizedwasyears yearsandyearsforfiscalyearsandrespectivelysharebasedcompensationcosts capitalizedaspartofinventorywereinsignificantinallperiods thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthrough marketpurchasesthroughouttheyearforthenumberofsharesusedtosettleemployeebenefitequityissuances stockoptions stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant johnsonjohnsonannualreport thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableforandgrantsexpectedvolatilityrepresentsa blendedrateofyearweeklyhistoricaloverallvolatilityrateandaweekaverageimpliedvolatilityratebasedon atthemoneytradedjohnsonjohnsonoptionswithalifeofyearsforallgrantshistoricaldataisusedtodetermine theexpectedlifeoftheoptiontheriskfreeratewasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinfiscalyearsand respectivelythefairvaluewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyears expecteddividendyield asummaryofoptionactivityundertheplanasofjanuarydecemberanddecemberand changesduringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weighted value outstanding average dollarsin sharesinthousands shares exerciseprice millions sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninfiscalyears andrespectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatjanuary sharesinthousands outstanding exercisable weighted weighted average average average exercise exercise exercisepricerange options life price options price averagecontractualliferemaininginyears johnsonjohnsonannualreportstockoptionsoutstandingatdecemberanddecemberwereandanaveragelifeofyears andandanaveragelifeofyearsrespectivelystockoptionsexercisableatdecemberand decemberwereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunits thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistied tothecompletionofserviceperiodsthatrangefrommonthstoyearsandtheachievementoverathreeyearperiodof threeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnoperationalsales adjustedoperationalearningspershareandrelativetotalshareholderreturnbeginninginfiscalperformance sharesweregrantedwithtwoequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholder returnadjustedoperationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearned attheendofthethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberof performanceshareunitsgranted asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofjanuaryis presentedbelow outstanding outstanding restricted performance sharesinthousands shareunits shareunits sharesatdecember granted issued canceledforfeitedadjusted sharesatjanuary theaveragefairvalueoftherestrictedshareunitsgrantedwasandinfiscalyears andrespectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswas discountedfordividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueof restrictedshareunitsissuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandinfiscal yearsandcalculatedusingtheweightedaveragefairmarketvalueforeachofthecomponentgoalsat thedateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedwasmillionmillionandmillioninfiscalyearsand respectively johnsonjohnsonannualreport segments business geographic areas salestocustomers change dollarsinmillions vs vs consumerhealth otc us international worldwide skinhealthbeauty us international worldwide oralcare us international worldwide babycare us international worldwide womenshealth us international worldwide woundcareother us international worldwide totalconsumerhealth us international worldwide previouslyreferredtoasconsumer previouslyreferredtoasbeauty johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs pharmaceutical immunology us international worldwide remicade us usexports international worldwide simponisimponiaria us international worldwide stelara us international worldwide tremfya us international worldwide otherimmunology us international worldwide infectiousdiseases us international worldwide edurantrilpivirine us international worldwide prezistaprezcobixrezolstasymtuza us international worldwide otherinfectiousdiseases us international worldwide johnsonjohnsonannualreport salestocustomers change dollarsinmillions vs vs neuroscience us international worldwide concertamethylphenidate us international worldwide invegasustennaxeplioninvegatrinzatrevicta us international worldwide risperdalconsta us international worldwide otherneuroscience us international worldwide oncology us international worldwide darzalex us international worldwide erleada us international worldwide imbruvica us international worldwide velcade us international worldwide zytigaabirateroneacetate us international worldwide johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs otheroncology us international worldwide pulmonaryhypertension us international worldwide opsumit us international worldwide uptravi us international worldwide us international worldwide cardiovascularmetabolismother us international worldwide xarelto us international worldwide invokanainvokamet us international worldwide procriteprex us international worldwide us international worldwide totalpharmaceutical us international worldwide johnsonjohnsonannualreport salestocustomers change dollarsinmillions vs vs medicaldevices diabetescare us international worldwide interventionalsolutions us international worldwide orthopaedics us international worldwide hips us international worldwide knees us international worldwide trauma us international worldwide spinesportsother us international worldwide surgery us international worldwide advanced us international worldwide general us international worldwide vision us international johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs worldwide contactlensesother us international worldwide surgical us international worldwide totalmedicaldevices us international worldwide worldwide us international worldwide previouslyreferredtoasspineother certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthanornotmeaningful incomelossbeforetax identifiableassets dollarsinmillions consumerhealth pharmaceutical medicaldevices total lessexpensenotallocatedtosegments generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumerhealth pharmaceutical medicaldevices segmentstotal generalcorporate worldwidetotal johnsonjohnsonannualreport salestocustomers longlivedassets dollarsinmillions unitedstates europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedassets worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperates exportsalesarenotsignificantinfiscalyearthecompanyutilizedthreewholesalersdistributingproductsforall threesegmentsthatrepresentedapproximatelyandofthetotalconsolidatedrevenuesinfiscalyear thecompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenuesinfiscalyearthecompanyhadthreewholesalers distributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenues amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense generalcorporateincludescashcashequivalentsandmarketablesecurities consumerhealthincludes litigationexpenseofbillionprimarilytalcrelatedreservesandcertainsettlements pharmaceuticalincludes litigationexpenseofbillionprimarilyrelatedtotheagreementinprincipletosettleopioidlitigation anunrealizedgainonsecuritiesofbillion arestructuringrelatedchargeofbillion medicaldevicesincludes acontingentconsiderationreversalofbillionrelatedtothetimingofcertaindevelopmentalmilestones associatedwiththeaurishealthacquisition litigationexpenseofbillion arestructuringrelatedchargeofbillion aninprocessresearchanddevelopmentexpenseofbillion amedicaldeviceregulationchargeofbillion consumerhealthincludes againofbillionrelatedtothecompanyspreviouslyheldequityinvestmentindrcilabo litigationexpenseofbillion arestructuringrelatedchargeofbillion pharmaceuticalincludes litigationexpenseofbillionofwhichbillionisrelatedtotheagreementinprincipletosettleopioidlitigation aninprocessresearchanddevelopmentexpenseofbillionrelatedtothealiosasset aresearchanddevelopmentexpenseofbillionforanupfrontpaymentrelatedtoargenx anunrealizedgainonsecuritiesofbillion actelionacquisitionandintegrationrelatedcostsofbillion arestructuringchargeofbillion medicaldevicesincludes againofbillionfromthedivestitureoftheaspbusiness arestructuringrelatedchargeofbillion johnsonjohnsonannualreport litigationexpenseofbillion aurishealthacquisitionandintegrationrelatedcostsofbillion consumerhealthincludes againofbillionfromthedivestitureofnizoral litigationexpenseofbillion pharmaceuticalincludes aninprocessresearchanddevelopmentchargeofbillionrelatedtothealiosandxoassetsandthe correspondingxocontingentliabilityreversalofbillion actelionacquisitionandintegrationrelatedcostsofbillion anunrealizedlossonsecuritiesofbillion againofbillionfromthedivestitureofcertainnonstrategicpharmaceuticalproducts medicaldevicesincludes litigationexpenseofbillion arestructuringrelatedchargeofbillion amoacquisitionandintegrationrelatedcostsofbillion againofbillionfromthedivestitureofthelifescanbusiness longlivedassetsincludepropertyplantandequipmentnetforfiscalyearsandofand respectivelyandintangibleassetsandgoodwillnetforfiscalyearsandofand respectively acquisitions divestitures certainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumedduringfiscalyear theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisition theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thefiscalyearacquisitionsprimarilyincludedallrightstotheinvestigationalcompoundbermekimabwhichhas multipledermatologicalindicationsalongwithcertainemployeesfromxbiotechincxbiotechmomenta pharmaceuticalsincmomentaacompanythatdiscoversanddevelopsnoveltherapiesforimmunemediateddiseases andtheoutstandingsharesinverbsurgicalincacompanywithsignificantroboticsanddatasciencecapabilities duringthefiscalfirstquarterofthecompanycompletedtheacquisitionofallrightstotheinvestigationalcompound bermekimabwhichhasmultipledermatologicalindicationsalongwithcertainemployeesfromxbiotechincfora purchasepriceofbillionthefairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangibleassets primarilyiprdforbillionapplyingaprobabilityofsuccessfactorthatrangedfromtotoreflectinherent developmentregulatoryandcommercialriskforthedifferentindicationsthediscountrateappliedwasapproximately xbiotechmaybeeligibletoreceiveadditionalpaymentsuponthereceiptofcertaincommercializationauthorizations thetransactionwasaccountedforasabusinesscombinationandincludedinthepharmaceuticalsegment additionallyinthefiscalfirstquarterofthecompanycompletedtheacquisitionofalloutstandingsharesinverb surgicalincacompanywithsignificantroboticsanddatasciencecapabilitiesincludingthosesharespreviouslyheldby verilythetransactionwasaccountedforasabusinesscombinationandincludedinthemedicaldevicessegmentthe fairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangibleassetsprimarilyiprdforbillion goodwillforbillionotherassetsofbillionandliabilitiesassumedofbillionthefairvalueofthecompanys previouslyheldequityinvestmentinverbsurgicalincwasbillion onoctoberthecompanycompletedtheacquisitionofmomentaforapurchasepriceofapproximately billionnetofcashacquiredthefairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangible assetsiprdofbilliongoodwillofbillionotherassetsofbillionandliabilitiesofbilliontheassets johnsonjohnsonannualreport acquiredareintendedtoaddresssubstantialunmetmedicalneedinmaternalfetaldisordersneuroinflammatory disordersrheumatologydermatologyandautoimmunehematologydependingontheassetprobabilityofsuccess factorsrangingfromtowereusedinthefairvaluecalculationtoreflectinherentdevelopmentandregulatory riskoftheiprdthediscountrateappliedwasapproximatelythegoodwillisprimarilyattributabletosynergies expectedtoarisefromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurposesthetransactionwas accountedforasabusinesscombinationandincludedinthepharmaceuticalsegment duringfiscalyearcertainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumed theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisition theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thefiscalyearacquisitionsprimarilyincludeddrcilaboajapanesecompanyfocusedonthemarketing developmentanddistributionofabroadrangeofdermocosmeticcosmeticandskincareproductsandaurishealthinca privatelyhelddeveloperofrobotictechnologiesinitiallyfocusedinlungcancerwithanfdaclearedplatformcurrently usedinbronchoscopicdiagnosticandtherapeuticprocedures onjanuarythecompanyacquireddrcilaboajapanesecompanyfocusedonthemarketingdevelopment anddistributionofabroadrangeofdermocosmeticcosmeticandskincareproductsforatotalpurchasepriceof approximatelybillionwhichequatestoapproximatelybillionusingtheexchangerateofjapaneseyen toeachusdollaronjanuaryadditionallyinthefiscalfirstquarterofthecompanyrecognizedapretax gainrecordedinotherincomeexpensenetofapproximatelybillionrelatedtothecompanyspreviouslyheld equityinvestmentindrcilabo thecompanytreatedthistransactionasabusinesscombinationandincludeditintheconsumerhealthsegmentduring thefiscalfirstquarterofthecompanyfinalizedthepurchasepriceallocationthefinalfairvalueoftheacquisition wasallocatedprimarilytoamortizableintangibleassetsforbilliongoodwillforbillionandliabilitiesof billiontheamortizableintangibleassetswerecomprisedofbrandtrademarksandcustomerrelationshipswitha weightedaveragelifeofyearsthegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness acquisitionandisnotexpectedtobedeductiblefortaxpurposes onaprilthecompanycompletedtheacquisitionofaurishealthincforapproximatelybillionnetofcash acquiredadditionalcontingentpaymentsofuptobillionintheaggregatemaybepayableuponreachingcertain predeterminedmilestonesaurishealthwasaprivatelyhelddeveloperofrobotictechnologiesinitiallyfocusedinlung cancerwithanfdaclearedplatformcurrentlyusedinbronchoscopicdiagnosticandtherapeuticproceduresthe companytreatedthistransactionasabusinesscombinationandincludeditinthemedicaldevicessegmentthefair valueoftheacquisitionwasallocatedprimarilytoamortizableandnonamortizableintangibleassetsprimarilyiprdfor billiongoodwillforbillionmarketablesecuritiesofbillionandliabilitiesassumedofbillionwhich includesthefairvalueofthecontingentpaymentsmentionedaboveduringthefiscalsecondquarterofthe companyfinalizedthepurchasepriceallocationduringfiscalthecompanyrecordedotherincomeof approximatelybillionforthereversalofallofthecontingentconsiderationrelatedtothetimingofcertain developmentalandcommercialmilestoneswhicharenotexpectedtobemetbasedonthecompanyscurrenttimelines duringthefiscalthirdquarterofthecompanyrecordedapartialiprdimpairmentchargeofbillionrelatedto timingandprogressionofthedigitalsurgeryplatformsaprobabilityofsuccessfactorrangingfromtowas usedinthefairvaluecalculationtoreflectinherentregulatoryandcommercialriskofthecontingentpaymentsandiprd thediscountrateappliedwasapproximatelythegoodwillisprimarilyattributabletosynergiesexpectedtoarise fromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurposes duringfiscalyearcertainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumed theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisitiontheexcessofpurchasepriceoverthe estimatedfairvalueoftangibleassetsacquiredamountedtobillionandhasbeenassignedtoidentifiableintangible assetswithanyresidualrecordedtogoodwill inaccordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleassets supplementalproformainformationforfiscalyearsandisnotprovidedastheimpactofthe aforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancial position johnsonjohnsonannualreportdivestitures subsequenttofiscalinseparatetransactionsthecompanydivestedtwobrandsoutsidetheuswithinthe pharmaceuticalsegmentandreceivedcombinedproceedsofapproximatelybillionthecompanywillreflectthese branddivestituresinitsfinancialresults duringfiscalyearthecompanysoldmillionsharesofidorsialtdidorsiaoritsownershipinthe companythetransactionresultedingrossproceedsofapproximatelychfmillionmillionbasedonasales priceofchfshareandanimmaterialnetlossthecompanycurrentlyhasrightstoatleastanadditional millionsharesorapproximatelyofidorsiaequitythroughaconvertibleloanwithaprincipalamountofchf millionduejuneidorsiaalsohasaccesstoanapproximatechfmillioncreditfacilitywiththecompany asofjanuaryidorsiahasnotmadeanydrawdownsunderthecreditfacility duringfiscalyearthecompanydivesteditsaspbusinesstofortivecorporationforanaggregatevalueof approximatelybillionconsistingofbillionofcashproceedsandbillionofretainednetreceivablesthe companyrecognizedapretaxgainrecordedinotherincomeexpensenetofapproximatelybillion duringfiscalyearthecompanydivestedthelifescanincbusinessforapproximatelybillionandretained certainnetliabilitiesotherdivestituresinfiscalyearincludednizoralrocandcertainnonstrategic pharmaceuticalproductsinthepretaxgainsonthedivestitureswereapproximatelybillion infiscalyearthecompanyacceptedabindingoffertoformastrategiccollaborationwithjabilinconeofthe worldsleadingmanufacturingservicesprovidersforhealthcareproductsandtechnologyproductsthecompanyis expandingayearrelationshipwithjabiltoproducearangeofproductswithintheethiconendosurgeryanddepuy synthesbusinessesthistransactionincludesthetransferofemployeesandmanufacturingsitesthetransferswere completedinfiscalyearasofjanuarytherewerenoassetsheldforsaleontheconsolidatedbalance sheetasofdecembertheassetsheldforsaleontheconsolidatedbalancesheetwerebillionof inventoryandpropertyplantandequipmentnetforadditionaldetailsontheglobalsupplychainrestructuringseenote totheconsolidatedfinancialstatements legal proceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialsupplierindemnificationandothermattersgovernmentalinvestigationsandotherlegal proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusinessduetotheongoingimpactsofthe covidpandemiccertaintrialshavebeenrescheduledordelayedthecompanycontinuestomonitoritslegal proceedingsasthesituationevolves thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuchestimatesandjudgmentscanbe affectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtintheproceedingsare unsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsarein earlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindisputeproceduralorjurisdictionalissues theuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachievecomprehensivemultiparty settlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerouspartiesinvolvedtothe extentadverseverdictshavebeenrenderedagainstthecompanythecompanydoesnotrecordanaccrualuntilalossis determinedtobeprobableandcanbereasonablyestimated inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod johnsonjohnsonannualreport productliability johnsonjohnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving multipleproductsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhile thecompanybelievesithassubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationfromtime totimeevenifithassubstantialdefensesthecompanyconsidersisolatedsettlementsbasedonavarietyof circumstancesthecompanyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithasc basedoncurrentlyavailableinformationwhichinsomecasesmaybelimitedthecompanyaccruesanestimate ofthelegaldefensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonably estimatedforcertainofthesemattersthecompanyhasaccruedadditionalamountssuchasestimatedcostsassociated withsettlementsdamagesandotherlossesproductliabilityaccrualscanrepresentprojectedproductliabilityfor thousandsofclaimsaroundtheworldeachindifferentlitigationenvironmentsandwithdifferentfactpatternschangesto theaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurfacing systemthepinnacleacetabularcupsystempelvicmeshesrisperdalxareltobodypowderscontaining talcprimarilyjohnsonsbabypowderinvokanaandethiconphysiomeshflexiblecompositemeshasof januaryintheunitedstatestherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuits regardinginjuriesallegedlyduetothedepuyasrxlacetabularsystemanddepuyasrhipresurfacingsystem withrespecttothepinnacleacetabularcupsystemwithrespecttopelvicmesheswith respecttorisperdalwithrespecttoxareltowithrespecttobodypowderscontainingtalc withrespecttoinvokanaandwithrespecttoethiconphysiomeshflexiblecompositemesh inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonthenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuits aresettledordismissedandadditionallawsuitsarefiledcasesfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationhas alsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaaustraliaireland germanyindiaanditalyinnovemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyers representingasrhipsystemplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunited stateswhohadsurgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustdepuyreached additionalagreementsinfebruaryandmarchwhichfurtherextendedthesettlementprogramtoincludeasr hippatientswhohadrevisionsurgeriesafteraugustandpriortofebruarythissettlementprogram hasresolvedmorethanclaimsthereforebringingtoresolutionsignificantasrhiplitigationactivityintheunited stateshoweverlawsuitsintheunitedstatesremainandthesettlementprogramdoesnotaddresslitigationoutsideof theunitedstatesinaustraliaaclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofasrhip patientsinthatcountryincanadathecompanyhasreachedagreementstosettletheclassactionsfiledinthatcountry thecompanycontinuestoreceiveinformationwithrespecttopotentialadditionalcostsassociatedwiththisrecallona worldwidebasisthecompanyhasestablishedaccrualsforthecostsassociatedwiththeunitedstatessettlement programanddepuyasrhiprelatedproductliabilitylitigation claimsforpersonalinjuryhavealsobeenmadeagainstdepuyorthopaedicsincandjohnsonjohnsoncollectively depuyrelatingtothepinnacleacetabularcupsystemusedinhipreplacementsurgeryproductliabilitylawsuits continuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipated numberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationinthe unitedstatesdistrictcourtforthenortherndistrictoftexaslitigationhasalsobeenfiledinsomestatecourtsandin countriesoutsideoftheunitedstatesseveraladverseverdictshavebeenrenderedagainstdepuyoneofwhichwas reversedonappealandremandedforretrialduringthefirstquarterofdepuyestablishedaunitedstates settlementprogramtoresolvethesecasesaspartofthesettlementprogramadverseverdictshavebeensettledthe companyhasestablishedanaccrualforproductliabilitylitigationassociatedwiththepinnacleacetabularcup systemandtherelatedsettlementprogram claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicons pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethecompanycontinuesto receiveinformationwithrespecttopotentialcostsandadditionalcasescasesfiledinfederalcourtsintheunitedstates hadbeenorganizedasamultidistrictlitigationmdlintheunitedstatesdistrictcourtforthesoutherndistrictofwest virginiathemdlcourtisremandingcasesfortrialtothejurisdictionswherethecasewasoriginallyfiledandadditional pelvicmeshlawsuitshavebeenfiledandremainoutsideofthemdlthecompanyhassettledorotherwiseresolveda johnsonjohnsonannualreportmajorityoftheunitedstatescasesandtheestimatedcostsassociatedwiththesesettlementsandtheremainingcases arereflectedinthecompanysaccrualsinadditionclassactionsandindividualpersonalinjurycasesorclaimshavebeen commencedinvariouscountriesoutsideoftheunitedstatesincludingclaimsandcasesintheunitedkingdomthe netherlandsandclassactionsinisraelaustraliaandcanadaseekingdamagesforallegedinjuryresultingfromethicons pelvicmeshdevicesinnovemberthefederalcourtofaustraliaissuedajudgmentregardingitsfindingswith respecttoliabilityinrelationtothethreeleadapplicantsandgenerallyinrelationtothedesignmanufacturepreand postmarketassessmentsandtestingandsupplyandpromotionofthedevicesinaustraliausedtotreatstressurinary incontinenceandpelvicorganprolapseinmarchthecourtentereddamagesawardstothethreeleadapplicants thecompanyisappealingthedecisionwithrespecttoothergroupmemberstherewillbeanindividualcase assessmentprocesswhichwillrequireproofofuseandcausallyrelatedlosstheformoftheindividualcaseassessment processhasnotyetbeendeterminedbythecourttheclassactionsincanadawerediscontinuedinasaresultof asettlementofagroupofcasesthecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation associatedwithethiconspelvicmeshproducts followingajuneworldwidemarketwithdrawalofethiconphysiomeshflexiblecompositemeshclaimsfor personalinjuryhavebeenmadeagainstethiconincandjohnsonjohnsonallegingpersonalinjuryarisingoutoftheuse ofthisherniameshdevicecasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrict litigationmdlintheunitedstatesdistrictcourtforthenortherndistrictofgeorgiaamulticountylitigationmclhas alsobeenformedinnewjerseystatecourtandassignedtoatlanticcountyforcasespendinginnewjerseyinaddition tothemattersinthemdlandmclthereareadditionallawsuitspendingintheunitedstatesdistrictcourtforthe southerndistrictofohiowhicharepartofthemdlforpolypropylenemeshdevicesmanufacturedbycrbardincand lawsuitspendingoutsidetheunitedstatesdiscoveryisproceedinginthesecasesandcertainofthecasesarein preparationfortrials claimshavealsobeenfiledagainstethiconandjohnsonjohnsonallegingpersonalinjuriesarisingfromtheproceed meshandproceedventralpatchherniameshproductsinmarchthenewjerseysupremecourtenteredan orderconsolidatingthesecasespendinginnewjerseyasanmclinatlanticcountysuperiorcourtadditionalcases havebeenfiledinvariousfederalandstatecourtsintheusandinjurisdictionsoutsidetheusdiscoveryisunderwayin thesecases inseptemberplaintiffsattorneyfiledanapplicationwiththenewjerseysupremecourtseekingcentralized managementofprolenepolypropyleneherniasystemphscasesthenewjerseysupremecourtgranted plaintiffsapplicationinjanuaryandthosecaseshavealsobeentransferredtoanmclinatlanticcountysuperior courtdiscoveryisunderwayinthesecases thecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithethicon physiomeshflexiblecompositemeshproceedmeshandproceedventralpatchandprolene polypropyleneherniasystemproducts claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutofthe useofrisperdalandrelatedcompoundsindicatedforthetreatmentofschizophreniaacutemanicormixedepisodes associatedwithbipolaridisorderandirritabilityassociatedwithautismlawsuitshavebeenprimarilyfiledinstatecourtsin pennsylvaniacaliforniaandmissouriotheractionsarependinginvariouscourtsintheunitedstatesandcanada productliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotential costsandtheanticipatednumberofcasesthecompanyhassuccessfullydefendedanumberofthesecasesbutthere havebeenverdictsagainstthecompanyincludingaverdictinoctoberofbillionofpunitivedamagesrelated toonesingleplaintiffwhichwassubsequentlyreducedinjanuarytomillionbythetrialjudgethecompany andplaintiffareeachappealingthisjudgmentthecompanyhassettledorotherwiseresolvedmanyoftheunitedstates casesandthecostsassociatedwiththesesettlementsarereflectedinthecompanysaccruals claimsforpersonalinjuryarisingoutoftheuseofxareltoanoralanticoagulanthavebeenmadeagainstjanssen pharmaceuticalsincjpijohnsonjohnsonjjandjpiscollaborationpartnerforxareltobayeragandcertain ofitsaffiliatescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationinthe unitedstatesdistrictcourtfortheeasterndistrictoflouisianainadditioncaseshavebeenfiledinstatecourtsacrossthe unitedstatesmanyofthesecaseswereconsolidatedintoastatemasstortlitigationinphiladelphiapennsylvaniaandina coordinatedproceedinginlosangelescaliforniaclassactionlawsuitsalsohavebeenfiledincanadainmarchjpi andjjannouncedanagreementinprincipletothesettlethexareltocasesintheunitedstatesthesettlement agreementwasexecutedinmaythesettlementbecamefinalindecemberandthesettlementwasfundedin januarythisresolvedthemajorityofcasespendingintheunitedstatesthecompanyhasestablishedaccrualsfor itscostsassociatedwiththeunitedstatessettlementprogramandxareltorelatedproductliabilitylitigation johnsonjohnsonannualreport personalinjuryclaimsallegingthattalccausescancerhavebeenmadeagainstjohnsonjohnsonconsumerincand johnsonjohnsonarisingoutoftheuseofbodypowderscontainingtalcprimarilyjohnsonsbabypowderthe numberofpendingpersonalinjurylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwith respecttopotentialcostsandtheanticipatednumberofcaseslawsuitshavebeenprimarilyfiledinstatecourtsin missourinewjerseyandcaliforniaandsuitshavealsobeenfiledoutsidetheunitedstatesthemajorityofcasesare pendinginfederalcourtorganizedintoamultidistrictlitigationmdlintheunitedstatesdistrictcourtforthedistrictof newjerseyinthemdlthepartiessoughttoexcludeexpertsthroughdaubertmotionsinaprilthecourtissued rulingsthatlimitthescopeoftestimonyincludingsometheoriesandtestingmethodsforcertainplaintiffexpertwitnesses anddeniedplaintiffsattempttolimitthescopeoftestimonyofcertainofthecompanyswitnesseswiththisrulingmade casespecificdiscoveryhasbegunperthecourtsdirective intalccasesthathavepreviouslygonetotrialthecompanyhasobtaineddefenseverdictsinanumberofthembutthere havealsobeenverdictsagainstthecompanymanyofwhichhavebeenreversedonappealinjunethemissouri courtofappealsreversedinpartandaffirmedinpartajulyverdictofbillionininghamvjohnsonjohnsonet alnoedmoappreducingtheoverallawardtobillionandwithadditionalinterestasofjanuary asthecompanypursuesfurtherappealiscurrentlybilliontheinghamdecisionanapplicationfortransferof thecasetothemissourisupremecourtwassubsequentlydeniedandthecompanyiscurrentlyseekingreviewbythe unitedstatessupremecourtthecompanycontinuestobelievethatithasstronglegalgroundsfortheappealofthis verdictaswellasotherverdictsthatithasappealednotwithstandingthecompanysconfidenceinthesafetyofitstalc productsincertaincircumstancesthecompanyhasandmaysettlecasesthecompanyhasestablishedanaccrualfor defensecostsandreservesfortheresolutionofcertaincasesandclaimsincludingtheinghamdecisioncurrentlyon appealinconnectionwithproductliabilitylitigationassociatedwithbodypowderscontainingtalc infebruarythecompanystalcsupplierimerystalcamericaincandtwoofitsaffiliatesimerystalcvermontinc andimerystalccanadainccollectivelyimerysfiledavoluntarychapterpetitioncommencingareorganizationunder theunitedstatesbankruptcycodeintheunitedstatesbankruptcycourtforthedistrictofdelawareimerys bankruptcytheimerysbankruptcyrelatestoimeryspotentialliabilityforpersonalinjuryfromexposuretotalcumpowder soldbyimerystalcclaimsinitsbankruptcyfilingimerysnotedcertainclaimsitallegesithasagainstthecompanyfor indemnificationandrightstojointinsuranceproceedsthecompanypreviouslyproposedtoresolveimerysandthe companysobligationsarisingoutofthetalcclaimsbyagreeingtoassumethedefenseoflitigationofalltalcclaims involvingthecompanysproductswaivingthecompanysindemnificationclaimsagainstimerysandliftingtheautomatic staytoenablethetalcclaimstoproceedoutsidethebankruptcyforumwiththecompanyagreeingtosettleorpayany judgmentagainstimerysinmayimerysandtheasbestosclaimantscommitteeplanproponentsfiledtheirplanof reorganizationtheplanandthedisclosurestatementrelatedtheretoagreeingtoputitsnorthamericanoperationsup forauctionwhichwassubsequentlyamendedthecompanyhasobjectedtothedisclosurestatementandintendsto objecttotheplanofreorganizationascurrentlystructuredadditionallyinjunecyprusminescorporationandits parentcyprusfiledanadversaryproceedingagainstthecompanyaswellasimerysseekingadeclarationofindemnity undercertaincontractualagreementsthecompanydeniessuchindemnificationisowedandfiledamotiontodismissthe adversarycomplaintarguingamongotherthingsthatthecourtdoesnothavesubjectmatterjurisdictionovercypruss claimsagainstthecompanytheplanproponentsfilednumerousamendmentstotheplananddisclosurestatementto whichthecompanyobjectedahearingontheplanproponentsdisclosurestatementwasheldinjanuaryandthe courtenteredanorderapprovingthedisclosurestatementfortheninthamendedjointchapterplanof reorganizationofimerystalcamericaincanditsdebtoraffiliatesallowingdebtorstoproceedwithsolicitingvoteson theplanthecompanyintendstocontinuetoobjecttotheplanahearingtoconsiderconfirmationoftheplanhasbeen scheduledforjune infebruaryasecuritiesclassactionlawsuitwasfiledagainstjohnsonjohnsonandcertainnamedofficersinthe unitedstatesdistrictcourtforthedistrictofnewjerseyallegingthatjohnsonjohnsonviolatedthefederalsecurities lawsbyfailingtodiscloseallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbaby powderandthatpurchasersofjohnsonjohnsonssharessufferedlossesasaresultplaintiffisseekingdamagesin aprilthecompanymovedtodismissthecomplaintandbriefingonthemotionwascompleteasofaugustin decemberthecourtdeniedinpartthemotiontodismissinmarchdefendantsansweredthecomplaint discoveryisunderway injuneashareholderfiledacomplaintinitiatingasummaryproceedinginnewjerseystatecourtforabooksand recordsinspectioninaugustjohnsonjohnsonrespondedtothebooksandrecordscomplaintandfiledacross motiontodismissinseptemberplaintiffrepliedandthecourtheardoralargumentthecourthasnotyetruledin thebooksandrecordsactioninoctoberdecemberandjanuaryfourshareholdersfiledfourseparate derivativelawsuitsagainstjohnsonjohnsonasthenominaldefendantanditscurrentdirectorsandcertainofficersas johnsonjohnsonannualreportdefendantsintheunitedstatesdistrictcourtforthedistrictofnewjerseyallegingabreachoffiduciarydutiesrelatedto theallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbabypowderandthat johnsonjohnsonhassuffereddamagesasaresultofthoseallegedbreachesinfebruarythefourcaseswere consolidatedintoasingleactionunderthecaptioninrejohnsonjohnsontalcstockholderderivativelitigation injulyareportwasdeliveredtothecompanysboardofdirectorsbyindependentcounselretainedbytheboard toinvestigatetheallegationsinthederivativelawsuitsandinaseriesofshareholderlettersthattheboardreceivedraising similarissuesfouroftheshareholderswhosentdemandsareplaintiffsintheinrejohnsonjohnsontalcstockholder derivativelitigationtheindependentcounselrecommendedthatthecompanyrejecttheshareholderdemandsandtake thestepsthatarenecessaryorappropriatetosecuredismissalofthederivativelawsuitstheboardunanimouslyadopted therecommendationsoftheindependentcounselsreportinoctobertheshareholdersfiledaconsolidated complaintandinjanuaryjohnsonjohnsonmovedtodismisstheconsolidatedcomplaint injanuarytwoerisaclassactionlawsuitswerefiledbyparticipantsinthejohnsonjohnsonsavingsplan againstjohnsonjohnsonitspensionandbenefitscommitteeandcertainnamedofficersintheunitedstatesdistrict courtforthedistrictofnewjerseyallegingthatthedefendantsbreachedtheirfiduciarydutiesbyofferingjohnson johnsonstockasajohnsonjohnsonsavingsplaninvestmentoptionwhenitwasimprudenttodosobecauseof failurestodiscloseallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbaby powderplaintiffsareseekingdamagesandinjunctivereliefinseptemberdefendantsfiledamotiontodismissin aprilthecourtgranteddefendantsmotionbutgrantedleavetoamendinjuneplaintiffsfiledanamended complaintandinjulydefendantsmovedtodismisstheamendedcomplaintasofoctoberbriefingon defendantsmotionwascomplete alawsuitpendinginthesuperiorcourtofcaliforniaforthecountyofsandiegoallegingviolationsofcalifornias consumerlegalremediesactrelatingtojohnsonsbabypowderhasbeenresolvedinthecompanysfavorinthat lawsuittheplaintiffsallegethatjohnsonjohnsonviolatedtheclrabyfailingtoproviderequiredproposition warningsinjulythecompanyfiledanoticeofremovaltotheunitedstatesdistrictcourtforthesoutherndistrict ofcaliforniaandplaintiffsfiledasecondamendedcomplaintshortlythereafterinoctoberthecompanymovedto dismissthesecondamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybegrantedinresponsetothose motionsplaintiffsfiledathirdamendedcomplaintindecemberthecompanymovedtodismissthethirdamended complaintforfailuretostateaclaimuponwhichreliefmaybegrantedinaprilthecourtgrantedthemotionto dismissbutgrantedleavetoamendinmayplaintiffsfiledafourthamendedcomplaintbutindicatedthatthey wouldbefilingamotionforleavetofileafifthamendedcomplaintplaintiffsfiledafifthamendedcomplaintinaugust thecompanymovedtodismissthefifthamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybe grantedinjanuarythecourtissuedanorderandopinionrulinginthecompanysfavorandgrantingthemotionto dismisswithprejudice injanuarytheabtahilawgroupfiledanactionunderpropositionagainstjohnsonjohnsonandjohnson johnsonconsumerincaswellasanumberofotherallegedtalcumpowdermanufacturersanddistributorsincludingone californiacompanyinthatactiontheplaintiffallegescontaminationoftalcumpowderproductswithunsafelevelsof arsenichexavalentchromiumandleadtheplaintiffseekscivilpenaltiesandinjunctivereliefdefendantsfiledamotionfor summaryjudgmentinjanuaryandahearinghasbeenscheduledforaprillimitedinformaldiscoveryis continuing inadditionthecompanyhasreceivedpreliminaryinquiriesandsubpoenastoproducedocumentsregardingthese mattersfromsenatormurrayamemberofthesenatecommitteeonhealtheducationlaborandpensionsthe departmentofjusticethesecuritiesandexchangecommissionsecandtheuscongressionalsubcommitteeon economicandconsumerpolicythecompanyproduceddocumentsasrequiredinresponseandwillcontinueto cooperatewithgovernmentinquiriesinnovemberthesecterminateditsinvestigation claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandjohnsonjohnsonarisingoutoftheuseofinvokanaaprescriptionmedicationindicated toimproveglycemiccontrolinadultswithtypediabetesindecemberlawsuitsfiledinfederalcourtsintheunited stateswereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofnewjerseycases havealsobeenfiledinstatecourtsclassactionlawsuitshavebeenfiledincanadaproductliabilitylawsuitscontinueto befiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casesthecompanyhassettledorotherwiseresolvedmanyofthecasesandclaimsintheunitedstatesandthecosts associatedwiththesesettlementsarereflectedinthecompanysaccruals johnsonjohnsonannualreport claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandjohnsonjohnsonarisingoutoftheuseofelmironaprescriptionmedicationindicatedfor thereliefofbladderpainordiscomfortassociatedwithinterstitialcystitistheselawsuitswhichallegethatelmiron contributestothedevelopmentofpermanentretinalinjuryandvisionlosshavebeenfiledinbothstateandfederalcourts acrosstheunitedstatesindecemberthefederalcasesincludingtwoputativeclassactioncasesseekingmedical monitoringwereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofnewjerseyin additionthreeclassactionlawsuitshavebeenfiledincanadaproductliabilitylawsuitscontinuetobefiledandthe companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcasesthe companyhasestablishedaccrualsfordefensecostsassociatedwithelmironrelatedproductliabilitylitigation intellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolve challengestothecoverageandorvalidityofthepatentsonvariousproductsandallegationsthatcertainofthecompanys productsinfringethepatentsofthirdpartiesalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto thesechallengesandallegationswithrespecttoallsignificantpatentstherecanbenoassuranceastotheoutcomeof thesemattersalossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproducts resultinlossofsalesduetolossofmarketexclusivityrequirethepaymentofpastdamagesandfutureroyaltiesandmay resultinanoncashimpairmentchargeforanyassociatedintangibleassetsignificantmattersaredescribedbelow medicaldevices innovembermedideallcmedideafiledapatentinfringementlawsuitagainstdepuyorthopaedicsincinthe unitedstatesdistrictcourtforthenortherndistrictofillinoisalleginginfringementbytheattunekneesystemin aprilmedideafiledanamendedcomplaintaddingdepuysynthesproductsincanddepuysynthessalesincas nameddefendantscollectivelydepuymedideaallegedinfringementofunitedstatespatentnos andrelatingtoposteriorstabilizedkneesystemsspecifically medideaallegesthatthesofcamtmcontactfeatureoftheattuneposteriorstabilizedkneeproductsinfringesthe patentsinsuitmedideaisseekingmonetarydamagesandinjunctivereliefinjunethecasewastransferredtothe unitedstatesdistrictcourtforthedistrictofmassachusettsinnovemberjudgmentwasenteredinfavorof depuyinjanuarytheuscourtofappealsforthefederalcircuitaffirmed indecemberdrfordalbrittonsuedacclarentincacclarentinunitedstatesdistrictcourtforthenorthern districtoftexasallegingthatacclarentsrelievaspinandrelieveaspinplusproductsinfringeuspatent nodralbrittonalsoallegesbreachofcontractfraudandthatheisthetrueownerofacclarentsuspatent notrialisscheduledtobegininoctober innovemberboardofregentstheuniversityoftexassystemandtissuegeninccollectivelyutfiledalawsuit intheunitedstatesdistrictcourtforthewesterndistrictoftexasagainstethiconincandethiconusllc collectivelyethiconallegingthemanufactureandsaleofvicrylplusantibacterialsuturesmonocrylplus antibacterialsuturespdsplusantibacterialsuturesstratafixpdsantibacterialsuturesandstratafix monocrylplusantibacterialsuturesinfringeplaintiffsunitedstatespatentnosand directedtoimplantablepolymerdrugreleasingbiodegradablefiberscontainingatherapeuticagentutisseeking damagesandaninjunctionindecemberethiconfiledpetitionswiththeunitedstatespatentandtrademarkoffice usptoseekinginterpartesreviewiprofbothassertedpatentsinjunetheusptodeniedinstitutionofthe patentiprandgrantedinstitutionofthepatentiprutdismissedthepatentfromthesuitandnolonger accusespdsplusantibacterialsuturesorstratafixpdsplusantibacterialsuturesofinfringementthe previouslyscheduleddistrictcourttrialhasbeenpostponed inaugustintuitivesurgicalincandintuitivesurgicaloperationsinccollectivelyintuitivefiledapatent infringementsuitagainstaurishealthincaurisinunitedstatesdistrictcourtforthedistrictofdelawareinthesuit intuitiveallegeswillfulinfringementofuspatentnos andbasedonaurismonarchplatform aurisfilediprpetitionswiththeusptoregardingtheandpatentsintuitive subsequentlydroppedtheandpatentsfromthesuitindecembertheusptoinstitutedreviewof thepatentanddeniedreviewofthepatentinfebruaryandmarchtheusptoinstitutedreviewofthe andpatentsanddeniedreviewofthepatentindecembertheusptodeclaredallof johnsonjohnsonannualreportthechallengedclaimsinthepatenttobeinvalidintuitivehasappealedthatdecisionthedistrictcourttrialis scheduledtobegininjune inaugustrsbspinellcrsbspinefiledapatentinfringementsuitagainstdepuysynthesincinunitedstates districtcourtforthedistrictofdelawareinoctoberrsbspineamendedthecomplainttochangethenamed defendantstodepuysynthessalesincanddepuysynthesproductsincinthesuitrsbspineallegeswillful infringementofunitedstatespatentnosandbyoneormoreofthefollowingproducts zeropvaspacerzeropspacerzeropnaturalplatesynfixlrspacerandsynfixevolution systemrsbspineseeksmonetarydamagesandinjunctivereliefinnovemberthesuitwasconsolidatedfor pretrialpurposeswithotherpatentinfringementsuitsbroughtbyrsbspineintheunitedstatesdistrictcourtforthe districtofdelawareagainstlifespineincmedactausaincandprecisionspineincinjunethecasewas stayedpendingiprproceedingsfiledbytheconsolidateddefendantsinvolvingtheassertedpatents inmarchosteoplasticsllcfiledapatentinfringementsuitagainstdepuysynthesincdepuysynthesproducts incmedicaldevicebusinessservicesincandsynthesinccollectivelydepuysynthesintheunitedstatesdistrict courtforthedistrictofdelawareinthesuitosteoplasticsallegeswillfulinfringementofuspatentnos andbasedontheproplancmfvirtual surgicalplanningservicesandthetrumatchcmfpersonalizesolutionsinaprilosteoplasticsfiledanamended complainttosubstituteuspatentnoforuspatentnoosteoplasticsseeksmonetarydamages andinjunctivereliefinjunedepuysynthesfiledamotiontodismissthecomplaintinoctoberthecourt dismissedmedicaldevicebusinessservicesincfromthecasebutotherwisedeniedthemotiontrialisscheduledfor october pharmaceutical litigationagainstfilersofabbreviatednewdrugapplicationsandas thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledandaswiththefdaorundertaken similarregulatoryprocessesoutsideoftheunitedstatesseekingtomarketgenericformsofproductssoldbyvarious subsidiariesofjohnsonjohnsonpriortoexpirationoftheapplicablepatentscoveringthoseproductstheseandas typicallyincludeallegationsofnoninfringementandinvalidityoftheapplicablepatentsintheeventthesubsidiariesare notsuccessfulinanactionortheautomaticstatutorystayoftheandasexpiresbeforetheunitedstatesdistrictcourt rulingsareobtainedthethirdpartycompaniesinvolvedwouldhavetheabilityuponapprovalofthefdatointroduce genericversionsoftheirproductstothemarketresultinginthepotentialforsubstantialmarketshareandrevenuelosses fortheapplicableproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangibleassetin additionfromtimetotimesubsidiariesmaysettlethesetypesofactionsandsuchsettlementscaninvolvetheintroduction ofgenericversionsoftheproductsatissuetothemarketpriortotheexpirationoftherelevantpatentstheinterpartes reviewiprprocesswiththeusptocreatedundertheamericainventsactisalsobeingusedattimesby genericcompaniesinconjunctionwithandasandlawsuitstochallengetheapplicablepatents zytiga innovemberjanssenincandjanssenoncologyinccollectivelyjansseninitiatedanoticeofapplicationunder sectionofthepatentedmedicinesnoticeofcomplianceregulationsagainstapotexincapotexandtheministerof healthincanadainresponsetoapotexsfilingofanabbreviatednewdrugsubmissionandsseekingapprovalto marketagenericversionofzytigabeforetheexpirationofcanadianpatentnothefinalhearing concludedinmayinoctoberthecourtissuedanorderprohibitingthecanadianministerofhealthfrom approvingapotexsandsuntiltheexpirationofthepatentinnovemberapotexfiledanappeal beginninginjanuaryjansseninitiatedstatementsofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsincanadaagainstapotexpharmascienceincpharmascienceanddrreddyslaboratories ltdanddrreddyslaboratoriesinccollectivelydrlinresponsetothosepartiesfilingofabbreviatednewdrug submissionsandsseekingapprovaltomarketgenericversionsofzytigabeforetheexpirationofthepatent thefinalhearingintheseactionsconcludedinnovemberandthecourtissuedadecisionholdingthepatent invalidinjanuaryinfebruaryjanssenappealedthedecision inaugustjansseninitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstjamppharmacorporationjampincanadainresponsetojampsfilingofanands seekingapprovaltomarketagenericversionofzytigabeforetheexpirationofthepatentthefinalhearingis scheduledtobegininmay johnsonjohnsonannualreport ineachofthesecanadianactionsjanssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsofzytigabeforetheexpirationofthepatent xarelto inaugustjanssenpharmaceuticalsincjpiandbayerintellectualpropertygmbhandbayeragcollectively bayerfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainst drreddyslaboratoriesincanddrreddyslaboratoriesltdcollectivelydrlwhichfiledanandaseekingapproval tomarketagenericversionofxareltobeforeexpirationofuspatentnointhislawsuitjpiand bayerwereseekinganorderenjoiningdrlfrommarketingtheirgenericversionsofxareltobeforetheexpirationof therelevantpatentsinnovemberjpiandbayerenteredintoaconfidentialsettlementagreementwithdrlandthe casewasvoluntarilydismissed invokanainvokametinvokametxr beginninginjulyjanssenpharmaceuticalsincjanssenresearchdevelopmentllccilaggmbhinternational andjanssenpharmaceuticanvcollectivelyjanssenandmitsubishitanabepharmacorporationmtpcfiledpatent infringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstanumberofgeneric companiesthatfiledandasseekingapprovaltomarketgenericversionsofinvokanainvokametandor invokametxrbeforeexpirationofmtpcsunitedstatespatentnosandor relatingtoinvokanainvokametandorinvokametxrjanssenistheexclusivelicenseeoftheasserted patentsnameddefendantsincludemsnlaboratoriesprivateltdandmsnpharmaceuticalsincmsnzydus pharmaceuticalsusainczydussandozincsandozandlupinltdandlupinpharmaceuticalsinclupinthese caseswereconsolidatedintooneactionpolymorphmainactionwhichhasbeenscheduledfortrialstartinginapril indecemberjanssenandmtpcenteredintoaconfidentialsettlementwithsandozandinjanuary janssenandmtpcenteredintoaconfidentialsettlementwithlupinthecasesagainstsandozandlupinwerevoluntarily dismissed injulyjanssenandmtpcfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstzyduswhichfiledandasseekingapprovaltomarketgenericversionsofinvokanaand ivokametbeforeexpirationofmtpcsunitedstatespatentnoandor relatingtoinvokanainvokametandorinvokametxrcompoundsmainactionjanssenis theexclusivelicenseeoftheassertedpatentstrialconcludedinoctober injulyjanssenandmtpcfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstmsnwhichfiledanandaseekingapprovaltomarketagenericversionofinvokametxrbefore expirationofthepatentandpatentrelatingtoinvokametxrinoctoberjanssenandmtpcinitiated apatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstmsnwhichfiled andasseekingapprovaltomarketgenericversionsofinvokanaandinvokametxrbeforeexpirationofthe patentinoctoberjanssenandmtpcinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtfor thedistrictofnewjerseyagainstdrreddyslaboratoriesincanddrreddyslaboratoriesltddrlwhofiledan andaseekingapprovaltomarketagenericversionofinvokametbeforeexpirationofthepatentinjanuary janssenandmtpcfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmacleodspharmaceuticalsltdandmacleodspharmausaincmacleodswhichfiledanandaseeking approvaltomarketagenericversionofinvokametxrbeforeexpirationofthepatentandpatentrelatingto invokametxrinfebruaryjanssenfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstmacleodspharmaceuticalsltdandmacleodspharmausaincmacleodswhichfiledan andaseekingapprovaltomarketagenericversionofinvokanabeforeexpirationofunitedstatespatent norelatingtoinvokanatheselawsuitshavenotbeenconsolidatedwiththemainactions ineachoftheseuslawsuitsjanssenandmtpcareseekinganorderenjoiningthedefendantfrommarketingtheir genericversionsofinvokanainvokametandorinvokametxrbeforetheexpirationoftherelevantpatents inoctoberjanssenincjanssenpharmaceuticanvandmtpcinitiatedastatementofclaimundersectionof thepatentedmedicinesnoticeofcomplianceregulationsagainstsandozcanadaincsandozincanadainresponse tosandozsfilingofanandsseekingapprovaltomarketagenericversionofinvokanabeforetheexpirationofthe canadianpatentnosandthefinalhearingisscheduledtobegininaugust janssenincjanssenpharmaceuticanvandmtpcareseekinganorderenjoiningsandozfrommarketingitsgeneric versionofinvokanabeforetheexpirationoftherelevantpatents johnsonjohnsonannualreportopsumit inoctoberactelionpharmaceuticalsltdactelioninitiatedapatentinfringementlawsuitintheunitedstates districtcourtforthedistrictofnewjerseyagainstlauruslabslimitedandpharmaqinccollectivelylauruswhich filedanandaseekingapprovaltomarketgenericversionsofopsumitbeforetheexpirationofuspatent noactelionwasseekinganorderenjoininglaurusfrommarketinggenericversionsofopsumit beforetheexpirationofthepatentinjanuaryactelionenteredintoasettlementagreementwithlaurus inmayjanssenincjanssenandactelioninitiatedastatementofclaimundersectionofthepatented medicinesnoticeofcomplianceregulationsagainstsandozcanadaincsandozincanadainresponsetosandozs filingofanandsseekingapprovaltomarketagenericversionofopsumitmgbeforetheexpirationofcanadian patentnotrialisscheduledtobegininjanuary inmayjanssenandactelioninitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexincanadainresponsetoapotexsfilingofanandsseeking approvaltomarketagenericversionofopsumitmgbeforetheexpirationofthepatenttrialisscheduledto begininfebruary injulyjanssenandactelioninitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstjamppharmacorporationjampincanadainresponsetojampsfilingofanands seekingapprovaltomarketagenericversionofopsumitmgbeforetheexpirationofthepatentandcanadian patentnotrialisscheduledtobegininapril ineachofthesecanadianactionsjanssenandactelionareseekinganorderenjoiningthedefendantsfrommarketing theirgenericversionsofopsumitbeforetheexpirationoftherelevantpatents invegasustenna injanuaryjanssenpharmaceuticanvandjanssenpharmaceuticalsinccollectivelyjansseninitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainsttevapharmaceuticalsusa inctevawhichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforethe expirationofunitedstatespatentnotrialconcludedinoctober inaugustjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmylanlaboratorieslimitedmylanwhichfiledanandaseekingapprovaltomarketagenericversionof invegasustennabeforetheexpirationofthepatentinfebruarymylanfiledapetitionforinterpartes reviewwiththeusptoseekingtoinvalidatethepatenttheusptodeniedthepetitioninseptemberand mylanappealed indecemberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtsforthedistrictsof newjerseyanddelawareagainstpharmascienceincmallinckrodtplcandspecgxllccollectivelypharmascience whichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforetheexpirationofthe patent ineachoftheseuslawsuitsjanssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof invegasustennabeforetheexpirationoftherelevantpatents infebruaryjanssenincandjanssenpharmaceuticanvcollectivelyjanssencanadainitiatedastatementofclaim undersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainsttevacanadalimitedteva canadainresponsetotevasfilingofanandsseekingapprovaltomarketagenericversionofinvegasustenna beforetheexpirationofcanadianpatentnosandjanssensubsequentlydiscontinued theportionofthelawsuitrelatingtothepatentinmaythecanadianfederalcourtissuedapublicjudgment andreasonsdeclaringthattevacanadasgenericversionofinvegasustennaifapprovedwouldinfringeclaimsof thepatentandthattheclaimsofthepatentarenotinvalidforobviousnesstevacanadaappealed innovemberjanssencanadainitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstpharmascienceincinresponsetopharmascienceincsfilingofanandsseeking approvaltomarketagenericversionofinvegasustennabeforetheexpirationofthepatentthefinalhearing isscheduledtobegininjuly johnsonjohnsonannualreport injanuaryjanssencanadainitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexinresponsetoapotexsfilingofanandsseekingapprovalto marketagenericversionofinvegasustennabeforetheexpirationofthepatentthefinalhearingisscheduled tobegininseptember ineachofthesecanadianlawsuitsjanssencanadaisseekinganorderenjoiningthedefendantfrommarketingageneric versionofinvegasustennabeforetheexpirationoftherelevantpatents imbruvica beginninginjanuarypharmacyclicsllcpharmacyclicsandjanssenbiotechincjbifiledpatentinfringement lawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberofgenericcompaniesthatfiled andasseekingapprovaltomarketgenericversionsofimbruvicamgcapsulesbeforeexpirationof pharmacyclicsunitedstatespatentnos andorrelatingtoimbruvicajbiistheexclusivelicenseeof theassertedpatentsthenameddefendantsincludethefollowinggenericcompaniesciplalimitedandciplausainc collectivelyciplasandozincandlekpharmaceuticalsddcollectivelysandoz injanuarypharmacyclicsandjbiamendedtheircomplaintagainstsandoztoallegeinfringementofunitedstates patentnosand infebruarypharmacyclicsandjbiamendedtheircomplaintagainstciplatoallegeinfringementofunitedstates patentnosand inmarchpharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainstalvogenpinebrookllcandnatcopharmaltdcollectivelyalvogenwhichfiledanandaseeking approvaltomarketgenericversionsofimbruvicatabletsassertinginfringementofunitedstatespatentnos inmaypharmacyclicsandjbiamendedtheircomplaintagainstciplatofurtherallegeinfringementofunitedstates patentnoinjunepharmacyclicsandjbiamendedtheircomplaintagainstalvogentofurtherallege infringementofunitedstatespatentno inaugustpharmacyclicsandjbiamendedtheircomplaintsagainstciplaandsandoztofurtherallegeinfringement ofuspatentnosandinaugustthecourtgrantedajointstipulationtostaythelitigation againstcipla trialintheactionsagainstsandozandalvogentookplaceinoctober inmarchsandozfiledaniprpetitionwiththeusptoseekingtoinvalidateunitedstatespatentnoin septembertheusptoissuedafinaldecisionintheiprinvalidatingcertainclaimsofthepatentand upholdingthevalidityofcertainclaimsinthepatentthefinaldecisionwasnotappealedbytheparties inmarchpharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainstalvogenandsandozassertinginfringementofunitedstatespatentnoinapril pharmacyclicsandjbiamendedtheircomplaintagainstsandoztofurtherallegeinfringementofuspatent noinoctoberpharmacyclicsandjbiamendedtheircomplaintagainstsandoztofurtherallege infringementofuspatentnosandandamendedtheircomplaintagainstalvogentofurther allegeinfringementofuspatentnoindecemberthecourtenteredajointstipulationdismissingthe complaintagainstsandoz inaprilpharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainstzydusworldwidedmccandcadilahealthcarelimitedcollectivelyzyduswhichfiledananda seekingapprovaltomarketgenericversionsofimbruvicatabletsassertinginfringementofunitedstatespatentnos trialsintheactionsagainstalvogenandzydusarescheduledtobegininmarch ineachofthelawsuitspharmacyclicsandjbiareseekinganorderenjoiningthedefendantsfrommarketinggeneric versionsofimbruvicabeforetheexpirationoftherelevantpatents johnsonjohnsonannualreportuptravi inaprilactelionpharmaceuticalsltdactelionandnipponshinyakucoltdnipponshinyakuinitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstanumberofgeneric companiesthatfiledandasseekingapprovaltomarketgenericversionsofuptravibeforeexpirationofnippon shinyakusunitedstatespatentnosandrelatingtouptraviactelionisthe exclusivelicenseeoftheassertedpatentsthedefendantsincludealembicpharmaceuticalslimitedandalembic pharmaceuticalsinccollectivelyalembicmsnlaboratoriesprivatelimitedandmsnpharmaceuticalsinccollectively msnvgyaanpharmaceuticalsllcvgyaanandzyduspharmaceuticalsusaincandzydusworldwidedmcc collectivelyzydusinjanuarythecourtenteredjointstipulationsdismissingvgyaanandmsnfromsuit actelionandnipponshinyakuareseekinganorderenjoiningthedefendantsfrommarketinggenericversionsof uptravibeforetheexpirationoftherelevantpatents invegatrinza inseptemberjanssenpharmaceuticalsincjanssenpharmaceuticanvandjanssenresearchdevelopment lcccollectivelyjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmylanlaboratorieslimitedmylanpharmaceuticalsincandmylaninstitutionalllccollectivelymylan mylanfiledanandaseekingapprovaltomarketgenericversionsofinvegatrinzabeforeexpirationofunitedstates patentnorelatingtoinvegatrinzajanssenisseekinganorderenjoiningmylanfrommarketinga genericversionofinvegatrinzabeforetheexpirationoftherelevantpatent governmentproceedings likeothercompaniesinthepharmaceuticalconsumerhealthandmedicaldevicesindustriesjohnsonjohnsonand certainofitssubsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunited statesandothercountriesinwhichtheyoperatesuchregulationhasbeenthebasisofgovernmentinvestigationsand litigationsthemostsignificantlitigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelisted belowitispossiblethatcriminalchargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfrom governmentinvestigationsorlitigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompanieswerenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolving allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise actionableconductbecauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesaleprice awpforthedrugsatissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsthe plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof thedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpmanyofthesecasesbothfederalactionsandstateactionsremovedtofederalcourtwereconsolidated forpretrialpurposesinamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofmassachusettswhere allclaimsagainstthejjawpdefendantswereultimatelydismissedthejjawpdefendantsalsoprevailedinacase broughtbythecommonwealthofpennsylvaniaotherawpcaseshavebeenresolvedthroughcourtorderorsettlement thecasebroughtbyillinoiswassettledaftertrialinnewjerseyaputativeclassactionbaseduponawpallegationsis pendingagainstcentocorincandorthobiotechincbothnowjanssenbiotechincjohnsonjohnsonandalza corporationallothercaseshavebeenresolved opioidlitigation beginninginandcontinuingtothepresentjohnsonjohnsonandjanssenpharmaceuticalsincjpialongwith otherpharmaceuticalcompanieshavebeennamedinmorethanlawsuitsrelatedtothemarketingofopioids includingduragesicnucyntaandnucyntaerthesuitsalsoraiseallegationsrelatedtopreviouslyowned activepharmaceuticalingredientsuppliersubsidiariestasmanianalkaloidsptyltdandnoramcoincbothsubsidiaries weredivestedinthemajorityofthecaseshavebeenfiledbystateandlocalgovernmentssimilarlawsuitshavealso beenfiledbyprivateplaintiffsandorganizationsincludingbutnotlimitedtothefollowingindividualplaintiffsonbehalfof childrensufferingfromneonatalabstinencesyndromehospitalsandhealthinsurerspayorstodatecomplaintsagainst pharmaceuticalcompaniesincludingjohnsonjohnsonandjpihavebeenfiledbythestateattorneysgeneralin johnsonjohnsonannualreport arkansasfloridaidahoillinoiskentuckylouisianamississippimissourinewhampshirenewjerseynewmexiconew yorkohiooklahomasouthdakotatexaswashingtonandwestvirginiacomplaintsagainstthemanufacturersalso havebeenfiledinstateorfederalcourtbycitycountyandlocalgovernmentagenciesinthefollowingstatesalabama arizonaarkansascaliforniaconnecticutfloridageorgiaillinoiskentuckylouisianamainemarylandmassachusetts mississippimissourinevadanewhampshirenewjerseynewmexiconewyorknorthcarolinaohiooklahoma oregonpennsylvaniarhodeislandsouthcarolinasouthdakotatennesseetexasutahvirginiawashingtonwest virginiaandwisconsinthegovernmentofpuertoricofiledsuitinsuperiorcourtofsanjuantherearemorethan casespendinginvariousstatecourtsthereareoverfederalcasescoordinatedinafederalmultidistrictlitigation mdlpendingintheusdistrictcourtforthenortherndistrictofohiomdlnoinadditiontheprovinceof britishcolumbiafiledsuitincanadainoctoberanantitrustcomplaintwasfiledbyprivateplaintiffsinfederalcourt intennesseeandispendingtransfertothemdltheseactionsallegeavarietyofclaimsrelatedtoopioidmarketing practicesincludingfalseadvertisingunfaircompetitionpublicnuisanceconsumerfraudviolationsdeceptiveactsand practicesfalseclaimsandunjustenrichmentthesuitsgenerallyseekpenaltiesandorinjunctiveandmonetaryreliefandin someofthesuitstheplaintiffsareseekingjointandseveralliabilityamongthedefendantsanadversejudgmentinanyof theselawsuitscouldresultintheimpositionoflargemonetarypenaltiesandsignificantdamagesincludingpunitive damagescostofabatementsubstantialfinesequitableremediesandothersanctions thetrialinthematterfiledbytheoklahomaattorneygeneralresultedinajudgmentagainstjohnsonjohnsonandjpiin theamountofmillionsubjecttoafinalordertobeissuedbythecourtthecourtissuedafinaljudgmentreducing theamounttomillionjohnsonjohnsonandjpihaveappealedthejudgmentthecompanybelievesthatithas stronggroundstooverturnthisjudgmentinoctoberjohnsonjohnsonandjpiannouncedasettlementofthefirst casesetfortrialinthemdlwithtwocountiesinohio johnsonjohnsonjpiandotherpharmaceuticalcompanieshavealsoreceivedsubpoenasorrequestsforinformation relatedtoopioidsmarketingpracticesfromthefollowingstateattorneysgeneralalaskaindianamontananew hampshiresouthcarolinatennesseetexasandwashingtoninseptemberjohnsonjohnsonandjpiwere contactedbythetexasandcoloradoattorneygeneralsofficesonbehalfofapproximatelystatesregardingamulti stateattorneygeneralinvestigationinoctoberthecompanyannouncedaproposedagreementinprinciplethat wouldincludethecompanypayingbillionassettlementofthesemattersinoctoberthecompanyagreedto contributeuptoanadditionalbilliontoanallinsettlementamountthatwouldresolveopioidlawsuitsfiledandfuture claimsbystatescitiescountiesandtribalgovernmentsforatotalofbillionwhichhasbeenaccruedsubjectto variousconditionsandanagreementbeingfinalizedthisagreementinprincipleisnotanadmissionofliabilityorwrong doingandwouldresolveopioidlawsuitsfiledandfutureclaimsbystatescitiesandcountiesthecompanycannotpredict iforwhentheagreementwillbefinalizedandindividualcasesareongoing inaugustjohnsonjohnsonreceivedagrandjurysubpoenafromtheunitedstatesattorneysofficeforthe easterndistrictofnewyorkfordocumentsrelatedtothecompanysantidiversionpoliciesandproceduresand distributionofitsopioidmedicationsinwhatthecompanyunderstandstobepartofabroaderinvestigationinto manufacturersanddistributorsmonitoringprogramsandreportingunderthecontrolledsubstancesactinseptember johnsonjohnsonreceivedsubpoenasfromthenewyorkstatedepartmentoffinancialservicesnydfsas partofanindustrywideinquiryintotheeffectofopioidprescriptionsonnewyorkhealthinsurancepremiumsin septemberthecompanylearnedthatnydfsfiledastatementofchargesrelatedtothisinvestigation fromjunethroughdecemberthecompanysboardofdirectorsreceivedaseriesofshareholderdemand lettersallegingbreachesoffiduciarydutiesrelatedtothemarketingofopioidstheboardretainedindependentcounselto investigatetheallegationsinthedemandsandinaprilindependentcounseldeliveredareporttotheboard recommendingthatthecompanyrejecttheshareholderdemandsandtakethestepsthatarenecessaryorappropriateto securedismissalofrelatedderivativelitigationtheboardunanimouslyadoptedtherecommendationsoftheindependent counselsreport innovemberoneoftheshareholderswhosentademandfiledaderivativecomplaintagainstjohnsonjohnsonas thenominaldefendantandcertaincurrentandformerdirectorsandofficersasdefendantsinthesuperiorcourtofnew jerseythecomplaintallegesbreachesoffiduciarydutiesrelatedtothemarketingofopioidsandthatjohnsonjohnson hassuffereddamagesasaresultofthoseallegedbreachesinmaytheshareholderfiledanamendedcomplaint challengingtheboardsrejectionofhisdemandinaugustjohnsonjohnsonmovedtodismisstheamended complaintandasofdecemberthatmotionwasfullybriefedinaugustanothershareholderwhosenta demandfiledaseparatederivativecomplaintinthesamecourtmakingsimilarallegationsinoctoberthecourt granteddefendantsrequesttoreassignthesecondfiledcasetothedivisionwherethefirstfiledcaseispending johnsonjohnsonannualreportindecembertwoadditionalshareholderswhosentdemandsfiledtwoseparatederivativecomplaintsmakingsimilar allegationsagainstjohnsonjohnsonasthenominaldefendantandcertaincurrentandformerdirectorsandofficersas defendantsintheunitedstatesdistrictforthedistrictofnewjerseyinaprilthetwofederalcaseswere consolidatedintoasingleactioncaptionedinrejohnsonjohnsonopioidstockholderderivativelitigationinjuly theshareholdersfiledaconsolidatedcomplaintinseptemberjohnsonjohnsonmovedtodismissthe consolidatedcomplaintandindecembertheshareholdersopposedjohnsonjohnsonsmotionjohnson johnsonfileditsreplyinfebruaryinjulyanadditionalshareholderwhosentademandfiledaderivative complaintinthesamefederalcourtmakingsimilarallegationsagainstthesamedefendantsnamedintheconsolidated actioninjanuarypursuanttoanorderintheconsolidatedactionthethirdcasewasconsolidatedintothe consolidatedactioninfebruarytheshareholdersintheconsolidatedactionfiledamotionforvoluntarydismissal inaugustdepuyorthopaedicsincdepuyincnowknownasdepuysynthesincandjohnsonjohnson servicesinccollectivelydepuyreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictof massachusettsandthecivildivisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionof materialsrelatingtothedepuyasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrict courtforthedistrictofmassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalseclaims actagainstthecompaniesinfebruarythedistrictcourtgrantedthecompaniesmotiontodismisswithprejudice unsealedthequitamcomplaintanddeniedthequitamrelatorsrequestforleavetofileafurtheramendedcomplaintthe quitamrelatorsappealedthecasetotheunitedstatescourtofappealsforthefirstcircuitinjulythefirstcircuit affirmedthedistrictcourtsdismissalinpartreversedinpartandaffirmedthedecisiontodenytherelatorsrequesttofile athirdamendedcomplainttherelatorsremainingclaimsarenowpendingbeforethedistrictcourtinjulythe courtorderedtherelatorstocompletediscoverybyaugusttherelatorshaverequestedanextensionoftheaugust deadlinethatdepuyopposedandadditionaldiscoveryrelatedmotionshavebeenfiledbybothpartiesadditionally depuyhasrequestedascheduleforthefilingofamotiontostrikeandtodismisstherelatorssecondamendedcomplaint inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonssubsidiaryethiconincethiconinmaycaliforniaandwashingtonfiledcivilcomplaints againstjohnsonjohnsonethiconandethiconusllcallegingviolationsoftheirconsumerprotectionstatutessimilar complaintswerefiledagainstthecompaniesbythefollowingstateskentuckymississippiwestvirginiaandoregonin apriljohnsonjohnsonandethiconsettledthewashingtoncasethecaliforniacasestartedtrialinjuly andconcludedinseptemberthetrialdateforthekentuckycasewasscheduledforseptemberbuthasbeen adjournedandnonewtrialdatehasbeenscheduledinoctoberjohnsonjohnsonandethiconsettledthemulti stateinvestigationwithotherstatesandthedistrictofcolumbiainjanuarythecourtincaliforniaissueda statementofdecisionfindinginfavorofthestateofcaliforniaandawardedcivilpenaltiesintheamountofmillion inaprilthecourtincaliforniadeniedthecompanysmotionforanewtrialinaugustthecourtentered judgmentwithrespecttothepenaltiesofmillionbutdeniedtheattorneygeneralsrequestforinjunctivereliefthe companyisappealingthepenaltyjudgmentinaprilthecompanysettledthewestvirginiainoctoberthe companysettledwiththeattorneygeneraloforegoninnovemberthecompanysettledwiththeattorney generalofmississippi indecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesales andmarketingofuvadexmethoxsalenandtheuvarxtsandcellexsystemsduringtheperiodtothepresent theunitedstatesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelateto theinvestigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpinjanuary andocdwasdivestedinjunefollowingthedivestitureofocdjohnsonjohnsonretainedocdsportionofany liabilityresultingfromtheinvestigationforactivitythatoccurredpriortothesaleoftherakosfollowingproductionof documentstoandsettlementdiscussionswiththeusattorneysofficejjaffiliatemedicaldevicebusinessservices incagreedtoresolveclaimsunderthefederalfalseclaimsactandanalogousstatelawsinasettlementannouncedin novemberinthesettlementagreementmedicaldevicebusinessservicesexpresslydeniedanywrongfulconduct asaresultofthesettlementaquitamcomplaintfiledbytworelatorspendingintheusdistrictcourtfortheeastern districtofpennsylvaniawillbedismissedseparatesettlementagreementswiththestatesparticipatinginthesettlement areintheprocessofbeingfinalized johnsonjohnsonannualreport injunethemississippiattorneygeneralfiledacomplaintinchancerycourtofthefirstjudicialdistrictofhinds countymississippiagainstjohnsonjohnsonandjohnsonjohnsonconsumercompaniesincnowknownas johnsonjohnsonconsumerincjjcithecomplaintallegesthatdefendantsviolatedthemississippiconsumer protectionactbyfailingtodiscloseallegedhealthrisksassociatedwithfemaleconsumersuseoftalccontainedin johnsonsbabypowderandjohnsonsshowertoshoweraproductdivestedinandseeksinjunctive andmonetaryreliefthematterisstayedpendinginterlocutoryappealofadecemberdenialofjohnsonjohnson andjjcismotionforsummaryjudgmentthemississippisupremecourtgrantedjjandjjcisrequesttofilean interlocutoryappealofthedenialofthemotionforsummaryjudgmentinlatebriefingiscompleteandoralargument washeldinfebruary injanuarythestateofnewmexicofiledaconsumerprotectioncaseallegingthatthecompanydeceptively marketedandsolditstalcumpowderproductsbymakingmisrepresentationsaboutthesafetyoftheproductsandthe presenceofcarcinogensincludingasbestosthestateofnewmexicofiledanamendedcomplaintinmarchthe companymovedtodismisscertainoftheclaimsintheamendedcomplaintwhichwasgrantedthecompanythenfiled amotionforpartialjudgmentonthepleadingsindecember fortyonestateshavecommencedajointinvestigationintothecompanysmarketingofitstalcumpowderproductsat thistimethemultistategrouphasnotassertedanyclaimsagainstthecompanyseveralstateshaveissuedcivil investigativedemandsseekingdocumentsandotherinformation inmarchjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandfromtheunitedstates attorneysofficeforthesoutherndistrictofnewyorkrelatedtojpiscontractualrelationshipswithpharmacybenefit managersovertheperiodfromjanuarytothepresentwithregardtocertainofjpispharmaceuticalproductsthe demandwasissuedinconnectionwithaninvestigationunderthefalseclaimsactthecompanyhasprovided documentsinresponsetothedemand injulyjohnsonjohnsonandjanssenproductslpwereservedwithaquitamcomplaintpursuanttothefalse claimsactfiledintheunitedstatesdistrictcourtforthedistrictofnewjerseyallegingtheofflabelpromotionoftwo hivproductsprezistaandintelenceandantikickbackviolationsinconnectionwiththepromotionofthese productsthecomplaintwasfiledundersealindecemberthefederalandstategovernmentshavedeclinedto interveneandthelawsuitisbeingprosecutedbytherelatorsinfebruarythecourtstayedthecaseandordered mediation inmarchjanssenbiotechincreceivedacivilinvestigativedemandfromtheunitedstatesdepartmentofjustice regardingafalseclaimsactinvestigationconcerningmanagementandadvisoryservicesprovidedtorheumatologyand gastroenterologypracticesthatpurchasedremicadeorsimponiariainaugusttheunitesstates departmentofjusticenotifiedjanssenbiotechincthatitwasclosingtheinvestigationsubsequentlytheunitedstates districtcourtforthedistrictofmassachusettsunsealedaquitamfalseclaimsactcomplaintwhichwasservedonthe companythedepartmentofjusticehaddeclinedtointerveneinthequitamlawsuitinaugustthecompanyfiled amotiontodismisswhichwasgrantedinpartanddeniedinpartdiscoveryisunderway inaprilandseptemberjohnsonjohnsonreceivedsubpoenasfromtheunitedstatesattorneyforthedistrictof massachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsfordarzalex olysioremicadesimponistelaraandzytigathesubpoenasalsoseekdocumentsrelatingtoaverage manufacturerpriceandbestpricereportingtothecenterformedicareandmedicaidservicesrelatedtothoseproducts aswellasrebatepaymentstostatemedicaidagenciesthecompanyhasprovideddocumentsinresponsetothe subpoenas injunejohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekinginformationregardingpracticespertainingtothesterilizationofdepuysynthesincspinal implantsatthreehospitalsinbostonaswellasinteractionsofemployeesofcompanysubsidiarieswithphysiciansat thesehospitalsjohnsonjohnsonanddepuysynthesinchaveproduceddocumentsinresponsetothesubpoenaand arefullycooperatingwiththegovernmentsinvestigation injulythepublicprosecutionserviceinriodejaneiroandrepresentativesfromthebrazilianantitrustauthority cadeinspectedtheofficesofmorethancompaniesincludingjohnsonjohnsondobrasilindstriaecomrciode produtosparasadeltdatheauthoritiesappeartobeinvestigatingallegationsofpossibleanticompetitivebehaviorand possibleimproperpaymentsinthemedicaldeviceindustrywecontinuetoactivelyrespondtoinquiriesregardingthe foreigncorruptpracticesactfromtheunitedstatesdepartmentofjusticeandtheunitedstatessecuritiesand exchangecommission johnsonjohnsonannualreportfromtimetotimethecompanyhasreceivedrequestsfromavarietyofunitedstatescongressionalcommitteesto produceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsontocooperatewith theseinquiriesbyproducingtherequestedinformation generallitigation inmarchapurportedclassactionwasfiledinthecircuitcourtthirdjudicialdistrictmadisoncountyillinois againstjohnsonjohnsonconsumerincjjciallegingviolationsofstateconsumerfraudstatutesbasedon nondisclosureofallegedhealthrisksassociatedwithtalccontainedinjohnsonsbabypowderthecomplaintseeks damagesbutdoesnotallegepersonalinjuryinoctoberjjcimovedtodismissthecomplaint inaugustunitedstatescustomsandborderprotectionuscbpissuedapenaltynoticeagainstjanssenortho llcjanssenorthoassessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolatetheactive pharmaceuticalingredientinprezistainconnectionwithitsimportationintotheunitedstatesinaugustus cbpformallyrejectedjanssenssupplementalpetitionchallengingthepenaltiesassessmentanddemandedpaymentof themitigatedpenaltyinoctoberuscbpagreedtonotreferthemattertotheofficeofchiefcounselatthistime pendingresolutionoftherelatedclassificationlitigationindecemberjanssenorthosuedtheunitedstatesinthe unitedstatescourtofinternationaltradetheclassificationlitigationseekingadeterminationthatdarunavirethanolate isexemptfromdutiesuponimportationintotheunitedstatesinfebruarythecourtruledthatdarunavirethanolate iseligiblefordutyfreetreatmentinapriltheunitedstatesappealedtotheunitedstatescourtofappealsforthe federalcircuit inseptembergenmabasbroughtanarbitrationagainstjanssenbiotechincpursuanttoalicense agreementbetweenthepartiesthearbitrationrelatestoroyaltiesforcertainjanssendaratumumabproducts inmarchandapriloverputativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourts aroundtheunitedstatesagainstjohnsonjohnsonvisioncareincjjvciandothercontactlensmanufacturers distributorsandretailersallegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlensesthe complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailers concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumerstheplaintiffsareseekingdamagesand injunctivereliefalloftheclassactioncasesweretransferredtotheunitedstatesdistrictcourtforthemiddledistrictof floridainjunetheplaintiffsfiledaconsolidatedclassactioncomplaintinnovemberdiscoveryandpretrial motionpracticeiscompletenotrialdatehasbeenset inaugusttwothirdpartypayorsfiledapurportedclassactionintheunitedstatesdistrictcourtfortheeastern districtoflouisianaagainstjanssenresearchdevelopmentllcjanssenorthollcjanssenpharmaceuticalsinc orthomcneiljanssenpharmaceuticalsincandjohnsonjohnsonaswellascertainbayerentitiesallegingthatthe defendantsimproperlymarketedandpromotedxareltoassaferandmoreeffectivethanlessexpensivealternative medicationswhilefailingtofullydiscloseitsrisksthecomplaintseeksdamagesinnovemberdefendantsmoved todismissthecomplaint inseptemberpfizerincpfizerfiledanantitrustcomplaintagainstjohnsonjohnsonandjanssenbiotechinc collectivelyjansseninunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniapfizerallegesthatjanssen hasviolatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecomplaintseeksdamagesand injunctivereliefdiscoveryisongoing beginninginseptembermultiplepurportedclassactionswerefiledonbehalfofindirectpurchasersof remicadeagainstjohnsonjohnsonandjanssenbiotechinccollectivelyjanssenallegingthatjanssenhas violatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecaseswereconsolidatedforpretrial purposesasinreremicadeantitrustlitigationinunitedstatesdistrictcourtfortheeasterndistrictofpennsylvania theconsolidatedcomplaintseeksdamagesandinjunctivereliefdiscoveryisongoing injunewalgreencoandkrogercofiledanantitrustcomplaintagainstjohnsonjohnsonandjanssenbiotech inccollectivelyjanssenintheunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniathecomplaint allegesthatjanssenhasviolatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecomplaint seeksdamagesandinjunctivereliefinmarchsummaryjudgmentwasgrantedinfavorofjansseninfebruary theunitedstatescourtofappealsforthethirdcircuitreversedthedistrictcourtsdecisiondiscoveryis ongoing johnsonjohnsonannualreport injunetheunitedstatesfederaltradecommissionftcissuedacivilinvestigativedemandtojohnson johnsoninconnectionwithitsinvestigationofwhetherjanssensremicadecontractingpracticesviolatefederal antitrustlawsthecompanyproduceddocumentsandinformationresponsivetothecivilinvestigativedemand inoctobercertainunitedstatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof pharmaceuticalandmedicaldevicescompaniesincludingjohnsonjohnsonandcertainofitssubsidiariesinunited statesdistrictcourtforthedistrictofcolumbiaallegingthatthedefendantsviolatedtheunitedstatesantiterrorism actthecomplaintallegesthatthedefendantsprovidedfundingforterroristorganizationsthroughtheirsalespractices pursuanttopharmaceuticalandmedicaldevicecontractswiththeiraqiministryofhealthinjulythedistrictcourt dismissedthecomplaintinjanuaryplaintiffsappealedthedistrictcourtsdecisiontotheunitedstatescourtof appealsforthedistrictofcolumbiacircuit inoctobertwoseparateputativeclassactionswerefiledagainstactelionpharmaceuticalltdactelion pharmaceuticalsusincandactelionclinicalresearchinccollectivelyactelioninunitedstatesdistrictcourtforthe districtofmarylandandunitedstatesdistrictcourtforthedistrictofcolumbiathecomplaintsallegethatactelion violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical manufacturerswithsamplesoftracleertracleerissubjecttoariskevaluationandmitigationstrategyrequired bythefoodanddrugadministrationwhichimposesrestrictionsondistributionoftheproductinjanuarythe plaintiffsdismissedthedistrictofcolumbiacaseandfiledaconsolidatedcomplaintintheunitedstatesdistrictcourtfor thedistrictofmarylandinoctoberthecourtgrantedactelionsmotiontodismisstheamendedcomplaint plaintiffshaveappealedthedecisiontotheunitedstatescourtofappealsforthefourthcircuit indecemberjanssenbiotechincjanssenoncologyincjanssenresearchdevelopmentllcandjohnson johnsoncollectivelyjanssenwereservedwithaquitamcomplaintfiledonbehalfoftheunitedstatesstatesand thedistrictofcolumbiathecomplaintwhichwasfiledindecemberinunitedstatesdistrictcourtforthenorthern districtofcaliforniaallegesthatjanssenviolatedthefederalfalseclaimsactandstatelawwhenprovidingpricing informationforzytigatothegovernmentinconnectionwithdirectgovernmentsalesandgovernmentfundeddrug reimbursementprogramsatthistimethefederalandstategovernmentshavedeclinedtointervenethecasehasbeen transferredtounitedstatesdistrictcourtforthedistrictofnewjerseyinseptemberjanssenmovedtodismiss thecomplaint inaprilbluecrossblueshieldoflouisianaandhmolouisianaincfiledaclassactioncomplaintagainst janssenbiotechincjanssenoncologyincjanssenresearchdevelopmentllcandbtginternationallimitedinthe unitedstatesdistrictcourtfortheeasterndistrictofvirginiaonbehalfofindirectpurchasersofzytigaseveral additionalcomplaintswerefiledthereafterinvirginiaandnewjerseytheindirectpurchasercomplaintsgenerallyallege thatthedefendantsviolatedtheantitrustandconsumerprotectionslawsofseveralstatesandtheshermanactby pursuingpatentlitigationrelatingtozytigainordertodelaygenericentryandseekdamagesthevirginiacaseshave beentransferredtotheunitedstatesdistrictcourtforthedistrictofnewjerseyandconsolidatedwiththenewjersey caseforpretrialpurposesinmayaclassactioncomplaintwasfiledagainstjanssenbiotechincjanssen oncologyincjanssenresearchdevelopmentllcandbtginternationallimitedintheunitedstatesdistrictcourt forthedistrictofnewjerseyonbehalfofdirectpurchasersofzytigathedirectpurchasercomplaintallegesthat defendantsviolatedtheshermanactbypursuingpatentlitigationrelatingtozytigainordertodelaygenericentryand seekdamagesandinjunctiverelief inmayaclassactionantitrustcomplaintwasfiledagainstjanssenrdirelandjanssenandjohnsonjohnsonin theunitedstatesdistrictcourtforthenortherndistrictofcaliforniathecomplaintallegesthatjanssenviolatedfederal andstateantitrustandconsumerprotectionlawsbyagreeingtoexclusivityprovisionsinitsagreementswithgilead concerningthedevelopmentandmarketingofcombinationantiretroviraltherapiescarttotreathivthecomplaintalso allegesthatgileadenteredintosimilaragreementswithbristolmyerssquibbandjapantobaccoinmarchthe courtgrantedinpartanddeniedinpartdefendantsmotionstodismissplaintiffsfiledanamendedcomplaintinapril defendantsmovedtodismisstheamendedcomplaintinjulythecourtgrantedinpartanddeniedinpartthe renewedmotiontodismissdiscoveryisongoing inoctoberinnovativehealthllcfiledacomplaintagainstbiosensewebsterincbwiintheunitedstates districtcourtforthemiddledistrictofcaliforniathecomplaintallegesthatcertainofbwisbusinesspracticesand contractualtermsviolatetheantitrustlawsoftheunitedstatesandthestateofcaliforniabyrestrictingcompetitioninthe saleofhighdensitymappingcathetersandultrasoundcathetersinjanuarybwifiledamotiontodismissthe complaintinaugustthecourtgrantedinpartanddeniedinpartbwismotiontodismissdiscoveryisongoing johnsonjohnsonannualreportinnovemberjohnsonjohnsonreceivedademandforindemnificationfrompfizerincpursuanttothestock andassetpurchaseagreementbetweenthecompanyandpfizeralsoinnovemberjohnsonjohnsoninc receivedademandforindemnificationfromsanoficonsumerhealthincpursuanttotheassetpurchase agreementbetweenjjincandsanofiinjanuaryjohnsonjohnsonreceivedademandforindemnificationfrom boehringeringelheimpharmaceuticalsincpursuanttotheassetpurchaseagreementamongthecompany pfizerandboehringeringelheimthenoticesseekindemnificationforlegalclaimsrelatedtooverthecounterzantac ranitidineproductsplaintiffsintheunderlyingactionsallegethatzantacandotheroverthecounterranitidine medicationscontainunsafelevelsofndmannitrosodimethylamineandcancauseandorhavecausedvariouscancers inpatientsusingtheproductsandseekinjunctiveandmonetaryrelief inoctoberfortisadvisorsllcfortisinitscapacityasrepresentativeoftheformerstockholdersofaurishealth incaurisfiledacomplaintagainstjohnsonjohnsonethiconincandcertainnamedofficersandemployees collectivelyethiconinthecourtofchanceryofthestateofdelawarethecomplaintallegesbreachofcontractfraud andothercausesofactionagainstethiconinconnectionwithethiconsacquisitionofaurisinthecomplaintseeks damagesandotherreliefindecemberethiconmovedtodismisscertaincausesofactioninthecomplaint johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation johnsonjohnsonannualreport restructuring inthefiscalsecondquarterofthecompanyannouncedplanstoimplementaseriesofactionsacrossitsglobal supplychainthatareintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilitiestechnologiesand solutionsnecessarytomanufactureandsupplyitsproductportfolioenhanceagilityanddrivegrowththeglobalsupply chainactionsincludeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexityimprove costcompetitivenessenhancecapabilitiesandoptimizethesupplychainnetworkforadditionaldetailsontheglobal supplychainrestructuringstrategiccollaborationsseenotetotheconsolidatedfinancialstatementsinfiscalyear thecompanyrecordedapretaxchargeofbillionwhichisincludedonthefollowinglinesoftheconsolidated statementofearningsbillioninrestructuringbillioninotherincomeexpenseandbillionincostof productssoldtotalprojectcostsofapproximatelybillionhavebeenrecordedsincetherestructuringwas announcedseethefollowingtableforadditionaldetailsontherestructuringprogram intotalthecompanyexpectstheglobalsupplychainactionstogenerateapproximatelybilliontobillionin annualpretaxcostsavingsthatwillbesubstantiallydeliveredbythecompanyexpectstorecordpretax restructuringchargesofapproximatelybilliontobillionoverthetoyearperiodofthisactivitythesecosts areassociatedwithnetworkoptimizationsexitcostsandaccelerateddepreciationandamortization thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe fiscalyearended dollarsinmillions severance assetwriteoffssales total reservebalancedecember activity reservebalancedecember currentyearactivity charges cashsettlements settlednoncash reservebalancejanuary cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenextyearsinaccordancewiththecompanysplans andlocallaws otherincludesprojectexpensesuchassalariesforemployeessupportingtheseinitiativesandconsultingexpenses relatestopensionrelatednetactuariallossesassociatedwiththetransferofemployeestojabilincaspartofthestrategic collaboration representsgainonsaleofanasset thecompanycontinuouslyreevaluatesitsseverancereservesrelatedtorestructuringandthetimingofpaymentsdueto theplannedreleaseofassociatesregardingseverallongertermprojectsthecompanybelievesthattheexisting severancereservesaresufficienttocovertheglobalsupplychainplansgiventheperiodoverwhichtheactionswilltake placethecompanywillcontinuetoassessandmakeadjustmentsasnecessaryifadditionalamountsbecomeprobable andestimable johnsonjohnsonannualreportreport independent registered public accounting firm totheboardofdirectorsandshareholdersofjohnsonjohnson opinionsonthefinancialstatementsandinternalcontroloverfinancialreporting wehaveauditedtheaccompanyingconsolidatedbalancesheetsofjohnsonjohnsonanditssubsidiariesthe companyasofjanuaryanddecemberandtherelatedconsolidatedstatementsofearningsof comprehensiveincomeofequityandofcashflowsforeachofthethreefiscalyearsintheperiodendedjanuary includingtherelatednotescollectivelyreferredtoastheconsolidatedfinancialstatementswealsohaveauditedthe companysinternalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrol integratedframeworkissuedbythecommitteeofsponsoringorganizationsofthetreadwaycommission coso inouropiniontheconsolidatedfinancialstatementsreferredtoabovepresentfairlyinallmaterialrespectsthefinancial positionofthecompanyasofjanuaryanddecemberandtheresultsofitsoperationsanditscash flowsforeachofthethreefiscalyearsintheperiodendedjanuaryinconformitywithaccountingprinciples generallyacceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespects effectiveinternalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrol integratedframeworkissuedbythecoso basisforopinions thecompanysmanagementisresponsiblefortheseconsolidatedfinancialstatementsformaintainingeffectiveinternal controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting includedintheaccompanyingmanagementsreportoninternalcontroloverfinancialreportingourresponsibilityisto expressopinionsonthecompanysconsolidatedfinancialstatementsandonthecompanysinternalcontroloverfinancial reportingbasedonourauditsweareapublicaccountingfirmregisteredwiththepubliccompanyaccountingoversight boardunitedstatespcaobandarerequiredtobeindependentwithrespecttothecompanyinaccordancewiththe usfederalsecuritieslawsandtheapplicablerulesandregulationsofthesecuritiesandexchangecommissionandthe pcaob weconductedourauditsinaccordancewiththestandardsofthepcaobthosestandardsrequirethatweplanand performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial misstatementwhetherduetoerrororfraudandwhethereffectiveinternalcontroloverfinancialreportingwasmaintained inallmaterialrespects ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial misstatementoftheconsolidatedfinancialstatementswhetherduetoerrororfraudandperformingproceduresthat respondtothoseriskssuchproceduresincludedexaminingonatestbasisevidenceregardingtheamountsand disclosuresintheconsolidatedfinancialstatementsourauditsalsoincludedevaluatingtheaccountingprinciplesused andsignificantestimatesmadebymanagementaswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial statementsourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol overfinancialreportingassessingtheriskthatamaterialweaknessexistsandtestingandevaluatingthedesignand operatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalsoincludedperformingsuchother proceduresasweconsiderednecessaryinthecircumstanceswebelievethatourauditsprovideareasonablebasisfor ouropinions definitionandlimitationsofinternalcontroloverfinancialreporting acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare johnsonjohnsonannualreport recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statements becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate criticalauditmatters thecriticalauditmatterscommunicatedbelowaremattersarisingfromthecurrentperiodauditoftheconsolidated financialstatementsthatwerecommunicatedorrequiredtobecommunicatedtotheauditcommitteeandthatirelateto accountsordisclosuresthatarematerialtotheconsolidatedfinancialstatementsandiiinvolvedourespecially challengingsubjectiveorcomplexjudgmentsthecommunicationofcriticalauditmattersdoesnotalterinanywayour opinionontheconsolidatedfinancialstatementstakenasawholeandwearenotbycommunicatingthecriticalaudit mattersbelowprovidingseparateopinionsonthecriticalauditmattersorontheaccountsordisclosurestowhichthey relate uspharmaceuticalrebatereservesmanagedcaremedicareandmedicaid asdescribedinnotetotheconsolidatedfinancialstatementsthecompanyrecognizesrevenuefromproductsales whenobligationsunderthetermsofacontractwiththecustomeraresatisfiedrebatesanddiscountsprovidedto customersareaccountedforasvariableconsiderationandrecordedasareductioninsalestheliabilityforsuchrebates anddiscountsisrecognizedwithinaccruedrebatesreturnsandpromotionsontheconsolidatedbalancesheeta significantportionoftheliabilityrelatedtorebatesisfromthesaleofpharmaceuticalgoodswithintheusprimarilythe managedcaremedicareandmedicaidprogramswhichamountedtobillionasofjanuaryforsignificant rebateprogramswhichincludetheusmanagedcaremedicareandmedicaidrebateprogramsrebatesanddiscounts estimatedbymanagementarebasedoncontractualtermshistoricalexperiencepatientoutcomestrendanalysisand projectedmarketconditionsintheuspharmaceuticalmarket theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtouspharmaceuticalrebate reservesmanagedcaremedicareandmedicaidisacriticalauditmatterarethesignificantjudgmentbymanagement duetothesignificantmeasurementuncertaintyinvolvedindevelopingthesereservesandthehighdegreeofauditor judgmentsubjectivityandauditeffortinperformingproceduresandevaluatingtheassumptionsrelatedtocontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsintheuspharmaceutical market addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrols relatingtouspharmaceuticalrebatereservesmanagedcaremedicareandmedicaidincludingcontrolsoverthe assumptionsusedtoestimatetheserebatestheseproceduresalsoincludedamongothersidevelopingan independentestimateoftherebatesbyutilizingthirdpartyinformationonpriceandmarketconditionsintheus pharmaceuticalmarketthetermsofthespecificrebateprogramsandthehistoricalexperienceandtrendanalysisof actualrebateclaimspaidiitestingrebateclaimsprocessedbythecompanyincludingevaluatingthoseclaimsfor consistencywiththecontractualandmandatedtermsofthecompanysrebatearrangementsandiiicomparingthe independentestimatestomanagementsestimates litigationcontingenciestalc asdescribedinnotesandtotheconsolidatedfinancialstatementsthecompanyrecordsaccrualsforloss contingenciesassociatedwithlegalmattersincludingtalcwhenitisprobablethataliabilitywillbeincurredandthe amountofthelosscanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany managementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimatedfor thesemattersmanagementisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued amountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsand uncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuch estimatesandjudgmentscanbeaffectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtin johnsonjohnsonannualreporttheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnot completeproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindispute proceduralorjurisdictionalissuestheuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachieve comprehensivemultipartysettlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerous partiesinvolvedtherehavebeenverdictsagainstthecompanyforthismatterincludingaverdictinjulyof billionwhichwasreversedinpartandaffirmedinpartbythemissouricourtofappealsinjunereducingthe overallawardtobillionandwithadditionalinterestasofjanuaryasthecompanypursuesfurtherappealis currentlybillionanapplicationfortransferofthecasetothemissourisupremecourtwassubsequentlydeniedand thecompanyiscurrentlyseekingreviewbytheunitedstatessupremecourtasdescribedbymanagementthe companycontinuestobelievethatithasstronglegalgroundsfortheappealofthisverdictaswellasotherverdictsithas appealednotwithstandingthecompanysconfidenceinthesafetyofitstalcproductsincertaincircumstancesthe companyhasandmaysettlecasesthecompanyhasestablishedanaccrualfordefensecostsandreservesfor settlementofcertaincasesandclaimsaswellasonecasecurrentlyonappealinconnectionwithproductliability litigationassociatedwithbodypowderscontainingtalc theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtothetalclitigationisacriticalaudit matterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredandwhen determiningwhetherareasonableestimateofthelossorrangeoflossforeachclaimcanbemadewhichinturnledtoa highdegreeofauditorjudgmentsubjectivityandeffortinperformingproceduresandevaluatingmanagements assessmentofthelosscontingenciesassociatedwiththislitigation addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrols relatingtomanagementsevaluationofthetalclitigationincludingcontrolsoverdeterminingwhetheralossisprobable andwhethertheamountoflosscanbereasonablyestimatedaswellasfinancialstatementdisclosuresthese proceduresalsoincludedamongothersigaininganunderstandingofthecompanysprocessaroundtheaccounting andreportingforthetalclitigationiidiscussingthestatusofsignificantknownactualandpotentiallitigationwiththe companysinhouselegalcounselaswellasexternalcounselwhendeemednecessaryiiiobtainingandevaluatingthe lettersofauditinquirywithinternalandexternallegalcounselforsignificantlitigationivevaluatingthereasonablenessof managementsassessmentregardingwhetheranunfavorableoutcomeisreasonablypossibleorprobableandreasonably estimableandvevaluatingthesufficiencyofthecompanyslitigationcontingenciesdisclosures litigationopioids asdescribedinnotesandtotheconsolidatedfinancialstatementsthecompanyrecordsaccrualsforloss contingenciesassociatedwithlegalmattersincludingopioidswhenitisprobablethataliabilitywillbeincurredandthe amountofthelosscanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany managementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimatedfor thesemattersmanagementisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued amountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsand uncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuch estimatesandjudgmentscanbeaffectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtin theproceedingsareunsubstantiatedorindeterminatematterspresentlegaluncertaintiestherearesignificantfactsin disputeproceduralorjurisdictionalissuestheuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilityto achievecomprehensivemultipartysettlementscomplexityofrelatedcrossclaimsandcounterclaimsandorthereare numerouspartiesinvolvedthecompanyhasbeennamedinnumerouslawsuitsbroughtbycertainstateandlocal governmentsrelatedtoopioidsmattersthetrialinthematterfiledbytheoklahomaattorneygeneralresultedina judgmentagainstthecompanyintheamountofmillionwhichwassubsequentlyreducedtomillionthe companyhasappealedthejudgmentandasdescribedbymanagementbelievesthatithasstronggroundstooverturn thisjudgmentseparatelyinoctoberthecompanyannouncedaproposedagreementinprinciplethatwould includethecompanypayingbillionassettlementofthelawsuitsinoctoberthecompanyagreedtocontribute uptoanadditionalbilliontoanallinsettlementamountthatwouldresolveopioidlawsuitsfiledandfutureclaimsby statescitiescountiesandtribalgovernmentsforatotalofbillionwhichhasbeenaccruedsubjecttovarious conditionsandanagreementbeingfinalizedasdescribedbymanagementthisagreementinprincipleisnotanadmission ofliabilityorwrongdoingandwouldresolveopioidlawsuitsfiledandfutureclaimsbystatescitiesandcounties theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtotheopioidslitigationisacritical auditmatterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredforthe judgmentagainstthecompanyinoklahomaandwhendeterminingwhetherareasonableestimateoftherangeoflossfor johnsonjohnsonannualreport theproposedagreementinprincipletosettleopioidslitigationcanbemadewhichinturnledtoahighdegreeofauditor judgmentsubjectivityandeffortinperformingproceduresandevaluatingmanagementsassessmentoftheloss contingenciesassociatedwiththislitigation addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrols relatingtomanagementsevaluationoftheopioidlitigationincludingcontrolsoverdeterminingwhetheralossisprobable andwhethertheamountoflosscanbereasonablyestimatedaswellasfinancialstatementdisclosuresthese proceduresalsoincludedamongothersigaininganunderstandingofthecompanysprocessaroundtheaccounting andreportingfortheopioidslitigationiidiscussingthestatusofsignificantknownactualandpotentiallitigationand ongoingsettlementnegotiationswiththecompanysinhouselegalcounselaswellasexternalcounselwhendeemed necessaryiiiobtainingandevaluatingthelettersofauditinquirywithinternalandexternallegalcounselforsignificant litigationivevaluatingthereasonablenessofmanagementsassessmentregardingwhetheranunfavorableoutcomeis reasonablypossibleorprobableandreasonablyestimableandvevaluatingthesufficiencyofthecompanyslitigation contingenciesdisclosures spricewaterhousecoopersllp florhamparknewjersey february wehaveservedasthecompanysauditorsinceatleastwehavenotbeenabletodeterminethespecificyearwe beganservingasauditorofthecompany johnsonjohnsonannualreportmanagements report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciples internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofjanuaryinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof januarythecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofjanuaryhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappears herein salexgorsky sjosephjwolk alexgorsky josephjwolk chairmanboardofdirectors executivevicepresident chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreport shareholder return performance graphs setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingjanuaryagainstthecumulativetotalreturnofthestandardpoors stockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipmentindex thegraphsandtablesassumethatwasinvestedondecemberanddecemberineachofthe companyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexandthe standardpoorshealthcareequipmentindexandthatalldividendswerereinvested yearshareholderreturn performancejjvsindices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex yearshareholderreturn performancejjvsindices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreportitem changes disagreements accountants accounting financial disclosure notapplicable item controls procedures disclosurecontrolsandproceduresattheendoftheperiodcoveredbythisreportthecompanyevaluatedthe effectivenessofthedesignandoperationofitsdisclosurecontrolsandproceduresthecompanysdisclosurecontrols andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatit filesorsubmitsundertheexchangeactisrecordedprocessedsummarizedandreportedwithinthetimeperiods specifiedinthesecsrulesandformsdisclosurecontrolsandproceduresincludewithoutlimitationcontrolsand proceduresdesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatitfilesor submitsundertheexchangeactisaccumulatedandcommunicatedtothecompanysmanagementincludingitsprincipal executiveandprincipalfinancialofficersorpersonsperformingsimilarfunctionsasappropriatetoallowtimelydecisions regardingrequireddisclosurealexgorskychairmanandchiefexecutiveofficerandjosephjwolkexecutivevice presidentchieffinancialofficerreviewedandparticipatedinthisevaluationbasedonthisevaluationmessrsgorsky andwolkconcludedthatasoftheendoftheperiodcoveredbythisreportthecompanysdisclosurecontrolsand procedureswereeffective reportsoninternalcontroloverfinancialreportingtheinformationcalledforbythisitemisincorporatedhereinby referencetomanagementsreportoninternalcontroloverfinancialreportingandtheattestationregardinginternal controlsoverfinancialreportingincludedinthereportofindependentregisteredpublicaccountingfirmincludedin itemofthisreport changesininternalcontroloverfinancialreportingduringthefiscalquarterendedjanuarytherewereno changesinthecompanysinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequired underrulesaanddundertheexchangeactthathavemateriallyaffectedorarereasonablylikelyto materiallyaffectthecompanysinternalcontroloverfinancialreportingthecompanyhasnotexperiencedanymaterial impacttoitsinternalcontrolsoverfinancialreportingdespitethefactthatmostofitsemployeesareworkingremotelydue tothecovidpandemicthecompanyproactivelytookactionstoreevaluateandrefineitsfinancialreportingprocess throughadditionalmonitoringcontrolstoprovidereasonableassurancethatthefinancialresultsarereportedaccurately andtimelythecompanycontinuestomonitorandassesstheeffectivenessofthedesignandoperationofitsdisclosure controlsandprocedures thecompanyisimplementingamultiyearenterprisewideinitiativetointegratesimplifyandstandardizeprocessesand systemsforthehumanresourcesinformationtechnologyprocurementsupplychainandfinancefunctionstheseare enhancementstosupportthegrowthofthecompanysfinancialsharedservicecapabilitiesandstandardizefinancial systemsthisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessinthecompanysinternalcontrolover financialreportinginresponsetothisinitiativethecompanyhasandwillcontinuetoalignandstreamlinethedesignand operationofitsfinancialcontrolenvironment item b information notapplicable johnsonjohnsonannualreport part iii item directors executive officers corporate governance theinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheauditcommitteeunder thecaptionitemelectionofdirectorsboardcommitteesandthematerialunderthecaptionsitemelectionof directorsandifapplicablestockownershipandsectioncompliancedelinquentsectionareportsinthe proxystatementandthematerialunderthecaptionexecutiveofficersoftheregistrantinpartiofthisreport thecompanyscodeofbusinessconductwhichcoversallemployeesincludingthechiefexecutiveofficerchief financialofficerandcontrollermeetstherequirementsofthesecrulespromulgatedundersectionofthe sarbanesoxleyactofthecodeofbusinessconductisavailableonthecompanyswebsiteatwwwjnjcom codeofbusinessconductandcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttothesecretary atthecompanysprincipalexecutiveofficesanysubstantiveamendmenttothecodeofbusinessconductoranywaiver ofthecodegrantedtothechiefexecutiveofficerthechieffinancialofficerorthecontrollerwillbepostedonthe companyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysandretainedonthewebsiteforatleastone year inadditionthecompanyhasadoptedacodeofbusinessconductethicsformembersoftheboardofdirectorsand executiveofficersthecodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficers isavailableonthecompanyswebsiteatwwwinvestorjnjcomgovboardconductcfmandcopiesareavailableto shareholderswithoutchargeuponwrittenrequesttothesecretaryatthecompanysprincipalexecutiveofficesany substantiveamendmenttothecodeoranywaiverofthecodegrantedtoanymemberoftheboardofdirectorsorany executiveofficerwillbepostedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysand retainedonthewebsiteforatleastoneyear item executive compensation theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorcompensationanditemcompensationcommitteereportcompensation discussionandanalysisandexecutivecompensationtablesintheproxystatement thematerialincorporatedhereinbyreferencetothematerialunderthecaptioncompensationcommitteereportinthe proxystatementshallbedeemedfurnishedandnotfiledinthisreportandshallnotbedeemedincorporatedby referenceintoanyfilingunderthesecuritiesactofasamendedorthesecuritiesexchangeactofas amendedasaresultofthisfurnishingexcepttotheextentthatthecompanyspecificallyincorporatesitbyreference item security ownership certain beneficial owners management related stockholder matters theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitemstock ownershipandsectioncomplianceintheproxystatementandnotecommonstockstockoptionplansand stockcompensationagreementsofthenotestoconsolidatedfinancialstatementsinitemofthisreport johnsonjohnsonannualreportequity compensation plan information thefollowingtableprovidescertaininformationasofjanuaryconcerningthesharesofthecompanyscommon stockthatmaybeissuedunderexistingequitycompensationplans numberof securitiesto beissuedupon weightedaverage numberofsecurities exerciseof exercisepriceof remainingavailablefor outstanding outstanding futureissuanceunderequity plancategory optionsandrights optionsandrights compensationplans equitycompensationplansapprovedbysecurity holders equitycompensationplansnotapprovedbysecurity holders total includedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbythecompanysshareholders longtermincentiveplanandlongtermincentiveplan thiscolumnexcludessharesreflectedunderthecolumnnumberofsecuritiestobeissueduponexerciseofoutstandingoptions andrights thelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewere underthelongtermincentiveplan item certain relationships related transactions director independence theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorindependenceandrelatedpersontransactionsintheproxystatement item principal accountant fees services theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem ratificationofappointmentofindependentregisteredpublicaccountingfirmintheproxystatement johnsonjohnsonannualreport part iv item exhibits financial statement schedules thefollowingdocumentsarefiledaspartofthisreport financialstatements consolidatedbalancesheetsatendoffiscalyearsand consolidatedstatementsofearningsforfiscalyearsand consolidatedstatementsofcomprehensiveincomeforfiscalyearsand consolidatedstatementsofequityforfiscalyearsand consolidatedstatementsofcashflowsforfiscalyearsand notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial statementsornotes exhibitsrequiredtobefiledbyitemlofregulationsk theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheexhibitindexinthisreport item summary registrantsmayvoluntarilyincludeasummaryofinformationrequiredbyformkunderthisitemthecompanyhas electednottoincludesuchsummaryinformation johnsonjohnsonannualreportsignatures pursuanttotherequirementsofsectionofthesecuritiesexchangeactoftheregistranthasdulycausedthis reporttobesignedonitsbehalfbytheundersignedthereuntodulyauthorized datefebruary johnsonjohnson registrant sagorsky agorskychairmanboardofdirectors andchiefexecutiveofficer pursuanttotherequirementsofthesecuritiesexchangeactofthisreporthasbeensignedbelowbythefollowing personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicated signature title date sagorsky chairmanboardofdirectors february agorsky chiefexecutiveofficer principalexecutiveofficer sjjwolk chieffinancialofficer february jjwolk principalfinancialofficer srjdeckerjr controllerandchiefaccountingofficer february rjdeckerjr principalaccountingofficer smcbeckerle director february mcbeckerle sdsdavis director february dsdavis sieldavis director february ieldavis sjadoudna director february jadoudna smahewson director february mahewson shjoly director february hjoly smbmcclellan director february mbmcclellan sammulcahy director february ammulcahy johnsonjohnsonannualreport signature title date scprince director february cprince saewashington director february aewashington smaweinberger director february maweinberger snywest director february nywest srawilliams director february rawilliams johnsonjohnsonannualreportexhibit index regsk exhibittable itemno descriptionofexhibit restatedcertificateofincorporationeffectivefebruaryincorporatedhereinbyreferencetoexhibitiofthe registrantsformkannualreportforthefiscalyearendedjanuary ii certificateofamendmenttothecertificateofincorporationofjohnsonjohnsoneffectiveaprilincorporatedherein byreferencetoexhibitoftheregistrantsformkcurrentreportfiledapril iii bylawsofthecompanyasamendedeffectivejuneincorporatedhereinbyreferencetoexhibitofthe registrantsformkcurrentreportfiledjune upontherequestofthesecuritiesandexchangecommissiontheregistrantwillfurnishacopyofallinstrumentsdefiningthe rightsofholdersoflongtermdebtoftheregistrant b descriptionofsecuritiesregisteredpursuanttosectionofthesecuritiesexchangeactofincorporatedhereinby referencetoexhibitoftheregistrantsformkcurrentreportfiledaugust longtermincentiveplanincorporatedhereinbyreferencetoexhibitoftheregistrantssregistrationstatement filedonmayfileno b formofstockoptioncertificateunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibitof theregistrantsformkcurrentreportfiledjanuary c longtermincentiveplanincorporatedhereinbyreferencetoappendixaoftheregistrantsproxystatementfiledon march formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformq quarterlyreportforthequarterendedapril e globalnonqualifiedstockoptionawardagreementglobalrestrictedshareunitawardagreementandglobalperformance shareunitawardagreementunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibits andoftheregistrantsformqquarterlyreportforthequarterendedapril f johnsonjohnsonexecutiveincentiveplanamendedasofnovemberincorporatedhereinbyreferencetoexhibit aoftheregistrantsformqquarterlyreportforthequarterendedmarch g domesticdeferredcompensationcertificateofextracompensationplanincorporatedhereinbyreferencetoexhibitg oftheregistrantsformkannualreportfortheyearendeddecember h amendmentstothecertificateofextracompensationplaneffectiveasofjanuaryincorporatedhereinbyreferenceto exhibitjoftheregistrantsformkannualreportfortheyearendeddecember certificatesoflongtermperformanceplanincorporatedhereinbyreferencetoexhibitoftheregistrantsform qquarterlyreportforthequarterendedseptember j amendedandrestateddeferredfeeplanfordirectorsamendedasofjanuaryincorporatedhereinbyreference toexhibitkoftheregistrantsformkannualreportforthefiscalyearendedjanuary k thejohnsonjohnsonexecutiveincomedeferralplanamendedandrestatedeffectivejanuaryincorporatedherein byreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterendedseptember l excesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreferencetoexhibitjoftheregistrants formkannualreportforthefiscalyearendeddecember amendmentstothejohnsonjohnsonexcesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreference toexhibitpoftheregistrantsformkannualreportforthefiscalyearendeddecember n amendedandrestatedexcessbenefitplanofjohnsonjohnsonandaffiliatedcompaniesamendedandrestatedeffective januaryexceptasotherwiseprovidedfiledwiththisdocument executivelifeplanagreementincorporatedhereinbyreferencetoexhibitioftheregistrantsformkannualreport forthefiscalyearendedjanuary p executivelifeplanagreementclosureletterincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedmarch q employmentagreementfordrpaulusstoffelsincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedseptember johnsonjohnsonannualreport r severancepayplanofjohnsonjohnsonandusaffiliatedcompaniesamendedandrestatedasofoctober incorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterended september firstamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestated effectiveoctoberincorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreport forthequarterendedjune secondamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestated effectiveoctoberincorporatedhereinbyreferencetoexhibitxoftheregistrantsformkannualreportfor thefiscalyearendedjanuary subsidiariesfiledwiththisdocument consentofindependentregisteredpublicaccountingfirmfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument exhibit exins instancedocumenttheinstancedocumentdoesnotappearintheinteractivedatafilebecauseitsxbrltagsareembedded withintheinlinexbrldocument exsch inlinexbrltaxonomyextensionschema excal inlinexbrltaxonomyextensioncalculationlinkbase exlab inlinexbrltaxonomyextensionlabellinkbase expre inlinexbrltaxonomyextensionpresentationlinkbase exdef inlinexbrltaxonomyextensiondefinitiondocument exhibit coverpageinteractivedatafilethecoverpageinteractivedatafiledoesnotappearintheinteractivedatafilebecauseits xbrltagsareembeddedwithintheinlinexbrldocument managementcontractorcompensatoryplan paperfiling acopyofanyoftheexhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest specifyingthedesiredexhibitstothesecretaryattheprincipalexecutiveofficesofthecompanypursuanttoitem biiiaofregulationskthecompanyhasnotfiledasexhibitstothisformkcertainlongtermdebt instrumentsincludingindenturesunderwhichthetotalamountofsecuritiesauthorizeddoesnotexceedofthetotal assetsofthecompanyanditssubsidiariesonaconsolidatedbasisthecompanyherebyagreestofurnishacopyofany suchinstrumenttothesecuponrequest thefollowingexhibitsindicatedasbeingfiledwiththisdocumentareomittedfromtheprintedversionofthis annualreport exhibitn exhibit exhibit johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact ialexgorskycertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrols andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedures tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingits consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepared bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciples cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunctions aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporting salexgorsky alexgorsky chiefexecutiveofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact ijosephjwolkcertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrols andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedures tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingits consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepared bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciples cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunctions aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporting sjosephjwolk josephjwolk chieffinancialofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact theundersignedalexgorskythechiefexecutiveofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany salexgorsky alexgorsky chiefexecutiveofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact theundersignedjosephjwolkthechieffinancialofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany sjosephjwolk josephjwolk chieffinancialofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportthispageintentionallyleftblankthispageintentionallyleftblankthispageintentionallyleftblankboard directors senior management alexgorsky chairmanboardofdirectors alexgorsky chiefexecutiveofficer marycbeckerle chairmanexecutivecommittee chiefexecutiveofficerhuntsmancancerinstitute attheuniversityofutah joaquinduato distinguishedprofessorofbiology vicechairmanexecutivecommittee collegeofscienceuniversityofutah paulusstoffels dscottdavis vicechairmanexecutivecommitteechiefscientificofficer formerchairmanandchiefexecutiveofficer unitedparcelserviceinc robertjdeckerjr ianeldavis corporatecontrollerchiefaccountingofficer nonexecutivechairmanrollsroyceholdingsplc petermfasolo formerchairmanandworldwidemanagingdirector executivevicepresidentchiefhumanresourcesofficer mckinseycompany jenniferadoudna ashleymcevoy professorofchemistryprofessorofbiochemistry executivevicepresidentworldwidechairman molecularbiology medicaldevices likashingchancellorsprofessorinbiomedical andhealthuniversityofcaliforniaberkeley thibautmongon executivevicepresidentworldwidechairman marillynahewson consumerhealth executivechairmanformerchairmanandchief executiveofficer mattheworlando lockheedmartincorporation corporatesecretary worldwidevicepresidentcorporategovernance hubertjoly formerchairmanandchiefexecutiveofficerbest michellerryan buycoinc treasurer markbmcclellan directordukerobertjmargolismd michaelesneed centerforhealthpolicydukeuniversity executivevicepresidentglobalcorporateaffairs chiefcommunicationsofficer annemmulcahy formerchairmanandchiefexecutiveofficer jennifertaubert xeroxcorporation executivevicepresidentworldwidechairman pharmaceuticals charlesprince formerchairmanandchiefexecutiveofficer michaelhullmann citigroupinc executivevicepresidentgeneralcounsel aeugenewashington dukeuniversityschancellorforhealthaffairs kathrynewengel presidentandchiefexecutiveofficer executivevicepresidentchiefglobalsupplychainofficer dukeuniversityhealthsystem josephjwolk markaweinberger executivevicepresidentchieffinancialofficer formerchairmanandchiefexecutiveofficerey memberexecutivecommittee nadjaywest formerlieutenantgeneralusarmy ronaldawilliams formerchairmanandchiefexecutiveofficer aetnainc johnsonjohnsonannualreportprincipaloffice stocklisting johnsonjohnsononline onejohnsonjohnsonplaza johnsonjohnsoncommonstock newbrunswicknewjersey listedonnewyorkstockexchange ourwebsitewwwjnjcom stocksymboljnj httpwwwjnjcommediacenter annualmeetingofshareholders shareholderrelationscontact thursdayapril mattheworlando corporatesecretary wwwfacebookcomjnj ameastern meetingwillbeheldvirtuallyat wwwtwittercomjnjnews wwwvirtualshareholdermeetingcomjnj investorrelationscontact wwwyoutubecomjnj allshareholdersasoftherecorddateof christopherdelorefice februaryareinvitedtoattend vicepresidentinvestorrelations httpwwwlinkedincomcompany aformalnoticeofannualmeetingand johnsonjohnson proxystatementandproxycardhavebeen madeavailabletoshareholders investorrelationswebsite wwwinvestorjnjcom thejohnsonjohnsonyearin annualreportonformkand proxystatement stocktransferagentandregistrar reviewisavailableonourwebsiteat johnsonjohnsonsannualreportonformk questionsregardingstockholdings httpswwwjnjcomyearinreview forthefiscalyearendedjanuaryis certificatereplacementtransferdividends theinformationonthesewebsitesshould includedinthisannualreportinitsentiretywith andaddresschangesshouldbedirectedto notbedeemedtobepartofthisannual theexceptionofcertainexhibitstheformk ourstocktransferagentandregistrarat report completewithallofitsexhibitsisavailableonour computersharetrustcompanyna websiteatwwwinvestorjnjcomseccfmandthe pobox secswebsiteatwwwsecgov louisvilleky shareholdersmayalsoobtaincopiesofthe overnightmail computersharetrustcompanyna exhibitsourannualreporton souththstreetsuite formkandourproxystatement louisvilleky withoutchargeuponwrittenrequesttothe officeofthecorporatesecretaryatour principalofficeaddressorbycalling shareholderwebsite wwwcomputersharecominvestor electronicdeliverynotification dividendreinvestmentplan theproxystatementandourannual theplanallowsforfullorpartialdividend reportareavailableonourwebsiteat reinvestmentandadditionalweeklycash wwwinvestorjnjcomgov investmentsuptoperyearin annualmeetingmaterialscfmshareholderswho johnsonjohnsoncommonstockwithout receivepapercopiesofourproxystatementand pershareorservicechargesonstock c annualreportbymailcanelecttoreceiveinstead purchasesifyouareinterestedin anemailmessagewithalinktothosedocuments participatingintheplanandneedan ontheinternetregisteredshareholdersmay enrollmentformandormoreinformation enrollinelectronicdeliveryat pleasecalltheplanadministrator thejohnsonjohnsonannualreport wwwcomputersharenacomgreenbeneficial computersharetrustcompanynaat containsmanyofthevaluabletrademarks shareholderswhoholdsharesofjohnson andtradenamesownedandusedbythe johnsoncommonstockthroughabankbrokeror outsidetheusoraccessonlineat johnsonjohnsonfamilyofcompaniesin otherholderofrecordgenerallycanenrollfor wwwcomputersharecominvestor theunitedstatesandinternationallyto electronicdeliveryatenrollicsdeliverycomjnj distinguishproductsandservicesof hearingimpaired outstandingquality shareholderswhohaveinquiriesregarding johnsonjohnson stockrelatedmatterscancommunicate directlywithcomputersharetrustcompany naviaatelecommunicationsdevicetdd thetelephonenumberforthisserviceis outsidetheus